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Functional polymeric biomaterials have attracted attention in tissue repair due to their 
tailorability, low cost, biocompatibility and, in certain cases, ability to promote wound 
healing. A successful biofunctional polymer needs to either be passive to the host or 
trigger a beneficial host response and, ideally, requires a matching of the material 
mechanical properties to that of the tissue it will replace.  
However, the design of biofuncional polymers relies on the ability to understand the 
complex interplay between the material properties and cell/tissue behaviour. The 
concept of my thesis is the development of “arrays of 3D polymers” as an approach 
to “scan” polymer–cell interactions and, simultaneously, examine the effect of 
numerous biomaterial compositions and various 3D microstructures on cellular 
behaviour. However, despite previous efforts, there is currently no route that efficiently 
permits control of 3D microstructures with multiple different polymers.    
To address these challenges, the work in my thesis set out to develop a new and 
efficient approach to produce arrays of 3D scaffolds. The scaffolds were constructed 
with numerous pores (like an Emmental cheese) that permit cells to travel deep into 
them and promote efficient mass transfer and oxygenation. The pores were obtained 
and controlled by polymerisation taking place around frozen solvent crystals, which 
acted as moulds for the formation of pores.  
The approach developed was applied here to fabricate porous scaffolds that were 
used to successfully identify a material that promoted vascularisation (formation of 









The field of functional biomaterials has seen huge progression with enormous efforts 
made to discover 3D scaffolds that support and promote tissue formation. Polymer-
based 3D scaffolds are used extensively as a consequence of their remarkable 
tunability and biocompatibility. 
However, the scope of possible scaffolds, with respect to their physical and chemical 
properties, is vast encompassing chemical composition, wettability, 3D structure and 
mechanical properties to name but a few. In addition, the combined effects of these 
properties on cellular fate, in association with scaffold/protein binding, leads to highly 
complex systems with numerous processes occurring simultaneously at multiple 
levels, which hinders a full understanding of the cell–material interface. Therefore, 
despite huge efforts to understand how the physical and chemical cues of these 3D 
scaffolds trigger and control cellular behaviour, the effect of these properties on cells 
remains vague, yet continues to be a key element of tissue engineering.  
2D polymer microarrays have been shown to be an efficient high-throughput 
technology to discover new functional polymers. However, these polymer features 
lack the necessary 3D structure and morphologies present within tissues. In this 
thesis, I present the development of a new strategy to fabricate arrays of 3D polymer 
scaffolds exploiting photo-polymerisation within a crystallisable solvent (dimethyl 
sulfoxide, DMSO), which serves as a template for the generation of pores. 
Initial studies involved the identification of suitable polyacrylates that were capable of 
binding and maintaining human bone osteosarcoma cells (SAOS-2 and MG-63). 
These were then used to optimise a polymerisation process that maximised the 
formation of pores in addition to analysing the effect of the solvent on the 3D structure 
of the scaffolds and their mechanical properties. An array of 24 different 3D polymer 
features was fabricated and screened with SAOS-2 cells as a proof of concept of the 
applicability of the array, showing that cell attachment, proliferation and morphology 
could be controlled by the composition of the scaffolds along with their 3D 
microstructures.  
A second project (a collaborative effort with the University of Southampton) used the 
developed screening platform to identify novel 3D scaffolds that promoted the 
formation of vascularised bone tissue with 45 different 3D polymer scaffolds (15 
iii 
different polyacrylates with 3 levels of porosity) and foetal bone marrow stroma cells 
(FBMSCs). A highly biocompatible scaffold was discovered that promoted 
osteoblastic phenotype expression and vascularisation - the first time for such 
phenomena had been observed in polyacrylate scaffolds without externally supplied 
factors. This was validated ex vivo, with a chick chorioallantoic membrane (CAM), and 
in vivo, with a subcutaneous mouse model, confirming biocompatibility and the 
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1. Tissue engineering for bone regeneration 
 
Tissue engineering is a field of regenerative medicine that develops new 
technologies, strategies and materials to promote tissue formation at sites where 
tissue would otherwise not form (e.g. after a traumatic injury). Tissue engineering 
involves typically the use of combinations of biomaterials, cells and growth factors.[1] 
In this context, tissue engineering offers the potential to solve the clinical need for 
technologies that permits the artificial regeneration of damaged or diseased tissues*. 
Moreover, tissue-engineering strategies could also improve “real-life” in vitro studies 
with the use of “human-like” tissue assemblies which could increase the robustness 
of preclinical assessment and success of clinical studies†.  
The definition for the term “biomaterial” proposed by the European Society for 
Biomaterials Concensus Conference II quotes: “a biomaterial is a material intended 
to interface with biological systems to evaluate, treat, augment or replace any tissue, 
organ or function of the body”. One of the properties of biomaterials is biocompatibility 
which has been defined by Williams as “the ability of a material to perform with an 
appropriate host response in a specific application”.[2] According to reports, one of the 
“first” biomaterials may have been a hybrid material (cow tooth and gold wire) used 
as a tooth replacement and attributed to the Etruscan civilisation (around 2,600 years 
ago).[3] 
The first generation of biomaterials developed during the 1960s and 1970s aimed to 
be “inert” to the host to “achieve a suitable combination of physical properties to match 
those of the replaced tissue with a minimally toxic response”.[4] By 1980, there were 
more than 50 implantable devices in clinical use, made from more than 40 different 
materials and with more than 2 million devices implanted in patients in the US. One 
of the first really successful biomaterials widely used in temporary devices such as 
fracture plates and screws was made of stainless steel (AISI 316L) that contained (by 
wt) 0.03% C, 17-20% Cr, 12-14% Ni and 2-3% Mo.[5] Titanium and its alloys attracted 
considerable attention since Branemark discovered that these materials integrated 
 
* About 4,000 transplants were undertaken in the UK in 2018 with more than 6,000 people on 
the transplant waiting list.[225]  
† 1.5 million experimental procedures were carried out with animals in the UK during 2018, 
with 17% having the purpose of addressing diseases such as cancer (28%) and infectious 
disorders (25%).[226] Although animal models are a tremendously valuable source of 
information, they cannot mimic the complexity of human physiology which has been identified 
as a possible source of clinical trial failure.[227,228]  
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into bones (osseointegration) reducing the risks of implant failure.[6] Resistance to 
corrosion of titanium alloys is due to the formation of an adhesive oxide layer (TiO2) 
in the implant surface and was another beneficial feature. Commercially pure titanium 
is used in dental implants whereas titanium alloys such as ASTM F67 and ASTM F136 
(Ti6Al14V) are applied in orthopaedic applications. However, vanadium (V) 
cytotoxicity has driven the development of new titanium alloys (e.g. Ti35Nb5Ta7Zr) 
based on titanium, niobium (Nb), tantalum (Ta) and zirconium (Zr). Acrylate bone 
cements based on poly(methyl methacrylate) provide excellent primary fixation of 
prosthesis although they do not promote any biological response and can create 
thermal damage during curing. Poly(ethylene) is used in combination with ceramics 
like alumina (Al2O3) in hip arthroplasties.[5] 
By the mid-1980s, a second generation of biomaterials, “bioactive materials”, had 
reached clinical use to produce a controlled physiological response with bioactive 
glasses, ceramics and composites applied in a variety of orthopaedic and dental 
applications.[4] The most common bioactive ceramics are based on calcium 
phosphate such as hydroxyapatite (HA, Ca10(PO4)6(OH)2) or β-tricalcium phosphate 
(β-TCP, Ca3(PO4)2). Although HA has low physiological solubility and remains 
integrated into the bone tissue, β-TCP is fully reabsorbed. Bioglasses like silica (SiO2) 
are also used to improve the formation of bone tissue and they are usually applied as 
dopants in orthopaedic devices. Moreover, bioabsorbable polymers such as 
poly(lactic acid) and poly(glycolide) are used in the fixation of bones (e.g. degradable 
screws).[5]  
The term third-generation biomaterials, also known as functional biomaterials, has 
been used since the turn of the new millennium and encompasses biomaterials that 
that produce specific cellular response at the molecular level affecting cellular genetic 
activation and protein expression.[4] Functional biomaterials also try to integrate with 
the properties and characteristics of the extracellular matrix (ECM), a collection of 
extracellular secretions such as proteins, polysaccharides and water that provide the 
structural and biochemical support to the cells of tissues.[7] Current clinical 
approaches typically involve the stimulation of the autologous healing in tissues. One 
example is INFUSE, a bone graft from Medtronic, for spinal fusion that includes bovine 
type I collagen sponge containing recombinant human bone morphogenetic protein-
2.[8] NOVOCART 3D from Aesculap is in phase 3 clinical trials and targets cartilage 
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regeneration using autologous chondrocytes seeded on type I collagen sponges with 
chondroitin sulphate.[9]  
Functional biomaterials can be shaped as “scaffolds” to promote tissue healing, 
delivering cells or growth factors in the damaged tissue. Scaffolds are defined as 
porous structures that serve as substrates to guide tissue regeneration, providing a 
three-dimensional (3D) microenvironment that produces adhesion focal points 
distributed in all three dimensions (Figure 1-1).[10,11]  
 
Figure 1-1. Cell-substrate interactions. Differences in the substrate microstructure (2D or 3D), 
mechanical properties (soft or rigid), topography (textured or smooth) and chemical 
composition all tune cell behaviour. Substrates and scaffolds are shown in grey, cellular 
cytoskeleton is represented in black, cytoplasm in illustrated in green with nucleus in yellow. 
Substrate adhesion points are shown in red with chemical clues in purple. 
 
Mechanical, physical and chemical properties of functional biomaterials all affect cell 
fate and, ultimately, can stimulate tissue healing or tune tissue characteristics. Cells 
can also modify their ECM in adaptation to external stimuli, for example, in the 
absence of gravitational loadings astronauts are known to increase bone resorption 
processes reducing bone density.[12]   
In tissues, external forces and physical loadings produce shear stresses that modify 
cellular membranes. These forces have a myriad of effects such as allowing calcium 
ions to flow more easily through stretch-activated ion channels with calcium signalling 
cascades propagating to neighbour cells through gap junctions.[13] Substrate stiffness, 
topography and chemical composition can modify the cells binding to them, altering 
the cellular membrane and cytoskeleton, which can change cell fate and trigger cell 
differentiation processes (Figure 1-1).[14–16] Outside-in signalling (substrate stiffness 
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or topography) are typically transmitted through focal adhesion and integrins 
(transmembrane receptors) that are connected to the cellular cytoskeleton (actin 
filaments) via vinculin (Figure 1-2).[17] At the same time, the cytoskeleton is connected 
to the nuclear envelope via linker of nucleoskeleton and cytoskeleton (LINC) 
complexes, which changes nuclear membrane tension in addition to nuclear pores 
and ion channels.[18] The LINC complexes have a variety of functions including DNA 
repair and the movement of chromosomes within the nucleus during meiosis, which 
can alter the genetic transcription profile.  
 
Figure 1-2. Mechanotransduction mechanisms in cells are the processes through which cells 
sense and respond to external stimuli. These stimuli can activate calcium signalling cascades 
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that regulate cell motility and proliferation among others or the Hippo signalling pathway that 
mediates cell proliferation by contact inhibition. Focal adhesions serve as mechanical linkages 
to the ECM that transmit external stimuli to the cytoskeleton, nuclear envelope and 
chromosomes via linker of nucleoskeleton and cytoskeleton (LINC) complexes. It can also 
change nuclear permeability to transcription factors such as yes-associated protein (YAP) and 
megakaryoblastic leukaemia 1 (MKL1).[18]  
 
Current clinical strategies for the repair of large skeletal disorders such as defects 
produced by tumour resection* involve the use of bone grafts.[19] These grafts can be 
autogenic bone (autografts), often considered the ideal bone graft because of their 
osteoconductive properties and absence of immune response. However, these 
procedures are associated with donor site problems such as pain and infection. 
Allografts from cadavers or living donors (hip replacement operations being the 
source of most allogenic bone) is also an alternative. Nonetheless, bone tissue must 
be decellularised to prevent the host’s immune response and be screened to reduce 
the inherent risk of disease transmission.[20] This has driven the exploration of new 
biomaterials and tissue engineering principles as an alternative to allow the 
generation of new bone inspired by the properties of natural tissues (Figure 1-3).  
 
Figure 1-3. Strategy needed to design a 3D polymer scaffold for skeletal repair.  
 
 
* In the UK there are ~600 new cases of bone sarcoma every year with ~85% of the patients 
undergoing bone replacements. Patients with bone osteosarcoma have a 55% survival rate of 
10 or more years.[229]  
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1.1 Discovery of synthetic polymeric biomaterials 
 
Considerable efforts have been dedicated to discover materials with improved 
biocompatibility due to the downsides that many tissue substitutes have. For instance, 
metals undergo corrosion causing allergic responses, while ceramics lack optimal 
mechanical properties.[5] As alternatives, bio-inspired materials based on 
biocompatible polymers have been extensively studied due to their versatile physical 
and chemical properties along with their ability to mimic the native ECM 
microenvironment.[21]  
Natural materials such as collagen, gelatin and polysaccharides in addition to 
synthetic polymers such as polyglycolides, polylactic acid, polycaprolactones, 
polyurethanes and polyacrylates have been investigated as musculoskeletal 
substitutes.[22–24] Naturally derived biomaterials like collagen, which is the most 
abundant protein of the ECM, have shown limited success in clinic because of 
difficulties in fabricating the material on a large scale and the high batch-to-batch 
variability.[25,26] However, their natural properties allows them to successfully 
reproduce many physiological processes, for example, mineralisation of collagen 
fibres.[27]  
Synthetic polymers such as polyurethanes and polyacrylates have attracted attention 
as functional biomaterials because of their remarkable biocompatibility, for example, 
with hepatocytes, progenitor and mature endothelial cells (ECs), human embryonic 
stem cells, mesenchymal stem cells (MSCs) or valve interstitial cells.[28–32] Hydrogels 
based on polyacrylates constitute a group of cross-linked polymers whose hydrophilic 
structure is capable of “holding” a large amount of water within their 3D network. The 
high water content of hydrogels as well as their physical and chemical properties 
matches extraordinarily well the characteristics of many soft natural tissues.[33] For 
instance, atom transfer radical polymerisation was used to synthesise a 
thermosensitive hydrogel based on poly(N-isopropylacrylamide) to encapsulate and 
deliver cardiac progenitor cells.[34] In another example, a hydrogel based on methyl 
methacrylate, methacrylic acid and poly(ethylene glycol) diacrylate was designed to 
recapitulate, growth factor-free, the characteristics of human articular cartilage.[35]  
The synthesis of novel polymers is in continuous development. In general, two 
different synthetic techniques can be differentiated to obtain polymers: step growth 
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polymerisation and chain growth polymerisation/addition polymerisation. Step growth 
polymerisation, also called polycondensation, consists of reactions carried out 
between monomers with two functional groups such as bis-amines with bis-acid 
chlorides or diols with isocyanates.[36] On the other hand, chain growth 
polymerisations typically refer to polymerisations that occur through activated species 
such as initiators or actives centres with chains growing sequentially, generating a 
new reactive site at the terminus of the chain after every new addition.[37]  Controlled 
chain growth polymerisation is extensively used to generate sequence-controlled 
copolymers and graft polymers e.g. via reversible addition fragmentation chain-
transfer (RAFT) polymerisation.[38–40]  
Microarrays are a platform whereby hundreds or hundreds of thousands of different 
probes such as DNA, proteins, drugs, tissue samples or polymers are immobilised 
onto a substrate (typically silica). Microarrays are valuable tools for basic biology and 
tissue engineering research because they have the capability to evaluate a large 
number of probes simultaneously, under identical conditions in a single assay. These 
characteristics give microarrays the ability to conduct experiments with great 
consistency, little expense and while providing a large amount of information. The first 
material arrays were reported by Hanak in 1970.[41] The “multiple-sample concept” 
was introduced to increase the efficiency of the discovery of new superconducting 
materials by sputter deposition. The fabrication of polymer microstructures achieved 
by photo-deposition on top of the distal end of an optical fibres reported by Healey in 
1995 was another step in the development of microarrays.[42] In 1998, a polymer array 
with 112 different features (materials spotted on the array) was prepared in order to 
study physical, mechanical properties as well as fibroblast binding and growth 
properties.[43] 
Polymer microarrays are based on a grid of polymers deposited at defined locations 
on the substrate (Figure 1-4). The polymers can be pre-synthesized and deposited 
onto the solid substrate through contact printing* or through in situ polymerisation 
through the deposition of the starting materials using contact printing or inkjet 
printing†.[44–46] Polymer microarrays have displayed an extraordinary capability to 
discover polymers for modulating cellular responses. For example, a gradient array 
 
* Contact printing uses metal pins to “collect” and then “deposit” polymer solutions on top of a 
substrate with direct contact between the pin and the substrate.  
† Inkjet printing allows deposition liquid droplets onto a substrate surface, which can turn into 
a solid as a result of chemical changes (e.g. UV mediated polymerisation). 
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was designed by Hansen in order to understand and control cellular adhesion with 
polymer composition.[47]  
The design and application of a polymer microarray requires the optimal selection of 
the substrate, the type of coating, the equipment used to fabricate the array and how 
the biology will be evaluated. Fluorescence scanners and microscopes are the most 
commonly used detection instruments for microarray analysis that requires, ideally, 
an automatic process controlled by appropriate software.[48]  
 
Figure 1-4. 1) Image of a polyacrylate microarray fabricated by in situ polymerisation following 
inkjet mediated printing. The microarray was interrogated with SAOS-2 cells, which binds to 
selected polymer features. 2) Assessment of cell attachment was carried out using 
fluorescence and high-content microscopy. In the example, one representative polymer is 
shown with cell nuclei and cytoplasm stained with DAPI (cyan) and CellMask™ deep red. 
Scale bar = 200 µm. 
 
1.2 Fabrication of 3D scaffolds 
 
Three-dimensional scaffolds can be defined as porous structures that serve as 
artificial 3D substrates that support cell culture.[2] As such, ideal scaffolds promote cell 
stability, enable cell proliferation and provide stimuli for cells that direct the assembly 
of tissue-like 3D structures.[49] Additive manufacturing prototyping technologies (also 
known as 3D printing)[50] such as stereolithography,*  selective laser sintering,† inkjet 
 
* Stereolithography is based on the selective curing of a photopolymer resin by a laser or light 
source. The laser polymerises each layer in a point-by-point and line-by-line style and requires 
a slowly descending platform. 
† Selective laser sintering is based on the selective sintering of a fine powder by a high-
temperature laser. After each layer is produced, a fresh layer of the powder has to be spread 
on the bed, following the sintering of a new layer. 
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printing, fused deposition modelling and extrusion-based techniques* (e.g. 3D 
bioprinting)[51] allow scaffolds to be directly constructed or printed, and offers an 
approach within the area of biomedical research to fabricate in a cost-effective and 
personalised manner medical solutions.[52] These approaches can provide a high level 
of control of the scaffold microstructure with resolutions in the micrometre scale (1-10 
µm) using stereolithography or in the nanometre scale (< 200 nm) using two-photon 
polymerisation.[53] An extrusion-based approach has been used to construct a 
gradient scaffold whose pore size changed from the bottom (500 µm) to the top (1100 
µm) to enhance osteogenic differentiation.[54] In another example, a soft granular gel 
was used to print complex structures such as ‘‘blood vessels’’ (hollow cylinders). The 
gel fluidised under high shear stresses, e.g. shear stress produced by a nozzle tip 
moving in the gel, and it solidified when the high shear stress disappeared. This was 
used for 3D printing and to trap a pre-polymer solution that was cured upon UV 
photopolymerisation (Figure 1-5).[55]  
 
Figure 1-5. 3D printing in a granular gel (0.2% w/v Carbopol in water). As the nozzle moves, 
the gel fluidises and then gellifies trapping the pre-polymer solution. The structures can then 
be consolidated upon UV polymerisation.[55]   
 
However, prototyping technologies are material-dependent i.e. properties of the 
material (viscosity, melting temperature, polymerisation time, etc.) determines the 
 
* Fused deposition modelling and extrusion-based techniques are based on the deposition of 
melted materials (fused deposition) or deposition of a gel (extrusion-based techniques). 
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‘‘printability’’. Moreover, all of these approaches are time-consuming and typically 
require costly equipment.  
Electrospinning has risen as an interesting approach to prototyping technologies for 
transforming polymers into homogenous fibres with diameter that can range from 
nanometres to micrometres with fibrous microstructures resembling the ECM.[56] 
Fibres are generated when the electrostatic charge, generated by an electric field 
between the collector and the jetting needle, overcomes the surface tension of the 
polymer solution. The polymer solution is dispensed by action of a syringe pump or 
gravity, and the solvent evaporates when the polymer ‘‘flies’’ to the collector resulting 
in solid polymer fibres. Characteristics of the fibres are conditioned by properties of 
the polymer solution such as conductivity, surface tension, viscosity and molecular 
weight; processing factors such as flow rate, electrical field; and environmental 
parameters, including humidity and temperature.[57]  
The generation of porous scaffolds using sacrificial materials as scaffold templates 
using solvent casting and particulate leaching or inducing phase separation by means 
of a porogen, a reaction or a change of temperature e.g. non-solvent induced phase 
separation, reaction-induced phase separation, gas foaming, thermally-induced 
phase separation have been shown to be reliable alternatives to prototyping and 
electrospinning. These approaches permit the generation of many scaffolds 
simultaneously and tolerate modification of the composition to explore 
biocompatibility. However, the control of the porous network size, shape, and porosity 
is not immediate and porous structures are considered ‘‘random’’. 
Solvent casting and particulate leaching is based on the creation of a sacrificial 
material ‘‘mould’’ that acts as a template to generate the pores (Figure 1-6, 1). The 
sacrificial material (e.g. sugar, salt, polymers) needs to be immiscible with the 
monomer or polymer solution to allow the generation of pores after polymerisation or 
drying and removing the template. For example, poly(methyl methacrylate) 
microspheres (90 µm) were used as “porogenic” solids to create interconnected pores 
(65 – 85 µm) in scaffolds prepared with ethyl acrylate and hydroxyethyl 
methacrylate.[58]  
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Figure 1-6. Generation of porous scaffolds. 1) Solvent casting and particulate leaching, where 
a porogenic solid such as salt acts as a template for the generation of pores during 
polymerisation. 2) Non-solvent induced phase separation uses a poor solvent for the polymer 
as a porogenic agent to form a porous structure. 3) Gas foaming applies an agent to generate 
a gas that acts as a template for the formation of pores. 4) Freeze-casting uses a crystallisable 
porogenic solvent that forms a template for the generation of pores. Porogenic agents are 
shown in red, polymerisation mixture in yellow, polymer structure in blue and pores in white. 
 
Non-solvent induced phase separation and reaction-induced phase separation 
involve the use of porogenic solvents that are efficient solvents for the monomers but 
poor or deficient solvents for the polymers themselves (Figure 1-6, 2). Porogenic 
solvents such as methanol, ethanol or poly(ethylene glycol) allow the progressive 
segregation of the polymer from the solution during the polymerisation e.g. 
aggregation of polymer and formation of pores.[59] For example, highly porous 
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materials are constructed by high internal phase emulsion polymerisation (HIPEs), 
where a discontinuous phase consisting of a porogenic solvent is dispersed in a 
continuous phase of liquid monomers. However, these systems need to be stabilised 
by a surfactant, which usually remains in the scaffold affecting the cellular 
behaviour.[60]  
Gas foaming approaches utilise the nucleation and growth of gas bubbles dispersed 
through a polymer with the bubbles either generated in situ or by adding a gas to the 
polymer phase.[61] One of the approaches more extensively studied involves the use 
of ammonium bicarbonate that decomposes above 36 °C to give ammonia, carbon 
dioxide and water (Figure 1-6, 3). Porous microspheres for 3D cell culture have been 
fabricated using poly(lactic acid)-co-poly(glycolide) and double emulsion methods 
using gas foaming to generate pores.[62]    
Thermally-induced phase separation or freeze-casting consists of cooling the polymer 
solution below the solvent’s freezing point to induce the formation of two phases; a 
polymer-rich and a solvent-rich phase with the formation of solvent crystals that force 
the polymer into the interstitial space. Pores are created when crystals are removed 
(Figure 1-6, 4). A variation of this approach is producing scaffolds by freeze-drying 
where the solvent is frozen rapidly and removed under vacuum. Freeze-casting offers 
several features: 
 Tailorability to form either homogenous or directional microstructures.  
 High porosity.  
 Large, open and interconnected pores or gradients of pores.  
 Complex shapes and fine features. 
 Simple equipment requirements.  
Characteristics of these porous networks are controlled by the concentration of the 
porogenic solvent, the freezing point of solvents, cooling rate and cooling time.[63]  
The porogenic solvents previously reported include water,[64,65] water-dimethyl 
sulfoxide (DMSO),[66] camphene,[67] naphthalene-camphor[68] and tert-butyl alcohol.[69] 
For example, biomimetic scaffolds with interconnected porous microstructures were 
fabricated using hydroxyapatite and poly(ethylene glycol), with  water as the 
crystallisable porogenic solvent.[65] In another example, a binary system of 
naphthalene-camphor allowed freeze-casting at room temperature (≈ 30 °C). The 
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freezing point of DMSO is 19 °C, which enables freeze-casting at moderate 
temperatures.[70]   
Control of the porous structure can be achieved by controlling the freezing rate and 
the freezing time. Small pores form with a rapid freezing rate as a consequence of 
crystal nucleation because it is kinetically more favourable than crystal growth. With 
larger temperature gradients, heat transfer is more efficient and crystals can grow 
leading to porous structures with larger pore sizes.[71] In the case of a long freezing 
time, crystals keep growing linking each other, consequently enhancing pore 
interconnectivity and large pore size. 
Among the different alternatives considered to generate arrays of 3D porous scaffolds 
(Table 1-1), freeze-casting produces highly porous structures with large and 
interconnected pores, with pore variation tuned by level of porogenic solvent and 
temperature. By contrast with prototyping approaches, freeze-casting enables the 
high-throughput fabrication of multiple 3D microstructures, simultaneously, by tuning 
the level of porogenic solvent (the more porogenic solvent is used, the larger are the 
pores) and the freezing parameters. 
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Table 1-1. Summary of the commonly used techniques to produce porous scaffolds and their key features.[21,72–75]  
Technique 










Support structure is needed  
Limited choice of resins 
Low resin biocompatibility  
Selective laser 
sintering 
50-1,000 <40 30-2,500 
Solvent free 
No support material 
Expensive equipment 
Removing trapped powder  
Fused deposition 
modelling 
100-500 <80 100-2,000 
Solvent free 
Fast processing 
Needs filament preparation 
Limited choice of filaments 
Medium accuracy 
Electrospinning - <90 <1-10 
Simple method 
Interconnected porosity 
Low mechanical integrity 




Polymer microspheres  
NaCl crystals  
<50 30-300 
Simple method 
Controlled porosity/pore size 







Controlled porosity  
Interconnected pores 
Residual solvent 
Complex control  
Gas foaming 
Pressured CO2, N2 
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1.3 Bone biology, an inspiration for the design of 3D 
scaffolds 
 
The adult human skeleton contains 206 bones with a broad range of functionalities 
such as protection for vital organs (e.g. brain, heart, lungs and spinal cord), 
maintenance of homeostasis (source of calcium and phosphate) and production of 
blood cells and innate immune system cells. Moreover, bones also act as supports 
for ligaments, tendons, muscles, and cartilage. Although traditionally bones have 
been seen as a static tissue, they are a highly complex living tissue, for example, the 
surfaces of bones are covered by a highly vascularised membrane called the 
periosteum that has osteogenic functions and maintains nutrient and waste 
exchange.[76]  
 
Figure 1-7. Hierarchical bone structure. Bone macrostructure consists of bone marrow, 
cancellous and cortical sections. Cancellous bone is made of a porous structure filled with 
bone marrow with cortical bone forming a protective outer surface around the internal structure 
of bones. Cancellous bone is made of osteons, a lamellae or concentric structure (350 to 250 
µm) that surround Haversian canals. Collagen fibres determine microstructure of osteons and 
they are constituted of apatite-mineralised tropocollagen at a molecular level.[77]  
 
Bone is a composite material comprised of an inorganic phase (~ 60%), an organic 
phase (~ 25%) and water (~ 15%), which confers bone unique mechanical and 
physical properties such as a compressive strength that exceeds 2,000 kg/cm2. 
Structurally, bone can be divided into a smooth surface (cortex or cortical bone) or an 
internal porous structure (trabecular or cancellous bone). Flat bones such as parietal 
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bones or hipbones are composed mainly of cortical bone whereas long bones such 
as the femur and tibia are composed of cancellous bone. Moreover, the internal 
surface of the long bone contains bone marrow. Red bone marrow (myeloid tissue) is 
hematopoietic and produces red blood cells (also known as red blood corpuscles or 
RBCs), white blood cells (leukocytes) and platelets (Figure 1-7). Red bone marrow is 
gradually substituted by yellow bone marrow (stroma) after the age of 5. The yellow 
bone marrow contains a higher amount of adipose tissue, as well as skeletal 
progenitor cells (also known as mesenchymal stem cells or MSCs), adipocytes and 
endothelial cells.[78] Hematopoietic stem cells (HSCs) are osteoclast progenitors that 
are believed to generate in yolk sac and aorta-gonad-mesonephros region in 
embryonic mammals with migration into liver for expansion and maturation, then into 
bone marrow and subsequently into the spleen.[79]  
Cortical bone, 80% bone mass*, has a hierarchical structure of cylindrical osteons 
(from 10 – 500 µm) with blood vessels in the centre called Haversian canals, which 
are the basic building block of cortical bone tissue. However, cancellous bone, 20% 
bone mass, exhibits a network with trabecular roads without Haversian canals.[77] 
Bone extracellular matrix consists of mineralised collagen fibres (100 to 2000 nm), 
which are made of collagen fibrils i.e. arrays of tropocollagen molecules (three left-
handed helices of peptides).[80] The inorganic component in bone lies in these 
collagen fibrils, containing calcium phosphate (~ 85%), calcium carbonate (~ 10%) 
and salts like potassium (~ 5%). Historically, calcium phosphate has been identified 
as hydroxyapatite, Ca10(PO4)6(OH)2, which is a hydroxyl-containing calcium 
phosphate mineral within the apatite group, Ca10(PO4)6(OH or F or Cl)2.[78] However, 
properties of this inorganic phase have been shown to vary within the body. For 
instance, bone apatite† is re-absorbable whereas tooth enamel hydroxyapatite resists 
 
* Mineral mass contents in a bone. The term is usually used to characterise diseases like 
osteoporosis, a pathological decrease in bone mineral content.  
† In this thesis the broader term apatite is used instead of hydroxyapatite for the calcium 
phosphate mineral/minerals in bones. Current research confirms that the term hydroxyapatite 
does not reflect the mineral component of bones although it is still broadly used in the literature. 
Although X-ray diffractograms confirm bone apatite lattice is coherent with geological 
hydroxyapatite, Raman and FTIR do not show the necessary OH  bands for bone apatite. 
Bone apatite has a considerable amount of CO3
2  that can directly displace two OH  groups. 
Bone apatite crystallite has been shown to be smaller (from one-tenth to one-hundredth) than 
the enamel crystallite structure; however, it has been observed than the smaller the crystallite 
size and the greater the atomic disorder within the lattice unit, the less energetically favourable 
apatite is to incorporate OH .[81] It is also found that when hydroxyapatite is incorporated in 
vivo it is not remodelled. 
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dissolution; therefore the inorganic component is perhaps more heterogeneous in its 
composition than typically thought.[81]  
The growth of bones, remodelling and repair are controlled by the behaviour of four 
bone cells (Figure 1-8): macrophage like osteoclasts, osteoblasts, osteocytes and 
bone lining cells, which are typically characterised using various markers (Table 1-2).  
 
Figure 1-8. Bone cellular biology. Mesenchymal stem cells (MSCs) and haematopoietic stem 
cells (HSCs) have their origin in bone marrow and their differentiation produces osteoblasts 
and osteoclasts, respectively. Osteoclasts are in charge of bone resorption processes. 
Osteoblasts help bone formation along with lining cells (osteoblastic origin) to cover unlined 
bone surfaces. Osteocytes are differentiated osteoblasts surrounded by mineralised bone 
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ECM and are part of bone regulatory system. Osteocytes maintain communication between 
them and other cells through canaliculi channels.[78]   
 
Osteoclasts are multinucleated cells that originate from HSCs and macrophages.[78] 
The osteoclast differentiation process is triggered/regulated by numerous cytokines 
with M-CSF, RANK(L) and OPG being the most important (described below). 
 M-CSF (macrophage colony-stimulating factor) is secreted by osteoprogenitor 
stem cells. M-CSF stimulates osteoclast proliferation and inhibits apoptosis 
(programmed cell death).  
 RANK(L) (receptor activator of nuclear factor κB ligand) is secreted by 
osteoblasts, osteocytes and stroma cells and induces osteoclastogenesis 
(formation of osteoclasts) when it binds to the RANK(R) (RANK receptor).  
 OPG (osteoprotegerin or osteoclastogenesis inhibitory factor) is secreted by 
osteoblasts, stroma cells and periodontal fibroblasts. OPG binds to RANK(L) 
inhibiting osteoclastogenesis.[82] 
Osteoclasts regulate bone resorption and their malfunction can lead to osteoporosis 
or osteopetrosis (pathological increase in bone mineral content). During bone 
remodelling osteoclasts polarise to form a sealing zone in contact with the bone. They 
then secrete hydrochloric acid (interstitial fluid pH drops to approx. 4.5) and collagen-
degrading proteolytic enzymes (e.g. cathepsin K) that dissolves the ECM.[83]   
Osteoblasts are differentiated from MSCs and osteoblast progenitor stem cells. The 
osteoblasts differentiation process is triggered and regulated by the Wnt signalling 
pathway and key transcription factors (described below).[78]  
 Wnt/β-catenin pathway via Wnt cell surface receptors LRP5 (low-density 
lipoprotein-related protein 5) triggers bone formation and stem cells 
differentiation.   
 DKK1/DKK2 (Dickkopf-related protein 1 and 2) and the glycoprotein sclerostin 
is secreted by osteocytes and downregulates bone formation. 
 BMPs (bone morphogenetic proteins) derives from TGF- β (tumor growth 
factor- β family) and is crucial for bone development, maintenance and 
fracture healing. BMP is necesasary for RUNX2 (Runt-related transcription 
factor 2) dependant induction of osteoblast phenotype.[84] 
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 RUNX2 is involved in a second level of control that regulates the expression 
of several osteoblast specific genes and the expression of OSX (transcription 
factor Sp7/Osterix).  
 OSX controls the expression of COL1A1 (collagen type I alpha 1 gene), the 
pre-osteoblast marker ALP (alkaline phosphatase), BSP (bone sialoprotein), 
OCN (osteocalcin) and OPN (osteopontin).[82]  
Osteoblasts are responsible for depositing bone ECM by secreting type I collagen, 
non-collagenous proteins such as OPN, OCN, BSP and proteoglycan such as decorin 
and biglycan. Subsequently, mineralisation of the ECM takes place in two phases: a 
vesicular phase and a fibrillary phase.[82] The vesicular phase begins with osteoblasts 
secreting matrix vesicles with calcium ions.[85] After that, ALP (a member of the famility 
of zinc metalloprotein enzymes) mediates dephosphorylation of phosphate-containing 
compounds like pyrophosphate a mineralisation inhibitor,[86] and phosphate 
monoesters, which allows phosphate to enter into the matrix vesicles. Fibrillary phase 
takes place when supersaturation of calcium and phosphate ions in the vesicles leads 
to apatite nucleation and rupture of the vesicle with apatite crystals spreading on top 
of the ECM.[83,87]    
Osteocytes are mature osteoblasts trapped in bone ECM occupying lacunae cavities. 
Although osteocytes maintain some similarities with osteoblasts, they are 
characterised by the following:    
 Organelles such as rough endoplasmic reticulum and Golgi apparatus 
decrease in quantify and osteoblasts markers like OCN, BSP and type I 
collagen are down regulated. 
 DMP1 (dentine matrix protein 1) and sclerostin are highly up-regulated 
controlling bone formation by osteoblasts.[78]  
 OPG is also secreted by osteocytes which regulates osteoclasts behaviour.[88]  
Osteocytes maintain cytoplasmic extension through canaliculi channels via gap 
junctions and interstitial fluids that permit osteocytes to ‘‘sense’’ mechanical signals 
and ‘‘communicate’’ between themselves. Osteocytes response to mechano-stimuli 
regulates osteoclast and osteoblast behaviour driving bone structure and density.[78,82]   
Bone lining cells are a class of flat shaped osteoblasts that cover the bone surface. 
Bone lining cells play a crucial role in osteoclast differentiation as they produce OPG. 
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It has been observed that bone lining cells act as a barrier to impede bone 
resorption/formation processes. However, their role is not yet fully understood.[82] 
































































Bone formation occurs during foetal development by two differentiated mechanisms: 
intramembranous ossification and endochondral ossification. Intramembranous 
ossification is typical of flat bones such as calvarian bones.  The process starts with 
layers of MSCs condensing around a vascularised connective tissue to differentiate 
into osteoblasts and osteocytes. As the tissue grows, osteons develop to make 
trabeculae interconnected structures forming woven bone*. Long bones like the femur 
develop through endochondral ossification where MSCs differentiate into 
chondrocytes and secrete a cartilaginous scaffold for bone formation. Cartilaginous 
scaffold is substituted by bone after several re-sorption and bone formation processes 
lead by osteoclasts and osteoblasts, respectively. Moreover, endochondral 
ossification is the natural healing process of bone fractures.[90]  
 
* Woven bone is characterised by a lack of organisation of collagen fibres and is mechanically 
week. 
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Figure 1-9. Bone fractures are stabilised by endochondral ossification where a soft callus is 
vascularised and mineralised. The mineralised callus is reabsorbed and substituted by new 
bone tissue by several bone remodelling cycles.[91]  
 
Bone repair is one of the few postnatal processes that is believed to be truly 
regenerative i.e. the healing process fully recovers pre-injury cellular composition, 
structure and mechanical functions.[91] Skeletal tissue repair initially involves an 
anabolic phase where immune cells remove necrotic tissue and stem cells are 
recruited to form new bone and vascularised tissue at stage 1 (Figure 1-9). Next to 
the fracture site a cartilaginous callus forms generated by chondrocytes. 
Simultaneously to cartilage formation, angiogenesis in the surrounding muscle sheath 
is promoted to construct new blood vessels that will supply the new bone at stage 
2.[92] The healing process progresses with the cartilaginous callus undergoing 
mineralisation by action of osteoblasts, which results in chondrocyte apoptosis and 
termination of the anabolic phase at stage 3.[93] Subsequently, a catabolic phase can 
be identified where cartilage tissue is resorbed. This mineralised tissue is resorbed 
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by osteoclasts with osteoblasts depositing new bone tissue at stage 4. After several 
cycles of osteoblast – osteoclast activity, the bone structure (bone remodelling) is 
completed at stage 5. At this stage, bone morrow tissue is formed with the 
repopulation of haematopoietic and myelopoietic cells. Bone repair terminates with 
final vascular remodelling where the vasculature in the surrounding muscle returns to 
the original level.[94]  
 
Figure 1-10. VEGF roles during bone regeneration. Hypoxia, as a consequence of fractures, 
produces an increase of hypoxia inducible factors (HIFs) that activates the increase of vascular 
endothelial growth factor (VEGF). VEGF stimulates angiogenesis bringing progenitor cells to 
the fracture callus. VEGF also promotes the differentiation of osteoblast cells and the 
production of osteogenic cytokines by endothelial cells.[95] Moreover, VEGF regulates the 
survival of chondrocytes and hypertrophic chondrocytes.[96] 
 
The presence of a functional vascular system is a crucial step for bone formation and 
repair, with blood vessels playing a pivotal role in supplying oxygen, nutrients and 
minerals (calcium and phosphate).[95] Bone repair starts when the damaged area 
becomes hypoxic as a consequence of the rupture of surrounding blood vessels. It 
activates the hypoxia-signalling pathway with the expression of HIF and stimulating 
the production of VEGF, which is secreted by endothelial cells, macrophages, 
fibroblasts, osteoblasts and hypertrophic chondrocytes. VEGF plays several roles in 
bone repair (Figure 1-10): 
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 Stimulates the formation of new blood vessels (angiogenesis), which brings 
skeletal progenitor cells to the fracture.[95] 
 Stimulates endothelial cells to produce osteogenic cytokines such as bone 
morphogenetic proteins (BMPs) that promote progenitor cell differentiation.[97] 
 Controls osteoblast chemotaxis, proliferation and differentiation.[98,99] 
 
Figure 1-11. Illustration of angiogenesis. Angiogenesis is activated as a response to local 
tissue hypoxia, which produces the release of endothelial growth factor i.e. VEGF. VEGF 
triggers the degradation of the ECM and activates endothelial cells, which changed their 
phenotype to “tip and stalk” cells that are in charge of guiding the new blood vessels and 
forming the lumen. The new blood vessels stabilise and increase cell – cell junctions, secreting 
new ECM and repopulating with pericyte cells.[100] 
 
Angiogenesis is the mechanism by which an organism produces new blood vessels. 
The sequence of events (Figure 1-11) starts with sprouting of endothelial cells where 
angiogenic growth factors activate endothelial cells to degrade the ECM, a process 
mediated by matrix metalloproteinases (MMPs).[101] In addition, some endothelial cells 
start to express filopodia and to increase their motility, which is regulated by the Notch 
pathway and VEGF. These endothelial cells with filopodia are also called tip cells and 
act as the leading front of the developing blood vessel.  Tip cells “feel” the ECM for 
attractive cues guiding the sprouts into the stroma. Endothelial cells also change into 
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stalk cells, which are responsible for forming tubes and branches mediated by their 
high proliferation rate and their ability to form a lumen. Finally, the new branches are 
stabilised by deposition of ECM, recruitment of pericyte cells that reduces endothelial 
cell proliferation and increases cell-cell junction formation.[100,101]  
Bone ECM composition along with the bone macrostructure and microstructure 
confers to bone its unique viscoelastic properties. Bone (macro) mechanical 
properties are heterogeneous with large variations between cortical and cancellous 
bone as a consequence of their compact and porous structure, respectively. 
Additionally, important variability in these mechanical properties has been also 
identified between different cancellous bones depending of their function. 
Compressive stress-strain curves of cancellous bone show three different regions: 
 The elastic response (linear region identified by the 0.2% strain offset 
technique).  
 The plastic region (where the structure collapses).  
 Densification (where the trabeculae structure stack on top of each other).  
Cancellous bone presents anisotropic mechanical properties with higher compressive 
strength than tensile strength both in longitudinal and transversal planes. Moreover, 
cancellous bone can resist greater deformation in the longitudinal plane than the 
transversal plane both in terms of compressive and tensile strength.[102] Compressive 
strength and elastic modulus have been shown to be high in cancellous bone with 
large variations between different bones according to their anatomical position and 
needs (Table 1-3). 
 
Table 1-3. Bone mechanical properties depends of their anatomical positions.   







Human tibia[102] Compression 27 211 
Femoral head[103] Compression - 1700 - 6900 
Calcaneus[104]  Compression 3.89 368 
 
A 3D environment that emulates the bone ECM is essential for bone regeneration as 
the majority of bone physiological phenomena are irreproducible in 2D substrates.[89] 
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A successful functional biomaterial for skeletal repair must provide the right stimuli 
that guide the formation of integrated functional bone tissue. Moreover, an ideal 
scaffold must also stimulate angiogenesis as it improves tissue viability and promotes 
osteogenesis.  
Historically, bone tissue substitutes have tried to match the physical and mechanical 
properties of bone tissue (e.g. Young’s modulus 0.5 – 3 GPa for cancellous bone). 
However, it has led to aberrant cell behaviour in the host tissue with excessive 
ossification or bone resorption.[105] Current trends with polymeric biomaterials are in 
the direction of enhancing endochondral bone regeneration where substrates try to 
mimic the properties of cartilaginous bone, e.g. young’s modulus approximately 100 
kPa, and ECM gradients. ECM is a heterogenous microenvironment that can display 
several gradients such as cell density, chemical cues or composition.[106] For example, 
in a previous report the fate of myeloid progenitor cells was controlled in vitro using 
polyacrylamide substrates with a stiffness comparable to collagenous bone (~ 44 kPa) 
and different proteins that mimic the composition of bone marrow. Fibronectin 
compositions that resembled the endosteal region maintained primitive myeloid 
progenitors whereas laminin compositions that resembled the vascular region 
promoted differentiation to an erythroid phenotype.[107]  
Micro-porosity (pore size < 10 µm) and macro-porosity (pores > 50 µm) have a strong 
impact in osteogenesis. Micro-porosity results in larger surface areas that contributes 
to higher adsorption of bone formation proteins.[108] High porosity results in an 
increase in cell proliferation due to increased available space/surface and enhanced 
nutrient diffusion. For example, it was identified that MC3T3 cell proliferation was 
enhanced in scaffolds made of poly(propylene fumarate) with pores of 350 µm 
whereas pores of 500 µm inhibited their proliferation[109]. On the other hand, lower 
pore sizes have been shown to improve osteogenic expression (upregulation of ALP 
and OCN) as a consequence of suppressing proliferation and increasing cell 
aggregation.[110] Generally, optimum bone regeneration is considered to happen in 
pores that resemble the size of trabeculae (100 µm to 400 µm) as demonstrated by 
the stimulation of proliferation and osteogenesis (100 µm to 200 µm) and 
angiogenesis (200 µm to 400 µm).[111–113] An interesting approach explored is the co-
culture of endothelial and osteoblast cells in a starch-based scaffold, which resulted 
in the spontaneous formation of blood vessels in the scaffolds.[114] However, little 
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evidence was found to support that these pre-made vascular-like structures could 
connect to the host vasculature when implanted in vivo. 
Overall, an ideal scaffold for bone regeneration would promote osteoinduction, 
osteoconduction and osseointegration of the functional 3D implant, permitting 
differentiation of stem cells into bone-forming cells, allowing bone growth into the 
implant with direct contact between the artificial tissue and the living bone.[115] To do 
so, a 3D scaffold must: 
 Support cell colonisation, proliferation and differentiation. 
 Be biocompatible and elicit minimal immune response.  
 Provide appropriate surface chemistry to stimulate production and remodelling 
equilibrium of the ECM.   
 Provide appropriate stiffness and mechanical strength. 
 Have an interconnected pore structure with large pores, to promote 
osteogenesis (100 µm to 200 µm) and angiogenesis (200 µm to 400 µm) 
To achieve the above, polymeric 3D biomaterials have attracted increasing attention 
as artificial bone ECM mimetics because of their remarkable physical and chemical 
tunabilities to match bone characteristics along with their biocompatibilities.[116]  
                                                                                                                                  
1.4 3D polymer scaffolds for skeletal repair 
 
In the design of graft substitutes, 3D scaffold structure and composition play a pivotal 
role in determining cell behaviour through surface chemistry and physical 
properties.[117] Previously, the Bradley group in collaboration with Oreffo’s group have 
successfully explored a number of 3D scaffolds that expand the current space of 
functional biomaterials for bone repair applications including polyurethanes[118] and 
hydrogels[119] as well as binary[120] and ternary blends[121] of commercial polymers.   
The first approach used polyurethanes and STRO-1(+)* skeletal progenitor cells, 
which have the ability to differentiate into multiple musculoskeletal cells promoting 
bone healing.[118] Current approaches for cell enrichment involve time-consuming 
approaches such as magnetic-activated cell sorting (MACS) and fluorescently-
 
*Antibody used as a mesenchymal stem cells marker.  
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activated cell sorting (FACS) both based on immunoselection. As an alternative to 
these approaches, a microarray constituted of 120 polyurethanes was interrogated 
with an enriched STRO-1(+) population isolated from adult bone marrow tissue with 
four polyurethanes selected as a result of their high STRO-1(+) affinity (Table 1-4). 
These four ‘‘hit’’ polymers were capable of supporting STRO-1(+) cell binding from a 
heterogeneous population of bone marrow cells where STRO-1(+) cells constituted 
11% of the population. Polymer selectivity was further studied by using MG-63 and 
SAOS-2 cells, osteoblast-like cells with robust STRO-1 expression. Both of the cell 
lines being unable to bind to the four candidate polymers. Differentiation potential of 
STRO-1(+) cells cultured on the top polyurethane showed invariance of the 
osteogenic gene markers RUNX2, ALP and COL1A1 after 25 days in basal medium 
and an increase of genetic expression in osteogenic medium. 
 
Table 1-4. ‘‘Hit’ polyurethanes discovered for STRO-1(+) binding.[118] 
Polyurethane Polyol Diisocyanate Chain extender 
PU-16 PEG (2000 Da) MDI - 
PU-17 PEG (900 Da) MDI - 
PU-61 PEG (2000 Da) MDI 1,4-butanediol 
PU-71 PEG (2000 Da) DIB 1,4-butanediol 
 
Although polyurethanes showed their capability to attach skeletal progenitor stem 
cells, an ideal polymeric scaffold for bone repair also has to promote cell differentiation 
which these polyurethanes were unable to do without the support of differentiation 
additives. To address this issue, binary blends consisting of one polymer with good 
mechanical strength and another polymer with suitable surface chemistry for cell 
compatibility were engineered and high-throughput screened to identify substrates 
that successfully promoted skeletal stem cells differentiation.[120] Seven commercially 
available polymers (Table 1-5) were blended to obtain 135 different substrates. 
STRO-1(+) cells, foetal skeletal cells and the osteosarcoma cells line MG-63 and 
SAOS-2 were used to screen these polymer blends. PLLA/PCL (20:80) exhibited 
remarkable competence binding all these skeletal cell populations. Additionally, 3D 
porous scaffolds obtained by freeze-drying were used in vitro to validate osteogenic 
differentiation of skeletal progenitors STRO-1(+) into mature osteoblasts. Expression 
of ALP along with collagenous and non-collagenous bone matrix proteins i.e. COL I, 
BSP, OPN, osteonectin and OCN were used as differentiation markers. However, 
osteogenic induction factors such as ascorbate, dexamethasone and human bone 
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morphogenic protein (BMP-2) were also needed to initiate differentiation. A femur 
defect model in mice was used to study in vivo responses to a PLLA/PCL (20:80) 
scaffold, which showed bone formation and substantial cell infiltration in the region of 
the defect by micro-CT with histology confirming the scaffold’s osteoinduction ability.   
 
Table 1-5. Commercially available polymers used to generate 135 binary blends for high-
throughput screening.[120] 
Polymer Abbreviation Mw (kDa) 
Poly(ethylenimine) PEI 750 
Chitosan CS 300 
Poly-L-lactic acid PLLA 152 
Poly-ε-caprolactone PCL 120 
Poly(ethylene oxide) PEO 100 
Poly(vinyl acetate) PVAc 260 
Poly-2-hydroxyethyl methacrylate PHEMA 300 
 
This successful attempt in small animals led to the study of the osteogenic potential 
of the PLLA/PCL (20:80) 3D porous scaffold in large animals (sheep).[122] The 
osteogenic effect of a scaffold seeded with ovine skeletal stem cells (isolated 2 weeks 
before surgery) and a scaffold without cells was studied in a long bone segmental 
defect with an empty defect used as control. Micro-CT revealed modest new calcified 
bone formation (compared to the control) after 12 weeks post-implantation with 
histological analysis showed regenerative tissue forming around the scaffolds. 
However, new tissue was not observed within the central scaffold area indicating the 
absence of large and interconnected pores that were necessary to allow cell 
penetration.  
The increasing demand for recapitulating properties of the ECM also involved the 
design of 3D hydrogels due to their ability to incorporate high water content. One 
approach explored the biocompatibility of chitosan – poly(ethyleneimine) hydrogels 
(Figure 1-12), which was achieved by mixing an acid solution (1% aqueous acetic 
acid, pH ≈ 4) of chitosan partially hydrolysed (250 kDa) and poly(ethylenimine) (300 
kDa, 10% in water, pH ≈ 11) in various molar ratios.[119] 40:60 CS/PEI showed an 
interconnected microporous morphology and enabled 3D cell culture by simply mixing 
cells with the hydrogel before full gelation. Human skeletal cells isolated from 
cartilaginous foetal femora presented spherical morphology with expression of PCNA 
(proliferating cell nuclear antigen) and chondrogenic markers, COL2A1 and aggrecan, 
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when cells were cultured in the 3D hydrogels for 28 days. In contrast, fibroblastic 
morphology with high levels of type I collagen expression and low levels of 
chondrogenic markers were observed in cells cultured in 2D tissue culture. However, 
TGF-β3 supplementation was essential to stimulate the differentiation cascade.    
 
Figure 1-12. Structure of chitosan (CS) and poly(ethylenimine) (PEI) used to obtain the 3D 
hydrogels.[119] 
 
Despite hydrogels having shown potential in 3D cell constructions, skeletal repair 
applications demand stiffer substrates capable of withstanding physiological loading. 
Moreover, a highly porous 3D network that enables vascularisation, cellular activity, 
and nutrient exchange is also crucial in designing effective biocompatible scaffolds. 
With this in mind, ternary blends of the commercial polymers previously explored 
(Table 1-5) were screened to study their ability to bind skeletal cells and subsequently 
used to obtain libraries of 3D porous scaffolds.[121] A microarray with 19 ternary 
polymer blends were contact printed and high-throughput screened with skeletal 
progenitor STRO-1(+) cells, foetal skeletal cells, SAOS-2 cells and MG-63 cells. 
Following microarray analysis, four polymers (Table 1-6) with high STRO-1 (+) binding 
were chosen to obtain 3D porous scaffolds. 3D scaffolds were fabricated by mixing 
the polymers in the appropriate ratio, flash-freezing in liquid nitrogen and subsequent 
solvent evaporation using freeze-drying. The porous polymer scaffold composed of 
CS/PVAc/PLLA (50/25/25) showed interconnected pores sized between 5 µm to 10 
µm in cross-section with channels between 50 µm to 600 µm, which was selected for 
further in vitro and in vivo studies because of its bone-like structure. The in vitro 
evaluation of skeletal stem cells STRO-1(+) in this scaffolds showed ALP expression 
although osteogenic culture conditions with BMP-2, ascorbate and dexamethasone 
were needed to promote differentiation to mature osteoblasts, confirmed by the 
expression of type I collagen, OPN, BSP and osteonectin after 28 days culture. Murine 
femoral defect models were used to evaluate the in vivo response of the selected 3D 
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scaffold with high resolution micro-CT showing more bone formation in defects with 
scaffold alone and scaffold with STRO-1(+) cells than the control without scaffold. 
Histological analysis demonstrated that the scaffold alone was able to generate 
woven bone within the osteotomy gap whereas scaffold with STRO-1(+) cells 
presented mature chondrocyte development prior to endochondral ossification. 
Additionally, endothelial tissue infiltration was identified by immunohistological 
analysis for the scaffolds with and without cells. However, vascularised tissue in the 
scaffolds was not observed.  
 
Table 1-6. Ternary blends with high binding of STRO-1(+) cells identified using microarray 
technology.[121]  






The design of functional 3D biomaterials involves a material selection step and a 3D 
fabrication step inspired by the tissue of interest. For example, bone tissues have 
tensile and compressive stress in the gigapascal range. Aiming to match these 
mechanical properties, a solvent, catalyst and photoinitiator-free polyurethane UV-
crosslinkable was synthesised with mechanical properties tuned by UV exposure time 
(Figure 1-13).[123] In addition to biocompatibility, the polymer showed an extraordinary 
tensile (0.6-2.7 GPa) and compressive (1.5-3.0 GPa) moduli plus the ability to 
withstand 10,000 cycles of physiological tensile loading.  
 
Figure 1-13. UV-crosslinkable polyurethane polymer was synthesised in a 1:0.5:1.5 molar 
ratio.[123] 
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The synergistic interplay between inorganic compounds and biocompatible polymers 
have been explored in order to further mimic some of the characteristic of the bone 
extracellular matrix, which is composed of apatite crystals embedded within type I 
collagen fibres. One example that illustrated the potential of these polymer 
composites was the calcium phosphate polymer induced liquid-precursor (PILP) to 
treat bone affected by osteoporosis, a disease characterised by the loss of mineral 
mass in the bone tissues.[124] Calcium phosphate PILP was obtained by mixing 
polyaspartic acid and polyacrylic acid, negatively charged biocompatible polymers, 
with high concentration of CaCl2 and Na2HPO4. Here, calcium phosphate PILP ability 
to form mineralised structures were demonstrated in vitro and in vivo with the large 
molecular weight of polyacrylic acid (450 kDa) playing a crucial role in the stabilisation 
of the necessary therapeutic concentration of CaHPO4. In another attempt to mimic 
human bone composition, gelatin methacrylate was UV photo-crosslinked with 
methacrylic anhydride to encapsulate hydroxyapatite (HA) and whitlockite (WH) 
nanoparticles, which is the major human bone inorganic phase.[125] The optimisation 
of the HA/WH ratio as well as scaffold stiffness (polymerisation time) proved the 
interdependent effect of these properties in the fabrication of successful scaffolds.   
Multi-material and multi-structure scaffolds have been developed as a consequence 
of the heterogeneity of human bone microenvironment. Examples of these scaffolds 
were obtained by constructing poly(limonene thioether)/poly(glycerol sebacate) 
scaffolds with primary and secondary porous structures.[126] The scaffolds composition 
was chosen to meet design criteria such as slow biodegradability and elastomeric 
mechanical properties and the double porous structure aimed at producing high cell 
infiltration and attachment in addition to promoting oxygen and nutrient diffusion. The 
double porous structure was achieved using a silicon wafer mould etched to obtain 
microchannels larger than 500 µm as a primary porous structure and poly(methyl 
methacrylate) spheres (5-20 µm) that served as a porogen for the secondary porous 
structure. In another example, three-layer scaffolds that tried to imitate the joint 
between bone and cartilage were obtained via thermally-induced phase separation 
with poly(lactic acid) and sulfate/phosphate cellulose nanocrystals.[127] The approach 
showed success with high biocompatibility with chondrocyte cultures and differences 
in vivo tissue infiltration that resembled human cartilage. However, scaffolds of both 
examples needed to be assembled manually layer-by-layer.  
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Vascularisation regulates the growth, differentiation and reconstruction of bone tissue 
and its surrounding soft tissue. Composition of 3D biomaterials play a crucial role to 
stimulate vascularisation and bone tissue regeneration.[128] For example, a 3D 
scaffolds with potential for therapeutic bone repair was made of polyvinyl alcohol 
(PVA), PCL and hydroxyapatite based bioceramic (HAB) with electrospinning. PVA-
PCL-HBA scaffolds showed growth of stromal stem cells, in vitro osteogenic 
differentiation and in vivo vascularised bone formation with the HBA degradation 
products stimulating the production of VEGF.[129] A biodegradable scaffold composed 
of polydiolcitrate-gelatin (PPCNG) was fabricated to release cytokines such as BMP-
9 in situ, one of the most potent known osteogenic differentiation factors.[130] The 
histological analysis of the subcutaneous injection of PPCNG with MSCs in mice 
showed the gel resorbed over time, the increase of VEGF expression and the 
formation of more mature trabecular bone-like structures.  
Cell-based pre-vascularised scaffolds showed the potential to repair large bone 
defects as an alternative to growth factors embedded in polymer scaffolds.[131] MSCs 
and human umbilical vein endothelial cells (HUVECs) were cultured independently to 
obtain cell sheets and combined with β-TCP scaffolds. In vitro results indicated that 
seeded HUVECs rearranged the ECM produced by MSCs, which led to rapid 
formation of functional blood vessels in vivo. Moreover, in vivo pre-vascularised 
scaffolds gained attention inspired by autografts, present gold standard for repairing 
long bones. For example, β-TCP scaffolds with MSCs and pre-vascularised with 
insertions of femoral vascular bundle showed increasing expression of VEGF.[132] 
Despite the huge amount of resources* used to develop successful 3D biomaterials 
for skeletal repair application, there are consistent limitations of current 3D scaffolds 
that impede clinical applications (Table 1-7).[13] Although long-term cell viability and 
biocompatibility has been proven in vitro and in vivo, cell functionality persists as a 
challenge. Growth factors and biochemical clues like BMPs have been used to 
overcome these challenges, however, the high concentrations (mg/ml) required, 
compared to their physiological concentration (ng/ml), can lead to adverse effect such 
as carcinogenesis and aberrant bone formation. In addition, efficient nutrient and 
waste removal has yet to be efficient enough to allow sustained tissue growth. 
Although angiogenesis occurs spontaneously upon scaffold implantation it is triggered 
 
* 60% of the publications with the term “polymer tissue regeneration” are focused on bone 
regeneration (ISI Web of Knowledge). 
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by inflammation, resulting in poor vascularisation of scaffolds and tissue penetration. 
These are significant and commonly observed limitation. Moreover, a full 
understanding of scaffold microstructure/mechanical properties and cell behaviour 
remains incomplete, which hinders the cell selection and the scaffold design. 
Furthermore, the translation of academic research in the absence of automated and 
controlled production, and the lack of methods to evaluate potential 3D materials adds 
real challenges to their clinical development and application.  
 
Table 1-7. Advantages and disadvantages of different 3D polymer for skeletal repair.  
Scaffolds Pros Cons 
Polyurethanes 
Isolation and maintenance of 
skeletal progenitor stem cells. 
Good mechanical properties. 
Poor osteogenic and 
angiogenic properties.  
Deficient 3D microstructure. 
Polyacrylates 
In vitro and in vivo osteogenic 
and angiogenic properties. 
Tailorability and good 
mechanical properties. 
Limited long-term osteogenic 
properties. 
Deficient 3D microstructure 
Hydrogels 
Recapitulation of ECM 
properties.  
Poor osteogenic and 
mechanical properties. 
Deficient 3D microstructure. 
Composites 
Good osteogenic and 
angiogenic properties. 
Limited long-term osteogenic 
properties. 
Poor mechanical properties. 
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2. Aims of the thesis 
 
In the design of 3D biomaterials, scaffold properties such as chemical composition, 
stiffness, wettability, porosity, pore size or pore distribution all affect cell fate. Given 
the impossibility of examining all of these variables simultaneously, the majority of 
current methods try to simplify the analysis studying the effect of one variable at a 
time on cell behaviour. However, this reductionist approach does not take into account 
the importance of interplay between these processes. 
This thesis aimed to develop a novel approach to generate an array of 3D polymer 
scaffolds that could be exploited in the identification of yet undiscovered biomaterials 
for biomedical applications. The premise was that this array would enable the high-
throughput analysis of the effect of multiple scaffold features such as composition, 
porosity, pore size and pore distribution on cellular fate, which would enhance the 
identification of successful functional biomaterials. Coupled with the classical 2D 
polymer microarray technology, this approach aimed to reduce the gap between the 
in vitro identification of a biomaterial and its subsequent in vivo application.  
To address the above, arrays of 3D scaffolds were fabricated via freeze-casting and 
UV photo-polymerisation as a convenient, yet powerful method to tune scaffold 
composition and 3D microstructure. Polyacrylates were selected as substrates due to 
their versatility, proven biocompatibility and their ability to support endothelial cells 
(ECs).[29] After establishing this new method, the applicability of the approach was 
demonstrated in the selection of 3D scaffolds for bone repair.  
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3. Material and methods 
3.1 Instrumentation 
 
 Plasma generator Zepto O2 (Diener Electronic GmbH, Germany). 
 Microarray printer SciFLEXARRAYER S5 (Scienion, Germany). 
 Fridge-Freezer Combi 263L (Lec Medical, UK). 
 Ultraviolet cross-linker CL-1000 (UVP, USA). 
 Freeze-dryer BenchTop Pro with Omnitronics (SP SCIENTIFIC, UK). 
 Fluorescence microscope Nikon Ni-U eclipse equipped with an automated 
stage and Pathfinder™ Wellscan software (IMSTAR S.A., France). 
 Biosafety cabinet HERAsafe KS 18 class II (Heraeus, Germany). 
 Incubator HERAcell 150 (Heraeus, Germany). 
 Microscope Zeiss LSM880 Airscan equipped with a 20X NA 0.8 air objective 
(Zeiss, Germany).  
 Scanning electron microscopy Hitachi S-4700 (HITACHI, Japan). 
 Micro computed tomography Skyscan 1172 (Bruker, Belgium). 
 Microplate reader GloMax® Explorer (Promega, USA). 
 In vivo optical imaging system IVIS Lumina S5 (PerkinElmer, USA).  
 Imaging System Odyssey® CLx (LI-COR, USA). 
 Universal mechanical testing system Instron (model 3367) equipped with a 50 
N load cell for compression and the software Bluehill 3 (INSTRON®, USA). 
 Histology slide scanner NanoZoomer XR (Hamamatsu, Japan). 
 Thermometer testo 905i (Testo, Germany). 
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3.2 Materials 
 
2-(Methylthio)ethyl methacrylate (MTEMA), butyl methacrylate (BMA), isobornyl 
acrylate (IBA), ethylene glycol dicyclopentenyl ether acrylate (EGDPEA), 1,6-
hexanediol diacrylate (HDOBA) and 2-hydroxy-2-methylpropiophenone (PI), pepsin 
from porcine gastric mucosa (Roche), Alizarin Red, Sirius red S, picric acid solution 
(1.3% in H2O), phosphatase substrate (P4744), 1.5 M alkaline buffer solution 
(A9226), Cellytic M, Igepal CA-630, p-nitrophenol (N7660), dexamethasone, β-
glycerophosphate disodium salt hydrate, molybdophosphoric acid (221856), Sirius 
red F3B (365548), Orange G (O3756), Light green SF (L5382),  Dulbecco's modified 
Eagle medium (DMEM), 2-phospho-L-ascorbic acid disodium and flat-bottom 
polypropylene 96-well plates (Greiner Bio-ONE)  were purchased from Sigma-Aldrich. 
4-tert-butylcyclohexyl acrylate (BHA) was obtained from Tokyo Chemical Industry.  
Alpha MEM eagle with UGln1 and nucleosides and penicillin/streptomycin/fungizone 
10K/10K/25 µg were purchased from Lonza. Fetal bovine serum, L-glutamine, DAPI 
(62248), Quant-iT™ PicoGreen™ dsDNA assay (Life Technologies), alamarBlue™ 
(Thermo Scientific), Live/Dead Cell imaging assay (R37601, Invitrogen) and Alexa 
Fluor™ 568 phalloidin (A12380, Invitrogen) were purchased from Thermo Fisher 
Scientific. RA Lamb Waxes (12624077, Thermo Scientific), Histo-Clear™, DPX 
mounting medium (10050080), Weigert’s Hematoxylin (10181710) and Alcian blue 
8GX (40046-0100, ACROS Organics) were acquired from Fisher Scientific. Herring 
sperm DNA (D1811) was purchased from Promega. Vitamin D3 was obtained from 
Cayman Chemical Company.  
Anti-Alkaline Phosphatase (ab65834), Anti-Osteopontin antibody (ab8448), Anti-
Collagen I antibody (ab34710), Goat Anti-Rabbit IgG Alexa Fluor® 647 (ab150079), 
BCA assay kit (ab207002) and Human Pro-collagen I SimpleSep ELISA® kit 
(ab210966) were purchased from Abcam.  
OsteoSense® 800 Fluorescent Imaging Agent was acquired from PerkinElmer. 
IRDye® 800CW BoneTag™ Optical Probe was purchased from LI-COR. 
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3.3 Cell characteristics and culture methods 
 
SAOS-2 or HTB-85 was purchased from ATCC and it is a human bone osteosarcoma 
adherent cell line with epithelial morphology. MG-63 or CRL-1427 was purchased 
from ATCC and it is a human bone osteosarcoma adherent cell line with fibroblast 
morphology. SAOS-2 and MG-63 were expanded to confluence in DMEM medium 
supplemented with foetal bovine serum (FBS, 10%), L-glutamine (4 mM) and 
antibiotics (penicillin/streptomycin, 100 units/mL) and used within 10 passages. 
FBMSCs, provided by Dr Stefanie Inglis and Ms Suzanne Renz from the University of 
Southampton, were isolated as per the ethical approval obtained from Southampton 
& South West Hampshire Local Research Ethics Committee (LREC296/100). 
FBMSCs were used within 4 passages. FBMSCs were expanded to confluence in 
supplemented α-MEM medium with FBS (10%) and penicillin/streptomycin/fungizone 
(100 units/mL), known as basal medium. Osteogenic differentiation medium was 
composed of α-MEM medium supplemented with FBS (10%), 2-phospho-L-ascorbic 
acid (50 µg/mL), calcitriol (10 nM) and penicillin/streptomycin/fungizone (100 
units/mL).[133] 
 
3.4 Microarrays  
3.4.1 Glass slide silanisation and mask fabrication 
 
Superfrost™ glass slides (ThermoFisher) were cleaned by washing with HPLC grade 
water and with acetone and dried in anoven at 110 °C for 5 min. O2-plasma treatment 
(Electronic diener ZEPTO at 50 NL/h O2, 10 minutes, 30 W) was then performed. 
A previously developed method was adapted to generate a fluorous mask on the 
surface of the glass slide (Figure 3-1).[30]  To do so, 10 drops (≈ 3.50 nL in total) of an 
aqueous solution of sucrose (20% w/v) was jetted on top of the cleaned glass slides 
to obtain the microarray pattern (540 polymer features were printed in an array of 12 
columns and 45 rows). Inkjet printing was carried out using a microarray printer 
(sciFLEXARRAYER S5, Scienion, Germany) equipped with a PDC 80 piezoelectric 
capillary with a 50 µm nozzle aperture.  
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Figure 3-1. Cleaned glass slides (exposed hydroxyl groups) were patterned (A) with sucrose 
(20% aqueous solution, green sphere). “Fluorosilane” (1) was used to functionalise the 
remaining areas (B). The sucrose mask was removed with water (C) to expose the hydroxyl 
groups, which were functionalised (D) with an “acrylatesilane” (2).  
 
“Fluorosilane” (tridecafluoro-1,1,2,2-(tetrahydrooctyl)dimethyl-chlorosilane) was used 
to functionalise the unprotected surface of the glass slides (where sugar was not 
printed) to generate a fluorous and cytophobic surface. The glass slides were placed 
in a high-density polypropylene plastic box (22×11×13 cm) and 10 µL of fluorosilane 
was dropped around the area printed with sucrose, sealed and reacted for 24 hours. 
Slides were washed with water (3 x 10 mL) and ethanol (3 x 10 mL) and dried at room 
temperature to remove excess reagent and the sucrose mask.  
Once the slides were dried, 5 µL of the “acrylsilane” (3-(trimethoxysilyl)-propyl 
methacrylate) was spread on top of the glass slide surface with a pipette tip and 
reacted for 48 hours with the “acrylsilane” pooling in the “masked” features. Slides 
were rinsed with acetone, dried at room temperature and kept in a dry atmosphere.   
 
3.4.2 Fabrication of microarrays and cell seeding on the 
microarrays 
 
Microarrays constituted of 540 polymer features (180 acrylate polymers with 3 
replicates) were fabricated by inkjet printing. Solutions of the monomers, UV photo-
initiator and cross-linker were prepared in NMP (A for full list of compositions). In-situ 
polymerisation was achieved by depositing 100 drops (≈ 35 nL in total) of the solutions 
(72 drops of the monomers, 18 drops of the cross-linker and 10 drops of the 
photoinitiator) on top of the masked glass slide. Photo-polymerisation was carried out 
using a UV cross-linker (CL-1000L 8W, λ = 365 nm) for 30 min. The printing procedure 
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was divided into 5 sections to avoid the slides drying out before polymerisation. NMP 
was removed under vacuum (40 °C, overnight). Subsequently, microarrays were 
washed with water and ethanol (1:1, 1 h) and water (24 h) before being dried at room 
temperature.  
Microarrays were sterilised under UV light (1 h) and washed with PBS (1 h) before 
seeding. SAOS-2 and MG-63 cells were expanded, and cell seeding was carried out 
with a suspension of SAOS-2 and MG-63 cells (1,000,000 cells/microarray in 5 mL of 
complete medium) in 4-well tissue culture plates at 37 °C and 5% CO2 in a humidified 
atmosphere.  
After 2 days, microarrays were washed with PBS (2 cycles) and cells were fixed with 
paraformaldehyde (4% PFA) for 5 min. Subsequently, removing excess fixative 
solution, cell nuclei were stained with a solution of DAPI (5 µg/mL) in PBS for 10 min 
(4 mL/microarray). A Nikon Ni-U eclipse fluorescence microscope equipped with an 
automated stage and the software Pathfinder Wellscan (IMSTAR) was used to 
acquire fluorescence and bright field images. Cell attachment was assessed by 
counting the number of cells on each polymer feature and measuring the polymer 
area with the image processing software ImageJ-Fiji. Results are presented as the 
number of cells per mm2 of the polymer.  
 
3.5 Fabrication of 3D polymer scaffolds and 
characterisation 
3.5.1 Fabrication of arrays and scaled-up scaffolds  
 
The fabrication of arrays of 3D polymer scaffolds was carried out through photo-
polymerisation with various porogenic solutions at sub-zero temperatures in 
polypropylene 96-well plates. The polymerisation mixtures (Table 4-1 and Table 5-1) 
were composed of the photo-initiator (2-hydroxy-2-methylpropiophenone, 10 mol %), 
the cross-linker (1,6-hexanediol diacrylate, 18 mol %) and the appropriate 
combinations of acrylate monomers (72 mol %). The polymerisation mixtures with 
DMSO were placed in polypropylene plates (80 µL/well) and cooled (5 °C for 16 h and 
-20 °C for 4 h). The arrays were photo-polymerised (UV cross-linker CL-1000L 8W, λ 
= 365 nm, 30 min) on top of a dry ice bath (Figure 4-5). Following polymerisation, the 
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scaffolds were washed with water and ethanol (1:1, 3 days) and water (4 days) at 37 
°C before freeze-drying (2 days). 
The method described above was modified to obtain larger 3D polymer scaffolds (≈ 
12 mm length × ≈ 12 mm width × ≈ 1 mm height) with the porogenic solutions (300 
µL/scaffold) cooled (5 °C for 16 hours and -20 °C for 4 hours) and UV-cured for 60 
min in square polystyrene moulds (12 mm length × 12 mm width × 7 mm height). After 
polymerisation, scaffolds were removed from the mould and washed with water and 
ethanol (1:1, 4 days) and water (5 days) at 37 °C before freeze-drying (2 days). 
 
3.5.2 Structural analysis using SEM 
 
Polypropylene plates were cut in sections of 3×6 wells before proceeding with the 
array fabrication. The sections were coated with gold/palladium alloy (3:2) using a 
sputter coater (30 mA, 0.75 Torr). A Hitachi S-4700 was employed to perform the 
image acquisition and the analysis was carried out using ImageJ-Fiji. SEM images 
were segmented using the thresholding plugin and filtered to separate the porous 
structure from the polymer. Subsequently the porous segmented areas were 
quantified (analyse particles plugin) using the pore descriptors porosity (%) and 
Feret’s diameter (the largest distance between the edge of the pores).  
 
3.5.3 Structural analysis using micro-CT 
 
Sections of the array of the 3D polymer scaffolds (2×2 wells) were stacked (3 rows 
high) to obtain a cuboid of 12 polymer scaffolds that was secured with adhesive tape 
and enclosed into a polystyrene box (5 cm diameter × 7 cm high), preventing 
movement of the sample during the scan. The sample was placed in a Skyscan 1172 
desktop micro-CT (Bruker, Kontich, Belgium) and scanned through 360° using a step 
of 0.48° between exposures. Micro-CT parameters were 34 kV source voltage, 210 
µA source current with an exposure time of 1.8 s to obtain a voxel resolution of 5.94 
µm. Noise was reduced using the average of four frames at each position.  
Data was reconstructed using Skyscan NRecon v1.6.9 (Bruker, Kontich, Belgium) 
applying a reconstruction thresholding window of 0.00 to 0.05 in attenuation 
coefficient with no beam hardening correction. Volume of interests (VOI) were 
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selected in each reconstructed micro-CT scans and Fiji-Bonej was used to analyse 
the porosity of the segmented VOIs.[134]  A circular region of interest of 4.75 mm 
diameter was extended by 0.62 mm (± 0.19 SD) through the structure to define the 
VOI, binarised (thresholding range of 52 – 255) and speckles removed (< 4 pixels). 
Morphological analysis of the thickness and connectivity density of the polymer 
structure in addition to pore diameter and open porosity were carried out using CTAn 
v1.16.4 (Bruker, Kontich, Belgium).  
 
3.5.4 Mechanical characterisation of the 3D polymer scaffolds 
 
Scaled-up 3D scaffolds (≈ 12 mm length × ≈ 12 mm width × ≈ 1 mm height) were re-
hydrated with PBS before mechanical characterisation. Indentation was carried out 
using an Instron testing system (model 3367) equipped with a 50 N load cell for 
compression and a flat cylindrical (ø = 1 mm) indenter (made in house). The software 
Bluehill 3 (INSTRON®, USA) controlled the equipment and digital Vernier callipers 
were used to measure the height of the samples (≈ 1.7 mm). Compression speed with 
a strain rate of 5% per minute for 20% of the strain was used.   
The indentation moduli were calculated between 0% and 5%, 5% and 10%, 10% and 
15%, and 15% and 20% strain percentage using a linear model for semi-infinite media 
(diameter sample to diameter indenter ≥ 3) as previously described.[135–137] The 
relaxation load (%) was described as percentage of load redaction after 1 min and 5 
min of relaxation.[138,139] 
 
3.5.5 Porosity and density of the 3D polymer scaffolds  
 
Porosity on the 96 well plate was calculated as the ratio between the volume of solvent 
in the pores (VP) and total volume of the scaffold (VT) with volumes determined by 
weighting the solvent (DMSO). The volume of solvent in the pores was firstly 
calculated. To do so, 200 µl of DMSO (V0) was added to the 3D polymers and empty 
wells (96-well plate, control). After 4 hours (to ensure complete filling of the pores), 
excess DMSO was removed and weighed. The volume of the pores (Vp= (M1- M2)/ 
ρDMSO) was calculated as the difference between the mass of DMSO in the empty 
wells (M1) and the mass of DMSO recovered from the well with the scaffolds (M2). 
Subsequently, the total volume of the scaffolds (VT= (M3- M4)/ ρDMSO) was measured 
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as the subtraction between the mass of DMSO needed to completely fill an empty 
well (M3) and the mass of solvent needed to entirely fill a well with a 3D porous 
polymer (M4). 
The method described above was modified to measure the density and porosity of 
the scaled-up scaffolds (≈ 12 mm length × ≈ 12 mm width × ≈ 1 mm height). Density 
was determined as the ratio between the weight of a dried scaffold and the volume 
that the scaffold displaced in a measuring cylinder with ethanol. The porosity was 
calculated as the ratio between the volume of ethanol in the pores and the total 
volume of the scaffold.  
 
3.6 Characterisation of cells 
3.6.1 Cell seeding on the arrays and 3D polymer scaffolds 
 
The arrays of 3D polymer scaffolds were UV sterilised overnight and pre-conditioned 
with 50 µL of culture medium for 1 h before cell seeding.  
SAOS-2 and MG-63 cells were seeded on the arrays in supplemented DMEM medium 
(20,000 cells/well in 150 µL). FBMSCs were expanded to confluency and seeded 
(10,000 cells/well in 150 µL) on the arrays in supplemented α-MEM medium or 
osteogenic differentiation medium. 
The 3D polymer scaffolds (≈ 12 mm length × ≈ 12 mm width × ≈ 1 mm height) were 
UV sterilised overnight and placed into inserts (Transwell® Ø = 12 mm, Corning®). 
FBMSCs were seeded in basal medium (40,000 cells/scaffold in 110 µL) forming a 
drop in the centre of the scaffold. Scaffolds were incubated for 45 min allowing cell 
attachment before adding 1 mL of medium to cover completely the scaffold.  
After seeding, the arrays and scaffolds were kept in a humidified atmosphere at 37 
°C and 5% CO2 with the media changed every two days.  
 
3.6.2 Cell viability and proliferation on the arrays 
 
The number of cells along with their metabolic activity was assessed using so-called 
alamarBlue™ (also called Alamar Blue or resazurin). At the appropriate time, the 
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culture medium was removed to add 100 µL of Alamar Blue in medium (10% v/v). 
Arrays were kept in the incubation chamber (dark) for 4 hours (37 °C, 5% CO2). 
Thereafter, the supernatant was collected, and fluorescence intensity was recorded 
using a microplate reader (λex/em = 530/590 nm). Alamar Blue excess was removed 
with PBS and medium was added (150 µL/well) to maintain the cells in culture for the 
next time point. Scaffolds and wells of a tissue culture plate without cells were used 
as negative controls to analyse Alamar Blue background fluorescence.   
 
3.6.3 Analysis of cell morphology and scaffolds using SEM 
 
The arrays of 3D polymer scaffolds were seeded as described above. At the 
appropriate time, the medium was removed before washing the scaffolds and cells 
with PBS (100 µL, 10 min). Cells were fixed with PFA (4%, 15 min) and washed with 
sodium cacodylate buffer (0.1 M, 1 h). Polymer scaffolds were removed from the wells 
using a needle. Post-fixation was carried out by applying osmium tetroxide (0.1M, 45 
min) followed by further washing with sodium cacodylate buffer (0.1 M, 15 min). 
Scaffold dehydration was achieved with increasing concentrations of acetone in a 
mixture of acetone/water (50%, 70%, 90% and 100% v/v) and critical point drying 
(liquid CO2). The scaffolds were coated with a gold/palladium alloy in a sputter coater 
with image acquisition on a Hitachi S-4700 scanning electron microscope (SEM). 
Scaffolds without cells were used as controls. 
 
3.6.4 Biomineralisation on the arrays  
 
Array sterilisation and seeding was carried out as described above. Mineralisation 
medium (culture medium supplemented with 50 µg/mL 2-phospho-L-ascorbate, 1 to 
20 mM β-glycerophosphate and 10 nM dexamethasone) was used to promote 
biomineralisation.[140–142] Scaffolds and wells of a tissue culture plate without cells 
were used as controls. 
Mineralisation assessment using Alizarin red.[143] Medium was removed at the 
appropriate time points and scaffolds were washed with PBS and fixed with PFA (4%, 
15 min). Arrays were washed with water (1 h) at 37 °C to remove free calcium present 
in medium.  Alizarin red (40 mM) was prepared in acetic acid (10% v/v) to give an 
acidic pH (pH 4.1). The scaffolds were incubated with the stain for 1 h in an orbital 
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shaker. Excess alizarin red was removed by washing the scaffolds extensively with 
water (5 h with the water changed every hour). Cetylpyridinium chloride (10% w/v) in 
an aqueous solution of Na2HPO4 (10 mM) was used to extract the stain from the 
scaffolds and the absorbance recorded using a microplate reader (λ = 550 nm). 
Mineralisation assessment using near infrared fluorescence dyes.[144] Medium 
was removed 24 h before analysis, icubating the cells with a solution of OsteoSense® 
800 (20 pmol/mL) and IRDye® 800CW BoneTag™ (2 pmol/mL) in culture medium (80 
µL/well). After incubation, scaffolds were washed with PBS (100 µL × 3 times) and 
fixed with PFA (4%, 30 min). After removing excess PFA, scaffolds were washed with 
PBS (10 min). Fluorescence intensity was recorded using an in vivo optical imaging 
system IVIS Lumina S5 (λex/em = 780/805 nm). 
 
3.6.5 Live/dead staining assay on the 3D polymer scaffolds 
 
Cells were stained with live/dead cell imaging assay (R37601) according to the 
manufacturer’s protocol with calcein AM (λex/em = 488/512 nm) for living cells and a 
nuclear red fluorescence dye (e λex/em = 570/602 nm) for dead cells. Culture medium 
was removed from the wells and cells were incubated for 15 min at room temperature 
(100 µL/well) with the “live/dead staining solution” diluted 1:1 with additive free 
medium. Image acquisition in 3D was performed using a Nikon Eclipse 50i 
microscope and the Pathfinder™ software (IMSTAR, France). Scaffolds without cells 
were used as controls. 
 
3.6.6 Cell cytoskeleton staining on the 3D polymer scaffolds 
 
Cells were fixed (4% PFA for 15 min), permeabilised (0.1% Triton X-100 in PBS, 15 
min) and washed with PBS (10 min). Cell nuclei were stained by applying a solution 
of DAPI (5 µg/mL, 10 min) in PBS (100 µL/scaffold). After removing excess DAPI and 
washing the scaffolds with PBS (10 min), the actin filaments were stained with Alexa 
FluorTM 568 phalloidin (1:40 dilution, 30 min) at room temperature. After three 
washing cycles, scaffolds were removed from the 96-well plates, sectioned with a 
scalpel (about 6 mm diameter × 1 mm thick) and mounted on glass slides with 
cultureWell™ gaskets. Image capture was performed on a confocal microscope Zeiss 
LSM880 Airscan equipped with a 20X NA 0.8 air objective. Cytoskeleton orientation 
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was assessed with the ImageJ-FIJI plugin OrientationJ.[145] Scaffolds without cells 
were used as negative controls to analyse scaffold autofluorescence and non-specific 
staining.  
 
3.6.7 Total collagen on the arrays 
 
Total collagen content was assed using a colorimetric method.[146,147] At the 
appropriate time point, medium was removed and 3D polymer scaffolds were 
incubated with pepsin digestion solution (1 mg/mL pepsin, 0.1 M acetic acid and 0.5 
M NaCl) for 48 hours at 5 °C (150 µL/well). Digested solutions (100 µL/sample) were 
dried in a 96-well plate at 37 °C overnight and treated with Sirius red solution (1 
mg/mL) in saturated picric acid (1.3% in water) for one hour. Arrays were washed (3 
× 5 min) with HCl solution (0.1 N) to remove excess sirius red before homogenising 
staining with NaOH (0.1 N, 100 µL/sample). Absorbance was recorded using a 
microplate reader (λ = 550 nm). Scaffolds and wells of a tissue culture plate without 
cells were used as negative controls. 
 
3.6.8 ALP quantification on the arrays 
 
Alkaline phosphatase was quantified according to a previously reported colorimetric 
method.[148,149]  Medium was removed and scaffolds were washed with PBS (1 × 5 
min) before treating with CelLytic M for 1 hour at 37 °C. Cell lysate (10 µL/sample) 
was placed in a 96-well plate with ALP substrate (90 µL/sample) solution (0.04 g 
phosphatase substrate in 10 mL of 1.5 M alkaline buffer solution, Sigma A9226, and 
30 mL of distilled water). Reactions were carried out at 37 °C between 10 to 60 min 
and was stopped by adding NaOH (100 µL/sample, 1 M). A standard calibration curve 
(0 to 2 µM) was obtained using dilutions of p-nitrophenol (10 mM) in assay buffer (30 
µL of Igepal CA-630, 5 mL of 1.5 M alkaline buffer solution A9226 made up to a final 
volume of 15 mL with distilled water). Absorbance was recorded on a microplate 
reader (λ = 410 nm) with ALP concentration calculated as nmol p-nitrophenol per 
mL/hour. Scaffolds and wells of a tissue culture plate without cells were used as 
negative controls. 
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3.6.9 DNA concentration on the arrays 
 
DNA concentration was evaluated according to a previously reported 
procedure.[148,149] Medium was removed and scaffolds were washed with PBS (1 × 5 
min) before treating with CelLytic M for 1 hour at 37 ºC. Cell lysate (10 µL/sample) 
was placed in a 96-well plate with TE buffer (1000 µL/sample) and Quant-iT™ 
PicoGreen™ dsDNA solution (90 µL/sample) according to the manufacturer’s 
protocol. A standard calibration curve (0 to 1000 ng/mL) was prepared with serial 
dilutions of herring sperm DNA (10 mg/mL) in TE buffer. Fluorescence intensity was 
recorded using a microplate reader (λex/em = 480/520 nm). Scaffolds and wells of a 
tissue culture plate without cells were used as controls. 
 
3.6.10 Immunofluorescence on the 3D polymer scaffolds 
 
At the desired time point, medium was removed and scaffolds were washed with PBS 
(1 × 5 min) before fixing the cells (4% PFA) for 30 min. Excess fixative was removed 
and scaffolds were washed with PBS (3 × 5 min) and treated with appropriate blocking 
solution and permeabilised (200 µL/sample) for 1 hour if necessary.  
 ALP blocking solution in PBS (w/v): 1% bovine serum albumin (BSA) and 10% 
normal goat serum in 0.1% TWEEN® 20 solution. 
 Collagen I blocking solution in PBS (w/v): 5% BSA.  
 Osteopontin blocking solution in PBS (w/v): 1% bovine serum albumin (BSA) 
and 10% normal goat serum in 0.1% TWEEN® 20 solution. 
Excess of blocking solution was removed by washing with PBS and scaffolds were 
treated overnight with the appropriate solution of the primary antibody (200 
µL/sample) according to the manufacturer’s protocol.  
 ALP primary antibody (ab65834, Abcam) solution (1/200) was made in BSA 
solution (1% w/v) in PBS. 
 Type I collagen primary antibody (ab34710, Abcam) solution (1/500) was 
made in BSA solution (3% w/v) in PBS. 
 Osteopontin primary antibody (ab8448, Abcam) solution (1/200) was made in 
BSA solution (1% w/v) in PBS. 
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Excess primary antibody was removed and scaffolds were washed with PBS prior to 
treating with a solution of secondary antibody Goat Anti-Rabbit IgG Alexa Fluor® 647 
(ab150079, Abcam) in PBS (1/250 dilution) for 1 hour. After three washing cycles with 
PBS, scaffolds were sectioned with a scalpel (≈ 6 mm diameter × 1 mm thick) and 
mounted on glass slides with cultureWell™ gaskets. Image capture was performed 
on a confocal microscope Zeiss LSM880 Airscan equipped with a 20X NA 0.8 air 
objective. Scaffolds without cells were used as negative controls. 
 
3.6.11 ELISA on the 3D polymer scaffolds 
 
FBMSCs were seeded (1,000,000 cells/scaffold) onto scale-up 3D scaffolds (12 mm 
length × 12 mm width × 1 mm height) and maintained for 21 days as described above. 
At the appropriate time point, scaffolds were washed with PBS, crushed with a scalpel 
and treated with 1X dilution of cell extraction buffer PTR (Abcam) (400 µL/scaffold) 
for 15 min on ice. Lysates were centrifuged at 15,000 rpm for 20 min at 4 ºC and 
supernatants passed through protein concentrators Pierce™ PES (30,000 K 
MWCO’s, 2-6 mL, Thermo Fisher Scientific). Total protein was quantified using a BCA 
assay kit and ELISA performed using a Human Pro-collagen I SimpleSep ELISA® kit 
according to manufacturer’s instructions. Absorbance was recorded on a microplate 
reader (λ = 450 nm). Scaffolds without cells were used as negative controls. 
 
3.6.12 CAM assay of the 3D polymer scaffolds 
 
Biocompatibility and angiogenesis of polymer scaffolds were evaluated using a chick 
embryo chorioallantoic membrane (CAM) model according to previously reported 
methods.[150] The CAM protocols were conducted by Mr. Michael Glinka from 
University of Southampton under Home Office Approval UK (Project license – PPL 
30/2762).  
FBMSCs (40,000 cells/scaffold) were incubated for 7 days on the 3D polymer 
scaffolds (12 mm length × 12 mm width × 1 mm height) before implantation. 3D 
scaffolds without cells were used as negative controls.   
Fertilised chicken eggs were incubated at 37 °C (60% humidified atmosphere and 1-
hour rotation) in a Hatchmaster egg incubator (Brinsea, UK) for 10 days. 
Material and methods  48 
Subsequently, a window (5 × 5 mm) was opened in the eggshell with a scalpel under 
sterile conditions. 3D polymer scaffolds with and without FBMSCs were cut with a 
scalpel (5 mm length × 5 mm width × 1 mm height) and implanted in the eggs with the 
windows sealed with sterile parafilm. After 7 days incubation, the samples were 
harvested and scaffold integration in the CAM inspected with a stereomicroscope with 
a digital camera (Canon Powershot G2) using a Chalkley score method to quantify 
angiogenesis (the Chalkley’s method uses an eyepiece grid with 25 randomised 
points that is oriented to permit the maximum number of points overlapping on the 
microvessels). The process is repeated in three different areas of the scaffolds.[151,152] 
Gestational process of chick embryos was terminated under Home Office guidelines.   
 
3.6.13 In vivo scaffold implantation in mice and micro-CT 
analysis 
 
The subcutaneous surgeries were conducted by Mr. Michael Glinka from the 
University of Southampton under Home Office Approval UK (Project license – PPL 
30/2762). Athymic BALB/cnu mice were grown until three months old (~33 g) before 
carrying out the implantation.  
3D polymer scaffolds (12 mm length × 12 mm width × 1 mm height) were seeded with 
FBMSCs (40,000 cells/scaffold) as described above and conditioned in basal and 
osteogenic media for 7 days before implantation. 3D polymer scaffolds without cells 
were used as a negative control. 3% (w/v) alginate gels with and without cells in basal 
and osteogenic media were used as a positive control.  
Animals were anaesthetised with an intra-peritoneal injection of a 1:1 mixture of 
Hypnorm™/Hypnovel™ before surgery. Incision on the back of the mouse skin was 
followed by implantation of pieces of the 3D polymer scaffolds and alginate gels (5 
mm length × 5 mm width × 1 mm height) in the subcutaneous pockets (6 small 
scaffolds/gels per mouse). The incisions were stitched and animals allowed to 
recover. 
Post-surgery evaluation of scaffolds and gels was carried out using a micro-CT 
system (Bruker Skyscan, Belgium) equipped with micro-focus X-ray source (20-90 
kV, 25 W). Experiments were terminated after 4 weeks with the euthanasia of mice 
under Home Office guidelines and samples collected.  
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3.6.14 Histological analysis of 3D polymer scaffolds 
 
Histological sample preparation was conducted by Mr. Michael Glinka from the 
University of Southampton along with Ms Melanie McMillan and Ms Lyndsey Boswell 
from the histological service of the University of Edinburgh (SuRF).  
Recovered in vivo samples (CAM assay and subcutaneous mouse model) were fixed 
overnight with paraformaldehyde (4%) at 4 °C and dehydrated with increasing 
concentrations of ethanol in a mixture of ethanol/water (50%, 90% and 100%) for 1 
hour each step in an auto-processing machine Shandon Citadel 200 (Thermofisher, 
UK). Dehydration was completed with Histo-Clear™. Afterwards, samples were 
embedded twice in hot wax for 1 hour each time and processed with a further 
embedding under vacuum in a Vacutherm Heraeus oven (Thermofisher, UK) for 1 
hour at 60 °C. Samples were sectioned (7 µm) on a microtome Microm330 (Optec, 
UK) and transferred to a pre-heated histological glass slides (37 °C for 2 h).  
Before staining, the tissue sections were treated with 100% Histo-Clear™ (2 × 7 min) 
and re-hydrated with decreasing concentrations of ethanol in a mixture of 
ethanol/water (100%, 90% and 50%) for 2 min each step. Cell nuclei in the tissue 
sections were stained with Weigert’s Hematoxylin according to the manufacturer’s 
instructions. Excess was removed by washing with hydrochloric acid (1% v/v) in an 
aqueous ethanol solution (70% v/v) followed by further washing with water. Tissue 
sections were stained with Alcian blue/Sirius red and Goldner’s Trichrome following a 
previously described protocol.[153,154]  
Alician blue/Sirius red protocol. Proteoglycans were stained with Alician blue 8GX 
(0.5% w/v) in an aqueous acetic acid solution (1% v/v). Slides were washed with an 
aqueous molybdophosphoric acid (0.6% w/v) solution before staining with a solution 
of Sirius red F3B (1% w/v) in saturated picric acid (1.3% in water) for collagen 
visualisation. Excess of staining solution was removed by washing with water. 
Goldner’s Trichrome protocol. Cytoplasm were stained with Ponceau-Fuchsin and 
Axophloxin solution (0.75% xylidine ponceau, 0.25% acid fuchsin and 0.5 azophloxin 
0.5% v/v) in aqueous acetic acid (1% v/v). Afterwards, slides were treated with an 
aqueous molybdophosphoric acid solution (0.6% w/v) prior to treating the tissue 
sections with Orange G solution (0.4% w/v) to visualise erythrocytes. Collagen was 
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stained with Light green SF solution in water (0.2% w/v). Excess of staining solution 
was removed by washing with an aqueous solution of acetic acid (1% v/v).   
VEGFR-2 protocol. Tissue sections on histological slides were treated with heated 
antigen retrieval (BOND Epitope Retrieval Solution 1, pH 6, Leica Biosystems) for 20 
min. After peroxidase block for 10 min, the sections were incubated with VEGFR-2 
antibody (Millipore 07-1294, 1/100 dilution) at room temperature for 60 min. Slides 
were then incubated with anti-rabbit horseradish-peroxidase labelled polymer for 10 
min before reacting with diaminobenzidine solution (1X) for 10 min. Nuclei 
counterstaining was performed with hematoxylin (BOND Polymer Refine Detection 
Kit, Leica Biosystems).  
Hematoxylin and eosin protocol. H&E staining of tissue sections was carried out 
according to a standard operation procedure at the University of Edinburgh (SuRF).  
Slides were dehydrated with ethanol and Histo-Clear with the procedure described 
above prior to mounting with PDX. Imaging acquisition was carried out on a Zeiss 
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4. Arrays of 3D polymer scaffolds via freeze-
casting 
 
The work presented in this section was carried out in collaboration with Dr 
Deepanjalee Dutta and Dr Robert Wallace. Dr Dutta performed the analysis of the 
orientation of the actin filaments while Dr. Wallace carried out the micro-computed 
tomography (micro-CT) data acquisition.  
 
Parts of this chapter have published as: 
 
 A. Conde-González, D. Dutta, R. Wallace, A. Callanan and M. Bradley. Rapid 
Fabrication and Screening of Tailored Functional 3D Biomaterials. Materials 




The extracellular matrix (ECM) consists of a vast assembly of materials with the 
specific predominance of any material typically dependant on the required properties 
of the tissue. Thus, molecules range from type I collagen to apatite-based minerals in 
bones, or type II collagen in cartilage often with specific 3D arrangements and, 
molecular gradients all playing vital roles in cellular function or control. Although 
significant research has been conducted to unravel this complex physiology, it still 
remains a key challenge in the field of tissue engineering.[155] It is clear that the 
conversion of physical and chemical signals into biological responses is a highly 
complex phenomenon with multiple convoluted factors interplaying, complicating full 
understanding.  
Polymer microarrays have been proven to be an excellent tool for shining light on 
complex biological systems via their application in the discovery of polymeric 
substrates in addition to deciphering cellular and biomaterial behaviour.[156–158] 
However, the features of most microarray lack the 3D architectures found in tissues 
and as such fail to recapitulate cell behaviour in its natural environment.[159]  
Arrays of 3D biomaterials have emerged as a method to overcome the limitations of 
current microarray technology as multiple chemical and physical properties of 
materials can be explored in a 3D format.[160] For example, a high-throughput 
approach to fabricate 3D microarrays of polymers using contact printing to spot pre-
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mixed solutions of hydrogels and cells was developed to study mesenchymal stem 
cells (MSCs) osteogenic potential under different conditions and substrates.[161] 
Additionally, a remarkable array of more than 1500 unique 3D microenvironments was 
established to study the combined effects of gel elasticity, proteolytic degradability 
and chemical cues such as fibronectin, E-Cadherin and bone morphogenetic protein 
4 on mouse embryonic stem cells.[162] Although hydrogels have been shown to be 
excellent candidates for repair of soft tissues (e.g. cartilage[35]) their mechanical 
properties are not suitable for stiffer tissues such as bone.[89]  
384 and 96 well plates have been explored as a platform compatible with common 
laboratory equipment. For example, solvent casting and particulate leaching (sodium 
chloride) have been used to create arrays of porous polymers in 96-well plate format 
for the study of osteogenic properties of tyrosine-derived polycarbonates.[163] 
However, modulation of the quantity or size of the porogen (salt particles) is necessary 
to generate an array of multiple 3D structures, which is cumbersome in the case of a 
solid. Gas foaming (ammonium carbonate and heat) has also been shown to be an 
elegant approach in the fabrication of 3D polymeric scaffolds based on poly-L-lactic 
acid, targeting the growth of neuronal stem cells.[164] However, gases in an immiscible 
liquid tend to minimise their interfacial free energy forming isolated bubbles, thus, 
interconnectivity between pores is compromised.  
To address the above challenges, a robust method to fabricate arrays of 3D polymer 
scaffolds was developed and put into practice, seeking to expand the current chemical 
and physical space of 3D biomaterials. The aim was to design a practical approach 
for the fabrication of multi-component polymer scaffolds in addition to tuning their 
mechanical properties and 3D microstructures. Thus, freeze-casting and photo-
polymerisation were utilised to obtain in situ porous acrylate polymers in 96-well 
plates. This approach to fabricate arrays of 96 porous polymers allowed the control 
and design of a variety of 3D microstructures and offered a wide range of mechanical 
properties. Sitting alongside the current polymer microarray technology, this novel 
system reduces the gap between the successful identification of biomaterials in vitro 
and their subsequent application in vivo. Moreover, this new platform is not just limited 
to the discovery of 3D biomaterials for tissue repair but could also be exploited to 
explore a range of applications such as studying the biomaterial – cell interface, 
designing tissue models for pre-clinical drug studies and producing artificial 
transplantable tissue to cite but a few possibilities.  
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As a proof of concept, the array developed was applied towards the identification of 
3D biomaterials using human osteosarcoma cells SAOS-2 and MG-63 with a push to 
develop vascularisation – a key step in any regeneration process. These cell lines 
were used as they are well established human osteoblast models that present similar 
alkaline phosphatase activity, genetic expression and mineralisation processes seen 
for osteoblasts.[165] Additionally, the high proliferation rate of both immortalised cell 
lines facilitates in vitro assays. As a starting point, “two-dimension” polymer 
microarrays were used to identify four polymeric substrates that were capable of 
supporting cell binding. Thereafter, these substrates were converted into 3D scaffolds 
and physically characterised. Subsequently, cell behaviour was analysed to identify 
the best 3D scaffolds. Finally, the combined effects of the physical properties of the 
3D biomaterials and biological responses were studied to gain a deeper 
understanding of the cell – material interface.   
 
4.2 Results 
4.2.1 Substrates for bone cell attachment 
 
In this chapter, the established polymer microarray technology of the Bradley group 
was used to fabricate microarrays of 180 different acrylate polymers prepared using 
inkjet printing and photo-polymerisation.[29–31,166,167] These microarrays included a 
range of biopolymers successfully identified within the group, and were interrogated 
using SAOS-2 and MG-63 cells, with polymer “suitability” assessed by counting the 
number of cells adhered onto each polymer feature.  
This initial microarray screening (appendix A, Figure 4-1 and Figure 4-2) allowed 
selection four co-polymer substrates (A-D) that were capable of supporting/promoting 
cell attachment (Figure 4-3). Thereafter, these four acrylate-based lead materials 
were used to develop an array of 3D polymer scaffolds (Figure 4-4 and Table 4-1).     
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Figure 4-1. Microarray screening with SAOS-2 cells. Two microarrays of 180 acrylate 
polymers were synthetised in situ using inkjet printing and photo-polymerisation. Human 
osteosarcoma SAOS-2 cells (1,000,000 cells/array) were cultured for two days, fixed (PFA, 
4%) and the cell nuclei stained (DAPI). Fluorescence and brightfield images were acquired by 
high-content microscopy. Cell attachment was analysed as the number of cells per mm2 of 
polymer measured with the image processing software ImageJ-Fiji. Hit polymers (Table 4-1) 
are highlighted. Mean ± SD, n=4. 
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Figure 4-2. Microarray screening with MG-63 cells. Two microarrays of 180 acrylate polymers 
were synthetised in situ using inkjet printing and photo-polymerisation. Human osteosarcoma 
MG-63 cells (1,000,000 cells/array) were cultured for two days, fixed (PFA, 4%) and the cell 
nuclei stained (DAPI). Fluorescence and brightfield images were acquired by high-content 
microscopy. Cell attachment was analysed as the number of cells per mm2 of polymer 
measured with the image processing software ImageJ-Fiji. Hit polymers (Table 4-1) are 
highlighted. Mean ± SD, n=4. 
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Figure 4-3. The leads selected from the microarray screening of 180 polymers. The number 
of SAOS-2 and MG-63 cells per mm2 of polymer after 2 days of incubation (seeding 1x106 




















Figure 4-4. Monomers, cross-linker and photo-initiator that were used to fabricate the four co-
polymers identified from the microarray screen. 4-tert-butylcyclohexyl acrylate (BHA), 
isobornyl acrylate (IBA), 2-(methylthio)ethyl methacrylate (MTEMA), butyl methacrylate 
(BMA), the cross-linker 1,6-hexanediol diacrylate (HDOBA) and the photo-initiator (PI) 
hydroxy-2-methylpropiophenone. 
 
Table 4-1. Polymers selected from the microarray screening.  
Polymer Monomers (mol %) CL  
(mol %) 
PI  
(mol %) 1 2 
A BHA (72) - 18 10 
B IBA (72) - 18 10 
C BHA (36) BMA (36) 18 10 
D IBA (36) MTEMA (36) 18 10 
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4.2.2 Development of a 3D polymer array and characterisation  
I.  Fabrication strategy 
 
An array of 3D polymer scaffolds was created in flat bottomed 96-well plates via UV 
polymerisation of frozen porogenic solutions. The solutions were obtained by mixing 
the porogenic solvent (DMSO) with the appropriate polymerisation mixture (Table 
4-1). As an example, P80 scaffolds were obtained by combining DMSO (80% v/v) with 
the suitable polymerisation mixture (20% v/v).  
 
Figure 4-5. Arrays of 3D polymer scaffolds formed via freeze-casting. Development of a four-
step process to obtain arrays of 3D polymer scaffolds. Templating (formation of a solid phase 
rich in DMSO), UV polymerisation and drying revealed the porous structure. A dry ice bath 
and an aluminium cooling block (A) were used to keep the scaffold frozen during the UV-
polymerisation of the arrays (B). 
 
The porogenic solutions (80 µL/well) were subjected to freezing (Figure 4-5). Below 
the melting temperature of DMSO, a phase separation (templating) in the porogenic 
solution gives rise to two distinct phases: a phase rich-in-solvent (pores) and a phase 
rich-in-polymer (scaffolds). Subsequent UV polymerisation was carried out on top of 
a dry-ice-bath and an in-house aluminium-cooling block (127 mm length × 85 mm 
width × 10 mm height). Washing and freeze-drying revealed the structure of the 
porous scaffolds.  
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The array of 3D polymer scaffolds generated was the result of both the combination 
of different polymer compositions and porosities. Freeze-casting allowed tunability of 
the 3D architecture using different levels of DMSO or the application of different 
cooling gradients during templating. For example, P80-A scaffolds (polymer A from 
above with 80% v/v DMSO) obtained in the presence or absence of freezing illustrates 
some of the morphological variations that were explored in the array (Figure 4-6).  
 
Figure 4-6. Effect of the templating temperature on the formation of pores. Representative 
SEM images of polymer P80-A in case of cooling the sample (freezing) before polymerisation 
and without cooling. Scale bar = 100 µm.  
 
II. Effect of the cooling gradient on the porous structure 
 
The effect of a cooling gradient was analysed for scaffolds with high porosity (P80) 
for the four polymers A-D prepared in the wells of a 96-well plate and analysed using 
scanning electron microscopy (SEM).  
Three different cooling methods (Figure 4-7) were explored so-called: fast, medium, 
slow with polymerisation at room temperature used as a control.  
 Fast cooling: a dry ice bath (-80 °C) for 15 min.  
 Medium cooling: a freezer (-20 °C) for 20 h.  
 Slow cooling: a fridge (5 °C) for 16 h and a freezer (-20 °C) for 4 h.  
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Figure 4-7. Cooling methods explored. A) Fast cooling (cooling gradient 15.6 °C/min). B and 
C) Slow cooling (1.0 °C/min and 2.6 °C/min). D) Medium cooling (2.5 °C/min). Wireless 
thermometer (Testo 905i, Germany) was used to record the temperature and time.  
 
After the different cooling stages, the arrays were placed on top of an aluminium 
cooling block in a dry ice bath and subsequently UV polymerised (30 min). After photo-
polymerisation, all the scaffolds were washed and lyophilised (Figure 4-5).  
 
Figure 4-8. SEM images of the scaffolds P80-B with the three cooling gradients. Scale bar = 
500 µm.  
 
Illustrative images for scaffolds P80-B exemplified the morphological changes that 
the different cooling gradients produced. Scaffolds fabricated at room temperature 
showed a surface devoid of large pores with no phase separation between the DMSO 
and the polymerisation mixture. The other scaffolds after the cooling procedure were 
highly porous (Figure 4-8). 
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Figure 4-9. Analysis of the SEM images using ImageJ-Fiji. SEM images were binarised 
(thresholding plugin) and filtered (median plugin, 2 pixels) to separate the polymer from the 
porous structure. The segmented images were analysed (analyse particles plugin) to quantify 
the pore descriptors. Scale bar = 500 µm.  
 
ImageJ-Fiji was used to quantify the morphological changes that the different cooling 
processes produced. To do so, porosity (%), as a percentage of area with pores, and 
the average Feret diameter (µm) of those pores were used as pore descriptors (Figure 
4-9).  
 
Figure 4-10. Effect of the cooling gradient on the polymer scaffolds. Porosity (%) and Ferret 
diameter (µm) for polymers A-D. Polymerisation at room temperature was used as a control. 
One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 
0.0001). Mean ± SD, n=2. 
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Analysis of the effect of the cooling rate on the P80 scaffolds of polymers A-D 
confirmed that the 3D architecture could be controlled by the templating temperature 
(Figure 4-10). Generally, the porosity (%) and Feret diameter of the scaffolds 
increased progressively when the cooling stage changed from “fast” to “slow”. 
Moreover, very low porosity and Feret diameter were observed in control scaffolds. 
For example, the porosity for P80-A scaffolds with “fast” and “slow” cooling were 30% 
and 38% (p ≤ 0.01) and their Feret diameter were 40 µm and 79 µm respectively.  
In summary, the “slow” cooling (5 °C for 16 hours and -20 °C for 4 hours) approach 
was selected going forward in order to maximize the formation of pores. 
 
III. Effect of porogenic solvent on the scaffold structure  
 
The ratio of the porogenic solvent (DMSO) to the polymerisation mixture was also 
used to control the architecture of the porous polymers with the “slow” cooling method. 
Three levels of DMSO (0% v/v, 60% v/v and 80% v/v) and polymers A-D were 
combined to give arrays with porous scaffolds (P60 and P80) and their non-porous 
controls (P0). 
 
Figure 4-11. SEM images of the polymers A and B obtained with different concentrations of 
porogenic solvent: P0 (0% v/v), P60 (60% v/v) and P80 (80% v/v) and the slow cooling method. 
Scale bar = 500 µm.  
 
SEM images of scaffolds P0, P60 and P80 of polymers A and B showed the effect 
of the concentration of porogenic solvent in the porous structure. The images showed 
that there were no pores (P0) in absence of DMSO and with the increase in the 
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concentration of DMSO there was a progressive increase in the porous structure 
(Figure 4-11). Quantification of the morphological descriptors revealed the 
enhancement of these descriptors when the concentration of DMSO was increased 
(Figure 4-12). For example, the porosity of scaffolds P0-A and P60-A increased from 
approximately 1% to 31% (p ≤ 0.0001) respectively and further rose to 38% (p ≤ 0.001) 
for P80-A. Moreover, the Feret diameter increased from 5 µm for P0-A to more than 
70 µm for P60-A and P80-A (p ≤ 0.01). 
 
Figure 4-12. Effect of the concentration of DMSO on the array of polymer scaffolds. Analysis 
of influence of the porogenic solvent (P0, P60 and P80) on the porosity (%) and Ferret 
diameter (µm) for polymers A-D. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001). Mean ± SD, n=2. 
  
The analysis of the distribution of the Feret diameter of the 12 scaffolds (P0, P60 and 
P80 for polymers A-D) allowed a deeper insight into the effect of the concentration 
of DMSO on the porous structure (Figure 4-13). Although the average size of the 
pores ranged from 50 µm to 70 µm for medium (P60) and high porosity (P80) 
scaffolds, the distribution of the Feret diameter showed the presence of pores larger 
than 100 µm which is deemed to be important for biological applications. For example, 
scaffolds P60-A and P80-A had voids of approximately 750 µm and 1000 µm 
respectively for 99% of the pores.  
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The distribution of the size of the pores were classified into three groups namely - 
pores smaller than 50 µm, pores between 50 µm and 300 µm and pores bigger than 
300 µm (Figure 4-14). The first group (< 50 µm) represents pores that are too small 
to allow cell migration into the scaffolds but could facilitate the diffusion of nutrients 
and the removal of metabolic waste. The pores from 50 µm and 300 µm include the 
range of pores that are considered ideal for polymer scaffolds as these pores allow 
the cells to acquire a “3D morphology”. Pores bigger than 300 µm are viewed as 
important candidates for allowing cell migration into deeper layers of the polymer 
scaffolds.[22,112]  
Independent of the polymer composition, P0 scaffolds had no significant pores. P60 
scaffolds showed porosities that varied from 24% to 31 % with about 29% of the pores 
in the optimal range of pores (from 50 µm to 300 µm) and about 3% of the pores 
bigger than 300 µm. Moreover, in the case of P80 scaffolds the porosity varied from 
36% to 50% with the optimal range of pores decreasing 22% compared to P60. 
However, a slight increase in the pores larger than 300 µm was also observed.  
Generally, it was observed that increasing the concentration of the porogenic solvent 
0%, 60% and 80% v/v DMSO produced an increase in the frequency of large pores.  
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Figure 4-13. Effect of the DMSO level on the polymer scaffolds. Analysis of the distribution of 
the Feret diameter (µm) for four polymers (A-D) and three levels of porogenic solvent (P0-
P80). Mean (white square), maximum and minimum values (white circles), 1% and 99% 
percentile (black squares), n=2. Representative SEM images of the scaffolds analysed. Scale 
bar = 500 µm.  
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Figure 4-14. Effect of the level of DMSO on the polymer scaffold porosity. Analysis of the 
combined effect of the porogenic solvent on the porosity (%) and distribution of the Feret 
diameter (µm) for three concentration of DMSO (P0-P80) and four polymers (A-C). The size 
of the pores was grouped to less than 50 µm, between 50 µm to 300 µm and greater than 300 
µm, n=2.  
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IV. Morphological analysis of the array of 3D polymer scaffolds 
 
A high-content screening approach using micro-CT was used to allow the 
morphological characterisation of 12 polymer scaffolds in a facile manner, while 
involving minimal sample preparation. An array was prepared in rectangular sections 
of 96-well plates (2×2 wells) that were stacked together to form a cuboid of 12 polymer 
scaffolds (2×2×3 wells). The array of 3D polymer scaffolds was prepared with the 
“slow” cooling approach employing the four polymers A-D. Six different concentration 
of the porogenic solvent (from 0% to 85% v/v) were explored giving the so-called 
scaffolds P0, P20, P40, P60, P80 and P85 to gain an understanding of the effect of 
the DMSO concentration on the morphological characteristics of 3D scaffolds. 
Representative stacks of the array of 24 polymer scaffolds displayed the expected 
reduction of polymer density as a result of the increase of the level of DMSO (Figure 
4-15). Abundant quantities of large pores (larger than 100 µm) in the transverse and 
coronal planes of the scaffolds P60 and P80 were observed with patterning of the 
polymer structure in some scaffolds e.g.  P80-B and P60-C.    
3D images of the micro-CT data (rendering of the longitudinal section of wells with 
polymer scaffolds) were obtained with the software Imaris (Figure 4-16 and Figure 
4-17). The scaffolds covered the entire surface of the well and had a concave surface 
as a consequence of their liquid origin. The majority of the polymers had enlarged 
pores as the volume of DMSO increased (from 0% to 85% v/v) demonstrating the 
effect of the porogenic solvent. The micro-CT of P0 scaffolds showed a compact 
structure of a polymer without pores. In the case of P20 and P40 scaffolds pores were 
seen at the bottom of the scaffolds. The P60, P80 and P85 scaffolds had a uniform, 
open, porous structure; however, P85 scaffolds displayed a broken and uneven 
polymer structure suggestive of a fragile nature.  
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Figure 4-15. Micro-CT analysis of the 24 3D polymer scaffolds. Images of a cross-section 
(square, left) and longitudinal section (rectangle, right) of polymers A-D fabricated with 
increasing levels of DMSO (P0-P85). The polymer is shown in white and grey with the pores 
in black. Scale bar = 1 mm. 
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Figure 4-16. 3D images of the micro-CT data of wells of the 3D polymer scaffolds (longitudinal 
sections) of polymers A and B varying the level of DMSO (P0-P85). Scale bar = 1 mm. 
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Figure 4-17. 3D images of the micro-CT data of wells of the 3D polymer scaffolds (longitudinal 
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The analysis of the CT data using the ImageJ-Fiji plugin BoneJ[134] (image processing 
software) of the 3D polymer scaffolds showed the enhancement of porosity with an 
increase in porogenic solvent independent of the polymer composition (Figure 4-18). 
For example, P0 (0% DMSO and 100% polymerisation mixture) had no porosity 
whereas for P80 had a porosity of 81% for the four polymers explored. 
 
Figure 4-18. Analysis of the 3D polymer scaffolds using micro-CT. Effect of the level of DMSO 
(from 0% to 85% v/v) on the porosity (%) of polymers A-D analysed using ImageJ-Fiji.  
 
The morphological characteristics of the 3D polymer scaffolds were further analysed 
using the scaffolds having medium (P60) and higher porosities (P80 and P85) for the 
four polymers. The percentage of “open” pores (pores connected to the surface of the 
volume analysed) and the size of the pores were used to describe the properties of 
the polymer scaffolds (Figure 4-19). 
The “open” porosity analysis defined as pores that were connected to the surface of 
the volume of interest (volume measured) confirmed that the pores were 
interconnected (porosity and open porosity were similar) and “open” to the surface. 
For example, the open porosity of P60-A was 66% and increased to 88% for P80-A 
and decreased to 78% for P85-A.The largest average diameter of the pores was 
identified in the P80 scaffolds (238 µm) with a slight decrease for the P60 scaffolds 
independent of the polymer composition. However, the P85 scaffolds showed an 
important characteristic in terms of reduction of the average pore diameter (144 µm) 
which could be attributed to possible collapse of the weaker polymer network.  
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Figure 4-19. Analysis of the 3D polymer scaffolds (A-D) using micro-CT. Effect of the level of 
DMSO (from 60% to 85% v/v) on the open porosity to the edges of the volume of interest and 
the diameter of the pores (µm) using the software CTAn. 
 
The size of the interconnected pores (throats) is one of the key characteristics in 3D 
polymer scaffolds. The diameter of the pore throats were modelled (with the software 
AVIZO) in order to shine light on this complex system.[168,169] 3D images were obtained 
and polymer/pores were defined (thresholding) using the micro-CT data. Thereafter, 
the pores were differentiated using a watershed algorithm where continuity of each 
pore was determined. The position where two adjacent pores narrowed was 
considered as a throat and its size was the interconnection diameter or throat 
diameter. These data were visualised constructing a model where the pores were 
represented as spheres of equivalent diameter to the size of the pore modelled while 
the position and size of the throats were shown with cylinders of equivalent size. 
Additionally, a colour map for the throat diameter was also included (Figure 4-20 and 
Figure 4-21). 
 
Arrays of 3D polymer scaffolds via freeze-casting 72 
 
Figure 4-20. 3D images of micro-CT data and the model of pore connectivity for polymer B 
with medium (P60) and high (P80) porosity. Micro-CT data was modelled to measure the pore 
diameters and their interconnection pore diameters or throat diameters. Pores and throats are 
showed as spheres and coloured lines with the sphere diameters and line thicknesses being 
proportional to the pore and throat sizes. Additionally, a colour scale was used to classify the 
diameter of the throats (large diameters were represented in red and small diameters in blue). 
Scale bar = 1 mm.    
 
 
Figure 4-21. Expansion of the pores and throats for the 3D model developed using the micro-
CT data of the scaffold P80-B. Scale bar = 1 mm.  
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Figure 4-22. Micro-CT analysis of the pore and throat diameter of the 3D polymer B (P60, 
P80 and P85). 
 
The analysis of the pore and throat models using AVIZO (Figure 4-22) corroborated 
previous analysis (Figure 4-19). The largest pore and throat diameters were achieved 
for scaffolds fabricated with 80% of DMSO (P80) in the case of the polymer B. The 
average pore diameter was 100 µm with the 99% of the pores smaller than 200 µm. 
Pore throats were shown to be around 50 µm with 99% smaller than 150 µm. Pore 
and throat diameter larger than 100 µm (cut-off target for cells in 3D) were confirmed 
for the three level of porosity explored (P60, P80 and P85) with the largest quantify of 
in the P80 scaffold.  
Overall, the control of the DMSO level was shown to tune the morphological 
characteristics of the 3D polymer scaffolds. Scaffolds having an open porosity, 
adequately interconnected porous network and large pores/throats were obtained by 
increasing the level of the porogenic solvent. Additionally, the average diameter of the 
pores in the scaffolds with large porosity was shown to be in the selected target range 
(100 µm to 300 µm), which can lead to cell migration into the scaffolds (cells in 3D) in 
addition to efficient nutrient and waste diffusion.    
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V. Mechanical analysis of the array of 3D polymer scaffolds   
 
Polymers A-D with low (P0), medium (P60) and high (P80) porosity were 
mechanically characterised using indentation, which allows the mechanical 
characterisation of a small sample like a scaffold or a piece of bone by applying a 
force with a punch onto its surface.[103]  
The 3D scaffolds formed a meniscus on their surface as a result of their liquid origin. 
This would produce aberrations in the mechanical testing as the contact between the 
indenter and the surface would not be homogenous. Thus the 3D polymer scaffolds 
were thus scaled-up from 80 µL to 300 µL using the slow cooling approach and photo-
polymerisation in a polystyrene mould 12×12 mm in order to minimise the meniscus 
(Figure 4-23).  
The scaffolds were then tested, hydrated with PBS in order to mimic physiological 
conditions. An Instron testing system equipped with a flat cylindrical indenter (ø = 1 
mm) used to compress the polymer scaffolds at a strain rate of 5% per minute for 20% 
of the strain. The characteristics features of each polymer scaffold were obtained from 
the curves of load-displacement and load-time. Moreover, the relaxation load was 
also measured for 5 min.[138,139] The indentation moduli (E) were calculated locally for 
4 percentages of strain (0% to 5%, 5% to 10%, 10% to 15% and 15% to 20%) using 
a linear model for semi-infinite materials (diameter sample to diameter indenter ≥3) 
as previously described.[135–137] 
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Figure 4-23. Mechanical characterisation of the 3D polymer scaffolds. Scaffolds (12×1.7 mm) 
were prepared in a polystyrene mould. Indentation was performed using an Instron and a flat 
indenter (Ø = 1 mm) at a strain rate of 5% per minute for 20% of the strain (340 µm). The 
indentation modulus (E) was calculated locally using a linear model where the radius of the 
indenter (R) was fixed and the increment of the load (dF) vs displacement (dD) were calculated 
from the gradient of the curves of load vs displacement for each polymer. 
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The analysis of the indentation moduli of control scaffolds (P0) revealed the effect of 
the polymer composition on the mechanical properties (Figure 4-24). Among the four 
compositions analysed, scaffold P0-B presented the highest indentation moduli and 
P0-C the lowest with no significant differences between P0-A and P0-D. P0-B 
scaffolds were significantly stiffer (40.4 MPa) than scaffolds P0-A, P0-C and P0-D for 
an initial load (0% to 5% strain). This trend was also observed between 5% – 10%, 
10% –15% and 15% – 20% strain although differences between the polymers reduced 
with the increase of the strain. For example, polymer P0-B (55.8 MPa) was again the 
stiffer polymer when compared with P0-A and polymer P0-C but significant 
differences were not observed for scaffolds P0-D between 15% to 20% strain.  
The porogenic solvent (P60 and P80) produced a reduction in the scaffolds 
indentation moduli with a further drop in the stiffness when DMSO was increased;  for 
example, indentation moduli for P0-B, P60-B and P80-B were 40.3 MPa, 27.0 MPa 
and 0.3 MPa between 0% to 5% strain (Figure 4-25).   
The porosity, polymer structure and morphological characteristics of the pores are 
well known to determine the mechanical properties of porous polymers.[170,171] The 
increase in scaffold porosity is inversely proportional to its density; thus, the density 
of the scaffolds is representative of their porosity.  
The density of scaffolds were calculated by the weight of the dried scaffolds divided 
by the volume of ethanol that the scaffold displaced after immersion in ethanol for 4 
hours (Figure 4-26). The density of polymer A in case of the P0 scaffolds was 631 
kg/m3 which changed to 364 kg/m3 and 151 kg/m3 for P60 and P80 respectively.  
The indentation moduli were normalised to the density of each polymer scaffold 
(Figure 4-27) in order to elucidate how the scaffold “softened” as the porogenic solvent 
increased, consequence of the porous network (the more porous the scaffolds, the 
softer the scaffold).  
The differences observed in the normalised indentation modulus between the P0 and 
P80 scaffolds were revealed to be smaller than observed in the original indentation 
modulus. For instance, normalised indentation moduli between P0-A and P80-A 
showed about a 6-fold decrease whereas their indentation moduli decreased 24-fold 
for the same change of porosity (from P0 to P80). In the case of polymer B scaffolds, 
normalised indentation moduli decreased about 35-fold for P0 and P80, while their 
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indentation moduli (not normalised) showed a 119-fold reduction between P0 and 
P80. Similar behaviour was observed for P80-C and P80-D with about a 20-fold 
decrease instead of 100-fold and about an 8-fold reduction instead of 40-fold. 
The comparison between the normalised indentation modulus and the indentation 
modulus directly measured confirmed that the P80 scaffolds were significantly softer 
than P0 and P60 scaffolds. A more random distribution of the polymer network was 
expected in the scaffolds with low porosity (P0) as the polymer fibres can grow in all 
the directions.[172] Moreover, decreasing the level of solvent and increasing the 
concentration of monomers is known to increase polymer stiffness.[173] Perhaps, the 
presence of DMSO during the polymerisation (incomplete phase separation in the 
templating stage) could explain the dramatic reduction of stiffness revealed with the 
increase in DMSO levels. 
The relaxation load is the observed reduction in load after applying a prolonged 
deformation. Two dynamic stress-relaxation mechanisms occur simultaneously in the 
case of the indentation of hydrated polymer scaffolds; a viscoelastic relaxation related 
to changes in the structure of the polymer chain and poroelastic relaxation associated 
with the transport of water out of the scaffolds.[174] Relaxation curves were obtained 
for the four polymers and three different levels of porogenic solvent (P0, P60 and 
P80). The relaxation load (percentage of decrease of the load) was calculated for the 
hydrated (PBS) polymer scaffold after 1 and 5 minutes (Figure 4-28). Polymers A 
and B exhibited similar decreasing relaxation profiles from P0 to P80 whereas 
polymers C and D showed the opposite, an increasing trend. Moreover, the scaffolds 
of polymer D displayed significant load relaxation which reduced to 45% for P0-D and 
57% for P80-D after 5 min. 
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Figure 4-24. Mechanical characterisation of the polymer scaffolds. Indentation modulus for 
polymers A-D with low porosity (P0) at 1) 0-5, 2) 5-10, 3) 10-15 and 4) 15-20 strain 
percentages. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
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Figure 4-25. Mechanical characterisation of the polymer scaffolds. Indentation modulus for 
polymers A-D with low (P0), medium (P60) and high porosity (P80) at four different strain 
percentages. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
and **** p ≤ 0.0001). Mean ± SD, n=4. 
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Figure 4-26. Density (kg/m3) for polymers A-D with low (P0), medium (P60) and high (P80) 
porosity. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and 
**** p ≤ 0.0001). Mean ± SD, n=4. 
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Figure 4-27. Mechanical characterisation of the polymer scaffolds. Normalised indentation 
modulus at four different strain percentages for polymers A-D with low (P0), medium (P60) 
and high (P80) porosity. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** 
p ≤ 0.001 and **** p ≤ 0.0001). Mean ± SD, n=4. 
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Figure 4-28. Mechanical characterisation of the polymer scaffolds. Load relaxation (%) after 
1 and 5 minutes for polymers A-D with low (P0), medium (P60) and high (P80) porosity. 
Statistics were calculated for the final relaxation load (5 min). One-way ANOVA with Bonferroni 
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VI. Analysis of porosity on the arrays of 3D polymer scaffolds 
 
To analyse the reproducibility of the approach, the entire array was explored using 
the four different polymer compositions (A-D) previously selected (Table 4-1) and six 
concentrations of porogenic solvent (P0, P20, P40, P60, P80 and P85) to give 24 
unique polymer scaffolds in the wells of a 96-well plate (Figure 4-29). The array was 
prepared with the “slow cooling” method, 5 °C for 16 hours and -20 °C for 4 hours, 
that showed maximum formation of the pores followed by photo-polymerisation for 30 
min. 
Visual inspection of the array showed evidence of an enlargement of the pore size 
with an increase in level of DMSO for the four polymer compositions (Figure 4-29). 
The scaffolds with low porosity (P0) were transparent and colourless whereas the 
porous polymers (from P40 to P85) were opaque and white in colour. Opacity of the 
polymers being a consequence of light scattering caused by the pores with air and 
the polymer.[175]  
 
Figure 4-29. The array of 3D polymer scaffolds. Polymers A-D were combined with different 
levels of DMSO, from 0% (P0) to 85% (P85), to give an array of 24 different polymer scaffolds. 
 
An approach based on solvent displacement was developed to measure the porosity 
of the scaffolds without extraction. P0 scaffolds for the four polymer compositions had 
no porosity as expected while maximum porosity was obtained at 80% with P80 
scaffolds (Figure 4-30).  
Comparison of the porosity of the polymers obtained from two independent synthesis 
allowed a study of intra and inter plate reproducibility in fabrication of the arrays. The 
measured porosity at each condition in the plate and between plates, batch 1 and 
batch 2, showed the consistency of the experimental approach (Figure 4-31), 
moreover, comparison of the porosity measured for the array of polymer scaffolds and 
the scaled-up scaffolds showed the scalability of the approach (Figure 4-32).  
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Figure 4-30. Porosity by liquid displacement calculated as the ratio between the volume of 
solvent inside the pores of the scaffold and the total volume of the scaffold. Polymers A-D 
were combined with six levels of porogenic solvent (P0, P20, P40, P60, P80 and P85) to 
fabricate 24 unique 3D polymer scaffolds. Mean ± SD, n=8 
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Figure 4-31. Dispersion of the measured porosity between replicates (squares batch 1 and 
circles batch 2) made at different times (quadruplicate scaffolds, shaded area). The porosity 
was calculated as the ratio between the volume of solvent inside the pores of the scaffold and 
the total volume of the scaffold. Mean ± SD, n=4.  
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Figure 4-32. Porosity of scaffolds fabricated in the array format (96-well plate, UV-curing 30 
min, porogenic solution 80 µL) or scaled-up scaffolds (polystyrene mould, UV-curing 60 min, 
porogenic solution 300 µL) for polymers A-D with three level of porogenic solvent (P0, P60 
and P80). Mean ± SD, n=8 (arrays) and n=4 (scale-up). 
 
4.2.3 Cell behaviour on the array  
I. Seeding conditions in the array 
 
The physical characterisation of the array of 3D polymer scaffolds confirmed that the 
fabricated scaffolds had close resemblance in terms of the physical properties of bone 
tissues such as an open porous structure and stiffness.[89] Polymer A was used to 
develop a strategy to screen cell behaviour in the array of 3D scaffolds. First, Polymer 
A fabricated with a range of porosities (P0, P20, P60 and P80) was used to optimise 
the seeding conditions and incubation time of SAOS-2 and MB-63 cells seeded at 
different concentrations (20,000 and 50,000 cells/well) with cell behaviour 
interrogated at days 2, 7 and 14 (tissue culture well plates were served as a control). 
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Cellular behaviour in the arrays was studied using alamarBlue™ (also known as the 
traditional Alamar Blue) as a descriptor of cells viability and proliferation. Alamar Blue 
relies on the reduction of resazurin (blue and weakly fluorescent) to resafurin (red and 
highly fluorescent) in living cells, which is related to cellular metabolism in addition to 
the number of cells (Figure 4-33).  
 
Figure 4-33. Calibration curve of the number of SAOS-2 cells plated and the resulting Alamar 
Blue fluorescence intensity. Alamar Blue in medium (10% v/v) was added to the wells 2 hours 
after seeding to ensure cell attachment to the plate. Incubation was performed for 4 hours in 
a humidified atmosphere (37 °C and 5% CO2). Supernatant was collected and, subsequently, 
fluorescence was read in a microplate reader (λex/em = 530/590). Mean ± SD, n=3. 
 
The seeding of 20,000 SAOS-2 cells on the 3D polymer scaffolds revealed the ability 
of the 3D polymers to attach and maintain the cells in addition to allowing proliferation 
(Figure 4-34). Polymer A showed a slightly lower cell attachment number and 
proliferation compared to tissue culture plates. For instance, cells in the control well 
tissue culture plates peaked at day 7 with about a 2.5-fold increase whereas polymer 
A showed a 1.5-fold increase at the same time. However, when the number of cells 
increased to 50,000 cells per well no proliferation was observed. MG-63 cells 
presented similar behaviour as the SAOS-2 cells (Figure 4-35). Polymer A allowed 
cell attachment and proliferation over 14 days in the majority of the 3D scaffolds 
seeded with 20,000 MG-63 cells while 50,000 cells produced no proliferation. Overall, 
both cell lines showed attachment and growth on the 3D polymer scaffolds. The 
seeding density of 20,000 cells per well was favoured as this showed differences in 
cell behaviour between scaffolds and proliferation over 14 days. The comparison 
between SAOS-2 and MG-63 cells suggested use of the first cell line over the second 
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for further studies as SAOS-2 cells were observed to be more selective whereas MG-
63 appeared to grow on all the 3D polymers explored. 
 
Figure 4-34. Viability of SAOS-2 cells over 14 days and optimisation of the cell seeding. 
Normalised fluorescence intensity at different time points for each sample (day 2, 7 and 14).  
Fluorescence intensity was normalised with SAOS-2 cells at day 2 in the control (tissue culture 
plate). Fluorescence changes were based on the reduction of resazurin (alamarBlue™). The 
arrays were fabricated using polymers A with different porosities (P0, P20, P60 and P80). 
Two-way ANOVA with Bonferroni post-test between day 2 and day 14 (* p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001 and **** p ≤ 0.0001). Mean ± SD, n=2. 
 
 
Figure 4-35. Viability of MG-63 cells over 14 days and optimisation of the cell seeding. 
Normalised fluorescence intensity at different time points for each sample (day 2, 7 and 14).  
Fluorescence intensity (alamarBlue™) was normalised with MG-63 cells at day 2 in the control 
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(tissue culture plate). Two-way ANOVA with Bonferroni post-test between day 2 and day 14 (* 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001). Mean ± SD, n=2. 
 
II. Morphology of cells and scaffolds using SEM 
 
The interaction between the polymer scaffold and the SAOS-2 cells was investigated 
using scanning electron microscopy (SEM). An array of 3D polymer scaffolds was 
prepared with “slow cooling” with different levels of DMSO. The cells were incubated 
on the arrays for 3 days (control scaffolds without cells) and fixed. After removing the 
polymers from the arrays and post-fixation of the cells with osmium tetroxide (OsO4) 
to improve contrast, the scaffolds were dried and coated (gold/palladium).  
Polymer microstructure in the presence and absence of cells was evaluated with 
SAOS-2 cells seen to attach and cover the surface of the scaffolds after 3 days (Figure 
4-36). A few rounded cells were also observed, which was an indication of poor 
attachment at some regions leading to cell death. Laminar organisation of the polymer 
with pores around 50 µm in size were seen in the P60 scaffolds with medium porosity. 
Pores of around 100 µm were observed to be populated with cells in the case of the 
P80 scaffolds.  
 
Figure 4-36. SEM images of the scaffolds incubated with SAOS-2 cells. Scaffolds P60-A 
(medium porosity) and P80-A (high porosity) with SAOS-2 (+) cells and without cells (-) after 
3 days of incubation. Pseudo colour added to the cells (green) to help their visualisation. Scale 
bar = 100 µm. 
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III. Cell mineralisation on the array of 3D polymer scaffolds 
 
Biomineralisation is one of key steps in the formation of bones where apatite minerals 
are formed as part of the extracellular matrix, mediated by osteoblasts.[176] The 
biomineralisation on the polymer scaffolds was assessed to further examine their 
functionality. As a preliminary approach, the mineralisation of SAOS-2 cells on the 
array of 3D polymer scaffolds were interrogated for polymer A with 4 levels of porosity 
(P0, P20, P60 and P80) over 7 days in mineralisation medium (L-ascorbic acid 2-
phosphate and potassium dihydrogen phosphate). Subsequently, SAOS-2 cells were 
fixed and stained with acid alizarin red.[143]  
Microscopy showed the absence of colour for P0-A scaffolds and increased intensity 
of the red stain with increase of porosity (Figure 4-37, 1). The positive control (96-well 
tissue culture plate) gave a result similar to P20-A. Additionally, negative controls 
(scaffolds without SAOS-2 cells) exhibited red staining with lower intensity compared 
to their counterparts.  
The quantitative data of the alizarin red staining in the scaffolds obtained with 
polymer A were calculated as the difference between an array with SAOS-2 cells and 
a control without cells. The normalised absorbances were also consistent with the 
qualitative analysis and the intensity of the alizarin red staining was found to be 
directly proportional to the increase of porosity (Figure 4-37, 2). For example, P0-A 
did not show any difference to the positive control tissue culture plate (TC) whereas 
P60-A and P80-A showed a significant increase with respect to the control. The higher 
background staining in the control array (SAOS-2 negative) was possibly due to the 
inherent non-specificity of the stain (alizarin red binds to calcium), which increased 
proportionately with porosity. Non-mineralised calcium or alizarin red stain could be 
retained in the polymer scaffolds because of the large surface areas and the 
extracellular matrix of the SAOS-2 cells. Consequently, a different approach was 
needed to examine the mineralisation which would be more specific towards apatite 
rather than just calcium. 
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Figure 4-37. Mineralisation of SAOS-2 cells on the 3D polymer scaffolds. 1) Representative 
images of polymer A with different levels of porosity (P0, P20, P60 and P80) and SAOS-2 
cells stained with acid alizarin red after 7 days of incubation in mineralisation medium. 
Scaffolds without cells and SAOS-2 cells in tissue culture plates (TC) were used as control. 
Scale bar = 500 µm. 2) Normalised absorbance (A/ATC) between SAOS-2 cells stained with 
alizarin red on the control plate (TC) and the scaffolds. Absorbance based on the extraction 
and homogenisation of the alizarin red staining. One-way ANOVA with Bonferroni post-test 
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IV. Cell viability assay on the array of 3D polymer scaffolds 
 
The viability of SAOS-2 cells was interrogated on all 24 3D polymer scaffolds 
fabricated in quadruplicate in 96-well plates (Figure 4-29). SAOS-2 cells were 
assessed with Alamar Blue at days 1, 3 and 7.  
Scaffolds P0 for polymers A, B and D were observed to allow attachment of SAOS-2 
cells whereas the cells did not bind to P0-C scaffolds (Figure 4-38). Most of the 
scaffolds also displayed a reduction in the number of SAOS-2 cells with an increase 
of porosity (from P0 to P85). Among the four different polymer compositions studied, 
polymer B was able to maintain a good number of cells (little differences compared 
TC) and promoted proliferation in the scaffolds P60 and P80. For instance, the 
normalised fluorescence intensity for P60-B changed from 0.9 to 1.4 from day 1 to 7 
and from 0.6 to 1.1 for P80-B in the same period. Contrary, porous scaffolds of 
polymers A and D showed a negligible or poor increase in the number of SAOS-2 
cells.  
Overall, the screening of the scaffolds using SAOS-2 cells revealed the significant 
influence of polymer composition and the 3D structure on the cellular behaviour of 
attachment and growth. Polymers A and B were selected for further experiments 
because of their ability to maintain SAOS-2 cells (polymers A and B) and stimulate 
proliferation (polymer B). 
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Figure 4-38. Viability of SAOS-2 cell over 7 days on the 3D polymer scaffolds. Normalised 
fluorescence intensity between the SAOS-2 cells seeded at day 1 in the control (tissue culture 
plate, 20,000 cells/well) and at day 1, day 3 and day 7. Two-way ANOVA with Bonferroni post-
test between tissue culture plate and the scaffolds. Colour scale shows the level of significance 
representing the differences to TC: No differences (cyan, p>0.5), different (yellow, p≤0.01) or 
very different (red, p≤0.0001). Two-way ANOVA with Bonferroni post-test between day 1 and 
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V. Live/dead staining assay on the array of 3D polymer scaffolds 
 
The cell viability assay using Alamar Blue was complemented with a live/dead staining 
assay. Polymers A and B were fabricated with four levels of porosity (P0, P60, P80 
and P80) and SAOS-2 cells were incubated for 7 days prior to live/dead staining. 
Differences in the cell attachment were confirmed between the non-porous P0 
scaffolds and the porous scaffolds P60, P80 and P85 with P60-B showing the highest 
cell density in the porous polymers (Figure 4-39). Interestingly, it was observed that 
some cells infiltered or moved into the pores. P80 and P85 for polymer A and B had 
much of their surface covered by healthy cells (labelled in green) although a few dead 
cells (labelled in red) were also observed.  
 
Figure 4-39. Viability of SAOS-2 cells on the 3D scaffolds. Live/dead staining of SAOS-2 cells 
after 7 days of incubation. Polymers A (1-2) and B (3-4) with low (P0), medium (P60) and 
high (P80 and P85) porosity. Merged images of live (calcein AM, green) and dead cells 
(nuclear dye, red). White dashed square indicates areas magnified (2 and 4). Scale bar = 200 
µm. 
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The array of 3D polymer scaffolds allowed live cell imaging and high-content 
screening using an automated imaging capturing systems. The presence of cells in 
different layers of the scaffolds and the uptake of the dyes by the porous structure, 
was revealed to be a major challenge of the method as they produced high signal to 
noise ratios in the images, which hindered quantification (Figure 4-40).  
 
Figure 4-40. Viability of SAOS-2 cells on the polymer A. Live/dead staining of SAOS-2 cells 
after 7 days of incubation. Merged images of live (calcein AM, green) and dead cells (nuclear 
dye, red). 1) Z-stack (100 µm per image) of SAOS-2 cells (+) in different scaffolds of polymer 
A with medium (P60) and high (P80 and P85) porosity. Arrows show the area with cells in the 
plane. 2) Porous scaffolds without SAOS-2 cells (-) were used as negative control. Scale bar 
= 200 µm. 
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VI. Morphology of SAOS-2 cells in the array of 3D polymer scaffolds 
and analysis of the cytoskeleton orientation 
 
The morphology of SAOS-2 cells and their cytoskeleton orientation was analysed for 
scaffolds P60 and P80 of polymers A and B as they had shown to be the best 3D 
polymer scaffolds in the library in terms of biocompatibility. Filamentous actin of 
SAOS-2 cells on porous scaffolds were stained with a phalloidin staining and scaffolds 
without cells were used as a control for non-specific staining.   
Cells in different layers* of the scaffolds were detected in the P80 scaffolds after 7 
days of culture (Figure 4-41), and observed to spread and grow along the polymer 
structure. Additionally, large pores (larger than 200 µm) were seen for these scaffolds. 
On the other hand, poor cell spreading and with a less elongated morphology were 
observed in case of the P60 scaffolds with cells growing mostly on top of the materials. 
Poor penetration of SAOS-2 cells in the scaffolds was a probable consequence of 
inappropriate pore size (smaller than 100 µm).  
 
Figure 4-41. Representative images of the actin cytoskeleton of SAOS-2 cells on the 3D 
polymer scaffolds with medium (P60) and high porosity (P80). F-actin stained with Alexa Fluor 
568 phalloidin is shown in red and nucleus in cyan. Scale bar = 100 µm.  
 
* Videos of SAOS-2 cells in P60 and P80 scaffolds are included in the electronic copy. Array 
of 3D polymer scaffolds: Actin staining of SAOS-2 cells 
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Figure 4-42. Analysis of the orientation of the filaments of the actin cytoskeleton of SAOS-2 
cells on the 3D polymer scaffolds after 7 days of incubation. 1) Colour map of orientation of 
the filaments of the actin cytoskeleton of SAOS-2 cells. Scale bar = 100 µm. 2) Quantification 
of the distribution of angles (degrees) of the filaments of actin. 3) Full width at half maximum 
(FWHM) of the distribution of orientations fitted to Gaussian curves for scaffolds P60 and P80 
(polymers A and B). Low FWHM indicates orientation of actin fibres. Two tailed t-tests 
between the paired scaffolds (** p ≤ 0.01). Mean ± SD, n=2. 
 
The potential organisation of actin filaments of SAOS-2 cells as a consequence of the 
polymer structure was analysed using the software ImageJ-Fiji (OrientationJ). The 
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orientation of the actin filament in the scaffolds shown using a colour map (Figure 
4-42, 1) and complementary distribution curves (Figure 4-42, 2) suggested the 
prevalence of one main direction of the actin filaments in the P80 scaffolds compared 
to the P60 scaffolds. The full width at half maximum (FWHM) of the histogram 
obtained for the distribution of orientation was used to analyse the orientation of the 
actin filaments (Figure 4-42, 3). Oriented actin filaments showed narrow histograms 
and low values of FWHM. The significant reduction of the full width at half maximum 
for P80-B compared to P60-B confirmed the change of morphology attributed to the 
3D structure of the scaffolds. 
 
4.2.4 The behaviour of SAOS-2 cells is altered by polymer 
composition, 3D structure and mechanical properties  
 
One of the objectives of developing arrays of 3D polymer scaffolds was to compare 
the mechanical and structural properties of the scaffolds with cell behaviour. Cell 
attachment and proliferation, viability for day 1 and day 7 with Alamar Blue, scaffold 
stiffness with indentation modulus and relaxation were compared. Each property was 
normalised with the highest property observed. For example, stiffness for the 12 
polymer scaffolds exploring polymers A-D with porosities P0, P60 and P80 were 
normalised to 40.3 MPa, the highest value obtained.  
Scaffolds P0-A and P0-B exemplified two polymer compositions that presented good 
cell attachment and maintenance (Figure 4-43). The increase of porosity (P60-A and 
P80-A) produced a reduction in initial binding and proliferation of SAOS-2 whereas 
scaffolds P60-B and P80-B were capable of maintaining proliferation although initial 
cell attachment was compromised. On the other hand, scaffolds P0-C neither showed 
significant cell attachment nor proliferation and the increase of porosity did not 
produce variations in this trend.  
Generally, the stiffness of the scaffolds was shown to decrease as porosity increased. 
However, the reduction of stiffness for P60-A and P80-A scaffolds was more 
pronounced than in the cases of P60-B and P80-B. Relaxation of the scaffolds was 
shown to be closely associated with the polymer composition and was not significantly 
affected by the porosity, moreover, an effect of relaxation on cell behaviour was not 
observed.   
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Figure 4-43. Spider plot analysis of the combined effect of the mechanical properties and 
porosity on the attachment of SAOS-2 cells and their proliferation behaviour. Polymers A - D 
with low (P0), medium (P60) and high (P80) porosity. Each property interrogated (attachment, 
proliferation, stiffness, relaxation load and porosity) was normalised with the highest identified 
value from the 3D screening. The highest and lowest values for each property of the 3D 
polymer scaffolds were: attachment fold change at day 2 (1.1 – 0.3), proliferation fold change 
at day 7 (1.4 – 0.1), stiffness (40.3 MPa – 13.4 kPa), percentage of relaxation load (58 – 5) 
and percentage of porosity (89 – 1). 
 
Overall, polymer composition, stiffness of the polymer and 3D architecture were 
shown to be closely interconnected and affected cell behaviour. Amongst the various 
structural properties of the scaffolds analysed, previous reports suggests that 
mechanical properties of the substrate are crucial for tuning cell behaviour.[177–180] The 
comparison of stiffness and proliferation exhibit the presence of a working range of 
stiffness from about 500 kPa to 20 MPa where the SAOS-2 cells were sustained or 
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proliferated independently of the polymer composition (Figure 4-44). Below or above 
this range, SAOS-2 cells were found to encounter difficulties in maintaining their 
growth on the scaffolds. Cell proliferation was optimum in scaffolds produced from 
polymer B even though the stiffness of scaffolds obtained with polymers A and D 
were also in the same range. Therefore, it indicates that the polymeric substrate also 
provides chemical cues and that the mechanical signals alone are insufficient to drive 
a specific cellular behaviour.  
 
Figure 4-44. Effect of the indentation modulus, “stiffness”, on the proliferation of SAOS-2 cells. 
Proliferation shown as fold increase of fluorescence based on Alamar Blue between day 1 and 
day 7. Scaffolds with low (P0), medium (P60) and high (P80) porosity were generated with 
polymers A - D. The indentation moduli of the scaffolds (stiffness) were analysed using a flat 
indenter for 20% of the strain. Each modulus was calculated using the linear model previously 
stated. Mean ± SD, n=3. 
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4.3 Discussion 
 
Microarray technology has been shown to be an outstanding approach to discover 
new polymeric biomaterials for multiple tissue engineering applications e.g. control 
the growth of human embryonic stem cells or mesenchymal stem cells.[30,31] These 
microarrays are generally comprised of thousands of different polymer features on a 
single glass slide, enabling their high-content screening with cells adhering to the 
polymers forming a “monolayer”. However, the loss of their native 3D 
microenvironment typically would give aberrant cellular behaviour. The development 
of an array of 3D polymer scaffolds could overcome these limitations offering variety 
in terms of composition, 3D architecture and mechanical properties. Previous reports 
have shown that 3D acrylate polymers are excellent candidates to engineer bone 
tissues.[120,121] Herein, an array of 3D polymer scaffolds was used to identify porous 
polymers that maintained human osteosarcoma bone cells, with SAOS-2 and MG-63 
cells selected as human osteoblast models.[165,181] Scaffolds and cells were targeted 
to constitute in vitro bone models as some properties of the scaffolds resemble the 
characteristics of bone tissue in terms of an open porous structure and stiffness.[89]  
Initially, four different polymer compositions (Table 4-1 and Figure 4-4) were selected 
based on standard microarray screening of 180 different polymers using SAOS-2 and 
MG-63 cells (Figure 4-3).  
The approach sought to allow the tuning of the 3D architecture and mechanical 
properties along with composition of the array features, which can lead to differences 
in cell behaviour. Herein, photo-polymerisation and freeze-casting were combined to 
robustly generate different acrylate polymers with 3D porous structures. The process 
included preparation of the solution, cooling/templating, UV photo-polymerisation and 
washing enabled the fabrication of multiple 3D scaffolds in a single 96-well plate 
(Figure 4-5). One of the key steps in the process was to maintain the solution in the 
frozen state during the photo-polymerisation and to ensure homogenous heat transfer 
through the polypropylene well plate, which was achieved using a custom-made 
aluminium cooling block and a dry ice bath.  
The porogenic solvent (DMSO) and the polymerisation mixture comprising of photo-
initiator, cross-linker and monomers, upon freezing, forms two phases: one rich-in-
monomers and another rich-in-solvent. The photo-polymerisation of the frozen 
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sample after phase separation, templating, produced the porous network, a phase 
rich-in-solvent, and the polymer scaffold, phase rich-in-monomers. Small pores were 
evident in the absence of the cooling stage (Figure 4-6) as a consequence of a second 
mechanism involved, polymerisation induced phase separation. In this second 
mechanism the cross-linked polymers become insoluble during the polymerisation, 
which also produces phase separation resulting in formation of porous polymers.[73] 
Although freeze-casting was shown to be more effective in large pores formation, the 
interplay of both mechanisms gave rise to the 3D polymer scaffold.  
Four cooling stages (Figure 4-7) were explored to maximise the quantity and size of 
the pores (Figure 4-8). SEM and ImageJ-Fiji (Figure 4-9) were used to analyse as 
well as quantifying the characteristics of the pores depicting the fact that a gradual 
change of the temperature (so-called “slow cooling”) in the freezing step produced 
optimal results (Figure 4-10). SEM and ImageJ-Fiji were also employed to determine 
the effect of the DMSO level on the polymer’s 3D architecture. Increasing the 
porogenic solvent was shown to favour the formation of pores, but the Feret’s 
diameter of these pores were found to be reduced (Figure 4-12). Approximately 30% 
of these pores were found to be in the range of 50 µm to 300 µm (Figure 4-14), 
deemed optimal for scaffolds in the case of bone repair.[22] 
SEM images are a 2D slice of a 3D structure of the scaffold’s surface thus the data 
obtained were limited. Moreover, the preparation of the samples for SEM with a 
conductive coating can modify some of the properties measured. A high-throughput 
approach using micro-CT was developed to overcome these limitations as well as to 
acquire the data related to the morphological characteristics of the array of 3D 
polymer scaffolds.[182] The 3D structure of the scaffolds was positively correlated with 
the concentration of DMSO (Figure 4-15). 3D images illustrated the gradual increase 
of pores (Figure 4-16 and Figure 4-17) and porosity (Figure 4-18) with the increment 
of porogenic solvent. An optimal porous scaffold with large open porosity and big 
pores was formed with 80% DMSO (Figure 4-19). Increase of porogenic solvent did 
not produce any additional improvement of the porous structure but weakened the 
polymer network, causing it to collapse.  
The size of the interconnection between pores (Figure 4-20 and Figure 4-21), a critical 
property to understand cell migration into the scaffolds, showed that a good proportion 
were larger than 100 µm for the P80 scaffolds (Figure 4-22). All together, these 
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findings suggest that the array of 3D polymer scaffolds developed can imitate the wide 
diversity of 3D microenvironment of bone tissues. For example, the outer layer of the 
cortical section of bones is highly dense with low number of cells and porosity, similar 
to the P40 or P60 scaffolds. On the other hand, the inner layer of many bones is an 
extremely porous and vascularised structure, trabecular section, with higher density 
of cells, comparable to P80 scaffolds.[89,104] Moreover, the presence of pores larger 
than 200 µm suggested that P80 scaffolds could be potential candidates to promote 
in vivo vascularisation.[112]  
Deeper insight into the physical properties of the polymeric biomaterials was gained 
using macro-indentation,[137,183] which allowed measurement of the indentation moduli 
of the 3D scaffolds (Figure 4-23). Mechanical properties of the polymer scaffolds were 
shown to be tuned with respect to the polymer composition (Figure 4-24) and the level 
of porosity (Figure 4-25). For example, scaffolds with large porosity (P80) displayed 
a significantly reduced indentation moduli compared to scaffolds of low and medium 
porosity (P0 and P60), which were comparable. Scaffold density was used to 
normalise the indentation moduli in order to elucidate the effect scaffold 3D 
microstructure has on its mechanical properties (Figure 4-27), confirming that porosity 
was the main reason for reduced stiffness. These differences between mechanical 
properties of scaffolds were a result of complex interplay of polymer composition, level 
of DMSO and 3D architecture characteristics. For example, the formation of an 
anisotropic material has been shown to increase the stiffness of a scaffold compared 
to a more randomly distributed structure.[172] Overall, the indentation moduli were 
found to cover a broad range of tissues such as kidneys or muscles (6 and 16 kPa 
correspondingly), collagenous bone (≈ 100 kPa) and mineralised bone (from 6 to 14 
GPa), which successfully shows that a variety of tissues can be explored in the 
future.[103,136] 
The relaxation load is an important mechanical property for tissues such as bone and 
cartilage that undergo sustained stress.[184] Healthy bone and cartilage are 
viscoelastic tissues with relatively good elastic properties that protect the tissues from 
plastic deformation.[185,186] Cancellous bone exhibits a broad relaxation load that vary 
from 19% after 7 min and 26% after 100 seconds,[187,188] while human costal cartilage 
has a relaxation load of about 60% after 2 min.[189] Relaxation load for the polymer 
scaffolds explored here varied from 16% to 57% after 5 min in the case of scaffolds 
P80-B and P80-D (Figure 4-28). Consequently, the polymer scaffolds were observed 
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in the range of both bone and cartilage which suggests that scaffolds could support 
either tissue, hence expanding their applicability in the area of both bone and cartilage 
repair.    
24 polymer scaffolds, 4 polymer compositions with 6 levels of DMSO, were 
constructed in quadruplicate to obtain an array of 96 scaffolds (Figure 4-29). The 
effect of DMSO level on the porosity was analysed using a liquid displacement 
approach (Figure 4-30). The reproducibility (Figure 4-31) and scalability (Figure 4-32) 
of the technique to fabricate arrays of porous polymers was confirmed. Porosity was 
independent of the polymer composition in agreement with previous SEM or micro-
CT analysis. Moreover, thermogravimetric analysis showed polymer stability below 
300 °C (appendix B).     
An array of 3D polymer scaffolds based on polymer A was used to develop an 
efficient route to screen SAOS-2 cellular behaviour on porous polymers. Alamar Blue, 
SEM and Alizarin red were used to assess cell viability, cell-scaffold morphology and 
biomineralisation. Alamar Blue showed that SAOS-2 cells were more selective to the 
scaffolds than MG-63 (Figure 4-34 and Figure 4-35), which was also consistent with 
the results of the microarray. The integration of SAOS-2 cells within the scaffolds and 
formation of ECM on the polymer structure was shown for scaffolds P60-A and P80-
A using SEM (Figure 4-36). The mineralisation of SAOS-2 cells in the model array of 
3D polymer scaffolds was tested using a colorimetric assay based on acid alizarin red 
after 7 days of cell incubation in mineralisation medium.[143] The scaffolds based on 
polymer A (P0 to P80) showed an increase of mineralisation with increase of porosity 
(Figure 4-37). However, negative controls showed a strong non-specific binding.[190] 
Among the three different assays performed in the array of polymer A (cell viability 
with Alamar Blue, cell morphology with SEM and mineralisation with alizarin red), 
Alamar Blue was chosen to further screen the 24 3D polymer scaffolds (Figure 4-29). 
Alamar Blue was non-destructive as several assessments on the same scaffold can 
be performed. Moreover, reagents and products, resazurin and resorufin, are highly 
soluble in water. 
From the four polymer compositions explored in the array only the scaffolds of 
polymer B were shown to be successful candidates to fabricate porous biomaterials 
(Figure 4-38). These scaffolds presented little differences in the number of SAOS-2 
cells compared with the tissue culture plate (control) and showed a significant 
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increase in the number of cells between days 1 and 7 suggesting robust cell 
proliferation. By contrast, polymer A could maintain SAOS-2 cell for the same length 
of time, but cell proliferation was not observed.  
SAOS-2 cell viability and scaffold toxicity were further evaluated by a live/dead 
staining (Figure 4-39).  Polymers A and B with low (P0), medium (P60) and high (P80 
and P85) porosity were selected as they represented different cell behaviour in the 
previous screening. The assay showed high cell viability for these scaffolds with few 
dead cells in the 3D scaffolds which was corroborated by Alamar Blue. Automated 
microscopy and high-content screening allowed live 3D cell imaging in the porous 
scaffolds, however, it was revealed as one of the challenges of the approach as the 
presence of cells in different layers and the uptake of dyes by the porous structure 
increased background fluorescence, compromising the quality of the imaging (Figure 
4-40). 
Distribution of SAOS-2 cells on the 3D scaffolds of polymers A and B with medium 
(P60) and high (P80) porosity showed the cells in different layers of the 3D structure 
(Figure 4-41). Polymers with the largest pore size (P80) had cells in deeper layers of 
the scaffolds in comparison with the P60 scaffolds, demonstrating the vast potential 
to construct tissue-like 3D structures. The analysis of the cytoskeleton orientation of 
SAOS-2 cells on the 3D scaffolds indicated that polymer scaffolds with large porosity 
changed the orientation of the filament of actin from disorganised (P60) to more 
organised (P80) distributions (Figure 4-42). The potential reorganisation of the actin 
filaments because of the polymeric structure, geometric cues, can promote 
differences in mechanotransduction mechanisms that guides differences in the 
cellular fate as previously described.[16,159]  
The analysis of the combined effect of mechanical properties (stiffness and load 
relaxation) and porosity on SAOS-2 cell behaviour (attachment and proliferation) 
allow for a deeper understanding of cell – biomaterial interactions (Figure 4-43) in the 
case of polymer scaffolds with low (P0), medium (P60) and high (P80) porosity. 
Stiffness of the 3D scaffolds in the range of 500 kPa to 20 MPa were shown to be the 
driving force for attachment of SAOS-2 cells and their maintenance over seven days 
in culture (Figure 4-44). Moreover, cell proliferation obtained on polymer B scaffolds 
highlighted the importance of providing the right chemical as well as physical cues.[191]  
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4.4 Conclusions 
 
Successful functional biomaterials need to provide the right collection of mechanical, 
physical and chemical signals that enhance or drive cell behaviour. However, the 
enormous variety of different cues that act simultaneously hinder a full understanding 
of these processes. High-throughput approaches have played a crucial role to 
untangle these mechanisms as they allow screening of multiple combinations 
simultaneously. However, current combinatorial technologies still struggle to take into 
account the material signals found in 3D architectures. 
Herein, a method to fabricate arrays of 3D polymer scaffolds was developed where 
the chemical composition of acrylate polymers in addition to their 3D structure and 
mechanical properties were controlled. Multifunctional 3D structures in the form of 
arrays of 96 polymer scaffolds were fabricated via freeze-casting in a standard cell 
culture platform. Characteristics of the porous polymers were tuned using different 
gradients of temperature and concentration of the porogenic solvent i.e. DMSO. A 
high-throughput micro-CT approach was developed to analyse the effect of DMSO 
concentration on the 3D structure, revealing the majority of the quantified pores and 
throats were larger than 100 µm. Additionally, the mechanical characteristics of these 
scaffolds were tuned using different levels of DMSO to cover a wide range of 
compressive properties that mimic the mechanical properties of a variety of tissues 
from muscles to collagenous bone.  
Bone tissue was selected as a proof of concept for understanding the applicability of 
developed method. The osteosarcoma bone cells, SAOS-2, were used to screen and 
select the scaffold composition in addition to exploring the limitations of the 3D 
platform. Proliferation was found to be maximal in porous scaffolds of polymer B, 
poly(IBA72-co-HDOBA18), fabricated with DMSO as the porogenic solvent via cryo-
polymerisation. Overall, the array of 3D scaffolds was shown to provide different 
polymer compositions, 3D structures and mechanical properties allowing a detailed 
study of the combined effects of these characteristics on cell behaviour.  
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5. Discovery of 3D polymer scaffolds with 
enhanced vascularisation for bone repair 
 
The work presented in this section was carried out in collaboration with Dr 
Deepanjalee Dutta and Mr Michael Glinka. Dr Dutta supported the 
immunofluorescence analysis of osteogenic markers while Mr Glinka carried out the 
in vivo implantation of scaffold in choriallantoic membrane (CAM) and mouse 
subcutaneous models.  
 
Parts of this chapter have been submitted as: 
 
A. Conde-González*, M. Glinka*, D. Dutta*, (equal contribution) R. Wallace, D. 
Norman, A. Callanan, R. O. C. Oreffo and M. Bradley (2019). 3D Porous Growth-




Stem cell-based transplantation therapies have shown huge potential in the treatment 
of diseased tissues. For example, human tracheal replacement therapy was explored 
using a decellularised trachea obtained from a cadaveric donor seeded ex vivo with 
MSCs.[192] However, these approaches need to artificially isolate and expand stem 
cells. Additionally, these approaches had a limited effect for an extended period. 
Synthetic polymer scaffolds have been successfully applied to support stem cell 
growth and function in stem cell transplantation strategies.[193] For example, Atala et 
al. successfully engineered an autologous bladder as an alternative to current end-
stage disease bladder therapy.[194] The approach used engineered scaffolds based 
on homologous decellularised donor bladder submucosa and a collagen-poly(glycolic 
acid) composite. Autologous urothelial and muscle cells were seeded into these 
scaffolds and implanted during cystoplasty as an alternative to current therapies using 
gastrointestinal tissue.  
Bone is known to be a highly challenging tissue to repair, owing to the complexity of 
its physiological microenvironment, which includes a mineralised extracellular matrix, 
a soluble phase of growth factors and multiple cellular components such as 
osteoblasts, osteoclasts and osteocytes. Additionally, bone tissue is also 
metabolically active with supply of oxygen and nutrients by an extensive vasculature. 
One particularly demanding aspect for 3D biomaterials is the ability to promote 
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vascularisation, which triggers a cascade of molecular and cellular events leading to 
bone healing processes.[89]  In order to induce successful bone tissue, scaffolds need 
to promote substantial vascularisation to avoid tissue necrosis. Angiogenesis is 
controlled by host endothelial cells in the blood vessel inner lining, secreting growth 
factors such as VEGF, vascular endothelial growth factor, triggered by hypoxia. 
Moreover, VEGF is known to control skeletal progenitor cell differentiation and 
osteoblast behaviour, which is considered to be a prerequisite for osteogenesis to 
occur.[95] On the other hand, a previous report suggests that primary human 
osteoblasts guide host endothelial cells to proliferate and migrate into silk fibroin 
scaffolds promoting vascularisation.[195] To enhance vascularisation, previous 3D 
scaffold approaches have also explored the use of calcium phosphate and metal ions 
as well as osteogenic dopants with the release of growth factors such as BMP-2 and 
VEGF.[196–199] For example, Oreffo demonstrated the release of encapsulated vitamin 
C (2-phosphate-L-ascorbic acid) and VEGF from poly(lactic-co-glycolic acid) 
nanoparticles covalently bonded to 3D porous scaffolds via biotin-avidin 
conjugation.[150]    
Microarray technology has enabled the high-throughput screening of biomaterials. 
However, these polymer biomaterials have been selected based on cells in “2D” 
(monolayer of cells adhered to the polymer surface) and current available approaches 
are not able to recapitulate the requisite “3D” in a multi-material and multi-
microstructure design.[160] In order to become truly outstanding alternatives, “3D”  
biomaterials need to recapitulate the complex physicochemical and mechanical space 
of native tissues.[180,200] In this chapter, a 3D screening method was established to 
study the effect of 3D polymer scaffolds on foetal bone marrow stromal cells 
(FBMSCs). FBMSCs were isolated as per the ethical approval obtained from 
Southampton & South West Hampshire Local Research Ethics Committee 
(LREC296/100).  These cells were selected for 3D screening because of their ability 
to drive osteoblastic differentiation and their highly proliferative behaviour.[201] 
Subsequently, the top 3D polymer candidates were validated in vitro, to assess 
FBMSCs differentiation state. Additionally, ex vivo validation was performed with 
chick chorioallantoic membrane (CAM) and an in vivo mouse subcutaneous model 
was employed to evaluate scaffold biocompatibility and angiogenic potential (Figure 
5-1).  
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Figure 5-1. 3D screening and validation approach to develop 3D polymer scaffolds with 
enhanced vascularisation for bone repair. An array of 3D polymer scaffolds based on porous 
and non-porous polyacrylate substrates was prepared through freeze-casting and photo-
polymerisation. FBMSCs were used to interrogate the 3D polymer scaffolds and identify 
optimal polymer composition and 3D microstructure. Selected candidates were scaled-up to 
assess osteogenic markers, biocompatibility and angiogenesis.   
 
5.2 Results 
5.2.1 Screening of 3D polymer scaffolds and characterisation 
I. Substrate selection and 3D array fabrication 
 
Five acrylate-based monomers were selected to fabricate 3D polymer scaffold arrays 
(Figure 5-2). These acrylates monomers were chosen on the basis of their ability to 
produce polymers that promoted bone cell line attachment (appendix A and section 
4.2.1) and control stem cell fate.[30] Moreover, polymers of EGDPEA were used as a 
control with low bone cell line attachment. These five monomers and their 
combinations were used to obtain 15 different co-polymers (Table 5-1).   
Arrays of 3D porous scaffolds in flat-bottomed polypropylene 96-well plates were 
obtained via freeze-casting and photo-polymerisation, using DMSO as the porogenic 
solvent and the slow cooling approach (5 °C for 16 h followed by -20 °C for 4 h) as 
previously established. FTIR fingerprints were used to characterise the scaffolds after 
cryo-polymerisation and to ensure the efficiency of the washing step in removing 
unreacted components (Figure 5-5).[202,203]  The 15 different polymer mixtures were 
combined with three levels of DMSO to obtain scaffolds P60 with “medium” (60% v/v 
Discovery of 3D polymer scaffolds with enhanced vascularisation for bone repair 110 
DMSO), P80 with “high” (80% v/v DMSO) porosity and their non-porous control P0 
(0% v/v DMSO). These combinations resulted in an array containing 45 different 3D 
structures.  
 
Figure 5-2. Monomers, cross-linker and photo-initiator that were used to fabricate the selected 
co-polymers. 4-tert-butylcyclohexyl acrylate (BHA), isobornyl acrylate (IBA), 2-
(methylthio)ethyl methacrylate (MTEMA), butyl methacrylate (BMA), ethylene glycol 
dicyclopentenyl ether acrylate (EGDPEA), the cross-linker 1,6-hexanediol diacrylate (HDOBA) 
and the photo-initiator (PI) hydroxy-2-methylpropiophenone. 
 
Table 5-1. The polymerisation mixtures/monomer ratios were obtained by mixing the acrylate 
monomers A and B, the cross-linker (18 mol %) and the photo-initiator (10 mol %).  
Polymer Monomers  Monomers (mol %) 
A B A B 
1 IBA  - 72 - 
2 MTEMA  IBA 36 36 
3 MTEMA EGDPEA 36 36 
4 BMA BHA  36 36 
5 BMA IBA 36 36 
6 BMA EGDPEA 36 36 
7 BHA IBA 36 36 
8 BHA EGDPEA 36 36 
9 IBA EGDPEA 36 36 
10 MTEMA BMA 36 36 
11 MTEMA BHA 36 36 
12 MTEMA - 72 - 
13 BMA - 72 - 
14 BHA - 72 - 
15 EGDPEA - 72 - 
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Figure 5-3.  FTIR spectra of polymerisation mixture 12 (Table 5-1) before and after 
polymerisation. The scaffolds were obtained using DMSO (80% v/v) as the porogenic solvent 
and UV photo-polymerisation carried out on top of a dry-ice-bath (– 70 ºC) to maintain the 
samples in a frozen form. Ester IR fingerprints were seen in the monomer, cross-linker and 
polymer spectra between 1714 and 1721 cm-1. Vibrational peaks of the uncured monomer and 
cross-linker revealed the presence alkenyl stretching vibration at 1632 cm-1, which were 
absent after polymerisation.  
 
II. Screening of 3D polymer scaffolds with FBMSCs 
 
Arrays of 3D polymer were used to assay FBMSCs behaviour with proliferation 
assessed with Alamar Blue (Figure 5-4) over 21 days on the 45 scaffolds obtained by 
combining polymers 1-15 with three levels of porgenic solvent (P0, P60 and P80). 
Control, non-porous scaffolds (P0), showed a rapid increase in the number of 
FBMSCs in the majority of the polymers between days 0 and 2 followed by a 
stationary phase between days 7 and 21 (Figure 5-5 and Figure 5-6). FBMSCs on 
scaffolds P60 and P80 had slower proliferation rates reaching a plateau in cell 
proliferation at day 7 for the majority of the polymers. These observations suggested 
that FBMSCs covered all the available surfaces on the 3D scaffolds during the first 
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week of culture. Moreover, large differences between FBMSCs on scaffolds and on 
tissue culture well plates (control) were not observed at day 21 (Figure 5-9).    
 
Figure 5-4. Calibration curve of the number of FBMSCs plated and the resulting Alamar Blue 
fluorescence intensity. Alamar Blue in medium (10% v/v) was added to the wells 2 hours after 
seeding to ensure cell attachment to the plate. Incubation was performed for 4 hours in a 
humidified atmosphere (37 °C and 5% CO2). Supernatant was collected and, subsequently, 
fluorescence was read in a microplate reader (λex/em = 530/590). Mean ± SD, n=3. 
 
Based on these initial results, polymers 1-6 were selected for further analysis as 
polymers 1, 2 and 4-6 had a high proliferative rate, while polymer 3 was included as 
a control as FBMSCs showed lower proliferative behaviour on this material. Polymers 
7-15 were discarded as they showed large error bars (indicating poor reproducibility 
in the polymer characteristics) or had lower proliferation rate than the candidates 
selected. 
Total collagen deposition was quantified on a 3D array of polymers 1-6 with “medium” 
(P60) and “high” (P80) porosity along with their non-porous control (P0) using the 
picro-sirius red assay.[146,147] Increased collagen expression at day 21 was observed 
in the porous scaffolds (P60 and P80) of polymers 2 and 3 compared to non-porous 
scaffolds and tissue well plate controls (Figure 5-7). Overall, the majority of the porous 
polymer scaffolds exhibited larger total collagen deposition than controls, suggesting 
that the 3D microenvironment supports the formation of extracellular matrix (Figure 
5-9). 
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Figure 5-5. FBMSCs proliferation on the 3D arrays. Fold change of fluorescence (based on 
Alamar Blue) between day 0 (seeding 10,000 FBMSCs/well) and the scaffolds of polymers 1-
8 with medium (P60) and high (P80) porosity and their non-porous controls (P0) at days 2, 7 
and 21 (n=3). Two-way ANOVA with Bonferroni post-test (** p ≤ 0.01, *** p ≤ 0.001 and **** p 
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Figure 5-6. FBMSCs proliferation on the 3D arrays. Fold change of fluorescence (based on 
Alamar Blue) between day 0 (seeding 10,000 FBMSCs/well) and the scaffolds of polymers 9 
-15 with medium (P60) and high (P80) porosity and their non-porous controls (P0) at days 2, 
7 and 21 (n=3). Two-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
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Figure 5-7. FBMSCs total collagen on the 3D arrays. Fold change of absorbance (picro-sirius 
red staining of collagen) between the TC control and the scaffolds of polymers 1-6 with 
medium (P60) and high (P80) porosity and their non-porous controls (P0) after 21 days of 
incubation. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05 and ** p ≤ 0.01) was carried 
out between the control P0 and the porous scaffolds P60 and P80. Mean ± SD, n=3. 
 
An array of 18 polymer scaffolds (versions P0, P60 and P80 of polymers 1-6) was 
prepared to assess alkaline phosphatase activity (ALP), an early osteoblast 
differentiation marker. ALP activity was quantified at days 2, 7 and 21 and normalised 
to total DNA concentration and control tissue well plates using a previously published 
chromogenic approach.[148,149] FEBMSCs seeded into 3D polymer scaffolds showed 
an increase of ALP activity at day 7 followed by a subsequent reduction in ALP levels 
at day 21 across the majority of the conditions (Figure 5-8). However, TC control show 
reduced variation of ALP in the same period. P0 and P60 scaffolds of polymer 1, 2, 5 
and 6 did not showed large differences with TC control and followed the same trends. 
On the other hand, P0 and P60 scaffolds of polymers 3 and 4 displayed more ALP 
than TC control. FBMSCs expressed high levels of ALP on P80 scaffolds of polymer 
1 to 3, 5 and 6 at day 7 than at day 2 with a decrease of ALP at day 21. The highest 
change of ALP was produced on P80-3 scaffolds that showed a fold increase over 4 
decreasing to 0 at day 21. However, FBMSCs on constructs of polymer 4 displayed 
a delayed ALP activity at day 21. Overall, ALP levels were higher in the majority of 
the polymer scaffolds with high porosity than the control tissue culture (TC) well plate 
at day 7 (Figure 5-9) 
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Figure 5-8. FBMSCs alkaline phosphatase (ALP) quantification on the 3D arrays. Fold change 
of absorbance (chromogenic enzymatic cleavage of phosphatase substrate) between the TC 
control at day 2 and the scaffolds of polymers 1-6 with medium (P60) and high (P80) porosity 
and their non-porous controls (P0) at days 2, 7 and 21. Two-way ANOVA with Bonferroni post-
test (* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001) was carried out between day 2, day 7 and day 
21. Mean ± SD, n=2. 
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Figure 5-9. Summary of FBMSCs behaviour on the arrays of 3D polymer scaffolds (P0-P80) 
normalised with control FBMSCs on tissue culture well plates (TC). 1) FBMSCs proliferation 
on scaffolds of polymers 1-15 at day 21 (FBMSCs day 21/FBMSCs TC day 21). 2) FBMSCs total 
collagen on scaffolds of polymers 1-6 day 21 (Collagen day 21/Collagen TC day 21). 3) FBMSCs 
ALP quantification on scaffolds of polymers 1-6 at day 21 (ALP day 7/ALPTC day7).  
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III. 3D microstructure and mechanical characterisation of the 3D 
scaffolds 
 
Analysis of the scaffold 3D microstructure was achieved using micro-computed 
tomography (micro-CT). The high-throughput screening method employed 
rectangular sections of 96-well plates to obtain cuboids of twelve 3D polymer scaffolds 
(2×2×3 wells) that were scanned simultaneously. It allowed rapid assessment of the 
3D structure of 18 polymer scaffolds (versions P0, P60 and P80 of polymers 1-6).   
Representative images illustrate the changes in porosity and pore size with different 
DMSO levels (Figure 5-10). Representative longitudinal and transverse section for 
scaffolds P60-2 and P80-2 demonstrated the highly interconnected porous structure 
of P80 scaffolds with high porosity (Figure 5-11, 1). In contrast, P60 scaffolds 
contained fewer interconnected pores as a consequence of having higher polymer 
density. The porosity and pore size distribution of the 3D polymer scaffolds were 
quantified using the BoneJ plugin in ImageJ-Fiji.[134] The level of DMSO in the 
polymerisation mixture (from 0% to 80% v/v) was shown to control the degree of 
porosity in the scaffolds as expected (Figure 5-11, 2). The porosity for P0 scaffolds of 
polymer 1 to 6 were below 1% whereas P60 scaffolds varied between 55% and 70%. 
The highest porosity was achieved for P80 scaffolds of polymer 1 to 6 which excided 
80%. 3D distance modelling, using BoneJ, showed that the average pore size of the 
P80 scaffolds was close to 100 µm independent of polymer composition. Moreover, 
pore size distribution of several scaffolds, such as P80-2, was spread out much more 
than 200 µm.  
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Figure 5-10. 3D images of the porous scaffolds. Longitudinal section constructed using the 
micro-CT data of the array of 3D porous scaffolds for scaffolds with medium (P60) and high 
(P80) porosity and their non-porous control (P0) for polymers 1-6 (scale bar = 1.5 mm).  
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Figure 5-11. Morphological characterisation of the 3D polymer scaffolds using micro-CT. 1) 
Binary images (white polymer and black pores) of the longitudinal and transverse section for 
representative scaffolds P60-2 and P80-2 (scale bar = 1.0 mm). 2) Scaffold porosity (%) and 
pore size distribution (µm) calculated with computed spheres that fitted the pore space (using 
the ImageJ-Fiji plugin BoneJ). Red for P0, blue for P60 and green for P80. Mean ± SD, n=2. 
 
Indentation moduli, also known as stiffness, of the 3D polymer scaffolds was 
assessed using indentation. Scaled-up polymer scaffolds (≈ 12 mm length × 12 mm 
width × 1 mm height) of polymer 1-6 with medium and high porosity (P60 and P80) 
and their non-porous control (P0) were prepared using polystyrene moulds (12 mm 
length × 12 mm width × 7 mm height). The indentation moduli were calculated locally 
for 4 ranges of strain percentages (0-5, 5-10, 10-15 and 15-20) using a linear model 
for semi-infinite samples, ratio sample area to indenter diameter ≥3, as previously 
described.[135–137] In addition, the relaxation load for the 3D polymer scaffolds was 
measured after 5 min.[138,139] 
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The indentation moduli were shown to be reduced with an increase of DMSO. P0 
scaffolds had higher indentation moduli than scaffolds P60 and P80 with the exception 
of P60-2, which was shown to be stiffer than P0-2 (Figure 5-12). Strain range between 
5% - 10% were determined to be suitable for reducing the effect of the surface 
properties. In this range, P80-2 and P80-3 were observed to be 3 MPa and 22 kPa, 
which illustrates the broad range of mechanical properties provided by these high 
porosity scaffolds.  
Relaxation load of the 3D scaffolds was governed by scaffold composition, showing 
an increase in the load relaxation with the increase in porosity with the exception of 
polymer 1 scaffolds that displayed the opposite behaviour (Figure 5-13). Generally, 
P80 scaffolds achieved relaxation loads around 40%, for example, relaxation was 
47% in the case of P80-2.  
 
Figure 5-12. Indentation moduli for porous scaffolds (P60 and P80) and their non-porous 
control (P0) for polymers 1-6. Macro-indentation approach using a mechanical system for 
compression (Instron) equipped with a flat indenter (Ø = 1mm). Indentation moduli were 
calculated from the gradient of the load-displacement curves between 0%-5%, 5%-10%, 10%-
15% and 15%-20%. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001 and **** p ≤ 0.0001). Mean ± SD, n=4. 
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Figure 5-13. Load relaxations for porous scaffolds (P60 and P80) and their non-porous control 
(P0) for polymers 1-6.  Load relaxation (%) was calculated as the percentage reduction of 
load at maximum strain (20% strain) for 5 min from the load-time curves obtained by macro-
indentation. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
and **** p ≤ 0.0001). Mean ± SD, n=4. Mean ± SD, n=4. 
 
IV. Selection of 3D polymer scaffolds 
 
Understanding how the behaviour of FBMSCs is altered by polymer composition, 3D 
structure and mechanical properties is crucial to allow selection of a successful porous 
scaffold for tissue repair applications. Proliferation, total collagen deposition, alkaline 
phosphatase activity, mechanical properties and 3D microstructure were used to 
compare the 3D polymer scaffolds. Each property was described as a percentage of 
the highest parameter observed, for instance, the highest proliferation rate was 
achieved by P0-5 (8.7-fold increase between day 0 and 21) and thus its normalised 
value was set to 100%. The proliferation rate on scaffolds P0, P60 and P80 of 
polymers 1-6 is shown as a percentage relative to P0-5 proliferation.  
This analysis allowed us to determine that total collagen and ALP increased with 
porosity and pore size, although the proliferation rate was also slightly reduced (Figure 
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5-14). Overall, P80 scaffolds were observed to maximise osteoblastic markers in 
comparison to their non-porous control P0 scaffolds.  
To further proceed in scaffold selection, FBMSCs behaviour (proliferation, collagen 
deposition and ALP levels) with indentation modulus and pore size as scaffold 
descriptors were compared using the highest value obtained within the P80 scaffolds. 
For instance, the highest proliferation rate on P80 scaffolds was obtained for P80-4 
(6.2-fold increase between day 0 and 21) and its normalised value was set to 1. The 
proliferation rate of scaffolds P80 of polymer 1-6 is thus shown relative to P80-4 
proliferation. P80-2 scaffolds were identified as a well-balanced material able to 
support proliferation and to enhance collagen deposition and ALP in “3D” (Figure 
5-15). Moreover, P80-2 exhibited an excellent indentation modulus, even in the 
presence of large pores. P80-3 scaffolds were also observed to promote remarkable 
collagen deposition and ALP expression despite the limited cell proliferation. This 
phenomenon could indicate that P80-3 perhaps supports osteoblastic differentiation.  
3D microstructure and mechanical properties of scaffolds P80-1 and P80-5 were 
shown to be similar to P80-2; however, their lower collagen deposition suggested 
reduced extracellular matrix formation. Scaffolds P80-4 and P80-6 showed properties 
comparable to P80-2 although their lower ALP expression at day 7 suggested lower 
osteoblastic differentiation. Given all of the above, P80-2 and P80-3 were chosen for 
further studies.  
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Figure 5-14. Spider plots of FBMSCs behaviour on the scaffolds P0 (blue), P60 (yellow) and 
P80 (green) were compared with mechanical properties (indentation and relaxation load) and 
scaffold 3D structure (pore size and porosity). Each property interrogated was normalised (%) 
with the highest identified value from the 3D screening. The highest and lowest values for each 
property of the 3D polymer scaffolds were: proliferation fold change at day 21 (8.7 – 1.9), total 
collagen fold change at day 21 (4.8 – 0.8), ALP fold change at day 7 (4.0 – 0), indentation 
moduli (96.4 MPa – 22.8 kPa), percentage of relaxation load (53 – 4), pore size (175 – 2 µm) 
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Figure 5-15. Scaffold cumulative analysis: FBMSCs behaviour on the P80 scaffolds 
(proliferation rate at day 21, total collagen at day 21 and alkaline phosphatase at day 7) were 
compared with mechanical properties (indentation modulus) and scaffold pore size. Each 
property was normalised with the highest identified value on P80 scaffolds (proliferation 6.2-
fold, collagen 4.7-fold, ALP 4.0-fold, indentation modulus 9 MPa and pore size 146 µm). 
 
5.2.2 Validation of osteogenic differentiation on 3D polymer 
scaffolds 
I. FBMSCs morphology on the 3D polymer scaffolds  
 
FBMSCs were cultured on the scaled-up scaffolds (12 mm length × 12 mm width × 1 
mm height) P80-2 and P80-3, obtained with the “slow cooling” approach and photo-
polymerisation, for 7 and 21 days with scaffolds without cells used as a control. 
FBMSCs morphology and microstructure of the 3D polymer scaffolds were analysed 
using SEM (Figure 5-16), which showed cells attached to the scaffolds occupying the 
available surface as well as the intraporous space forming 3D assemblies (arrows). 
The absence of rounded cells (an indication of poor cell attachment and death) along 
with the presence of ECM deposition were identified as indicators of a healthy cell 
population. The control scaffolds showed interconnected pores larger than 100 µm 
which was in accordance with allowing cells in “3D”.   
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Figure 5-16. Representative SEM images of FBMSCs in 3D polymer scaffolds. FBMSCs were 
incubated on P80-2 and P80-3 scaffolds for 7 and 21 days. Scaffolds without cells were used 
as a control. Dashed squares and arrows showmagnified areas and cells in pores respectively. 
Scale bar = 400 µm.  
 
II. FBMBSCs osteogenic markers on 3D polymer scaffolds 
 
In vitro expression of biomarkers was evaluated by immunofluorescence staining to 
determine the differentiation state of FBMSCs. Cells were incubated in scaled-up 
scaffolds P80-2 and P80-3 for 2 and 7 days and ALP levels was used as an early 
osteoblast differentiation marker. Scaffolds P80-2 and P80-3 without FBMSCs were 
used as a negative control to assess non-specific antibody binding (Figure 5-17). 
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Figure 5-17. Assessment of non-specific ALP antibody staining in scaffolds P80-2 and P80-3 
without FBMSCs. Immunofluorescence was carried out in parallel with the scaffolds with 
FBMSCs using the same concentration of dyes and incubation times. Image acquisition and 
analysis was performed with the same parameters as the scaffolds with FBMSCs using a 
confocal microscope Zeiss LSM880 Airscan and the image analyse software Imaris. Scaffolds 
were kept in culture for 7 days with ALP stained red and nuclei stained cyan (DAPI nuclear 
staining). Scale bar = 100 µm. 
 
ALP activity of FBMSCs was confirmed on the 3D polymer scaffolds with a significant 
increase in cell numbers between day 2 and 7 (Figure 5-18). Analysis software Imaris 
was used to quantify the number of cell nuclei and the fluorescence intensity of the 
ALP images obtained by confocal microscopy (appendix C). Quantification for P80-2 
and P80-3 showed about a 5 to 6 fold increase in cell number with a decrease in 
normalised ALP expression (ALP fluorescence intensity per cell) between days 2 and 
7, which suggested a progression towards a more osteoblast-like stage (Figure 5-19).  
 
Figure 5-18. Immunofluorescence assessment of FBMSCs ALP expression on the 3D 
polymer scaffolds. FBMSCs were cultured on scaffolds P80-2 and P80-3 for 2 and 7 days. 
ALP was stained red and nuclei were stained cyan (DAPI nuclear staining). Scale bar = 100 
µm. 
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Figure 5-19. Quantification of the immunofluorescence assessment of ALP expression of 
FBMSCs on the 3D polymer scaffolds P80-2 and P80-3. 1) Number of FBMSCs nuclei and 2) 
fluorescence intensity normalised by number of FBMSCs at days 2 and 7. Two tailed t-test (* 
p ≤ 0.05 and ** p ≤ 0.01). Mean ± SD, n=2.  
 
The osteogenic markers type I collagen and osteopontin were evaluated after 7 and 
21 days of culture in basal, α-MEM medium supplemented with FBS and antibiotics, 
and osteogenic media, basal medium supplemented with calcitriol and vitamin 
C.[204,205] FBMSCs cells in tissue culture plates (TC) for 21 days were used as a 
positive control. Scaffolds P80-2 and P80-3 without FBMSCs were used as a negative 
control to assess non-specific antibody binding (Figure 5-20Figure 5-17 and Figure 
5-21). FBMSCs in osteogenic medium showed more type I collagen at day 7 and 21 
than FBMSCs in basal medium. However, little effect was observed in the expression 
of osteopontin where both conditions showed a decrease after 21 days (Figure 5-22).  
 
Figure 5-20. Assessment of non-specific type I collagen antibody staining in scaffolds P80-2 
and P80-3 without FBMSCs. Scaffolds were kept in culture for 21 days with type I collagen 
stained red and nuclei stained cyan (DAPI nuclear staining). Scale bar = 100 µm. 
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Figure 5-21. Assessment of non-specific osteopontin antibody staining in scaffolds P80-2 
and P80-3 without FBMSCs.  Scaffolds were kept in culture for 21 days with osteopontin 
stained red and nuclei stained cyan (DAPI nuclear staining). Scale bar = 100 µm. 
 
 
Figure 5-22. Evaluation of the effect of basal and osteogenic media on FBMSCs osteogenic 
markers in tissue culture plates (TC). Immunofluorescence analysis for expression of type I 
collagen and osteopontin (stained red) and nuclear staining (DAPI, stained cyan) after 7 and 
21 days of culture. Scale bar = 100 µm. 
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Figure 5-23. Immunofluorescence analysis of FBMSCs type I collagen expression on 3D 
polymer scaffolds. FBMSCs were cultured on scaffolds P80-2 and P80-3 with basal and 
osteogenic media for 7 and 21 days. Type I collagen was stained red and nuclei were stained 
cyan (DAPI nuclear staining). Arrows show cell aggregation. Scale bar = 100 µm. 
 
 
Figure 5-24. Immunofluorescence analysis of FBMSCs osteopontin expression on 3D 
polymer scaffolds. FBMSCs were cultured on scaffolds P80-2 and P80-3 with basal and 
osteogenic media for 7 and 21 days. Osteopontin was stained red and nuclei were stained 
cyan (DAPI nuclear staining). Arrows show cell aggregation. Scale bar = 100 µm. 
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Scaffolds P80-2 and P80-3 exhibited an increase of type I collagen from day 7 to 21 
in basal and osteogenic media with no need to supplement the medium to have strong 
expression (Figure 5-23). Moreover, type I collagen expression was significantly 
higher in the 3D polymer scaffolds than the 2D control. On the other hand, FBMSCs 
osteopontin expression was retained at 21 days in the P80-3 scaffolds whereas 
osteopontin decreased in P80-2 scaffolds. It could suggest that P80-3 maintained cell 
phenotype and P80-2 promoted differentiation into a more osteoblast-like 
phenotype.[206] Scaffolds without cells used as a control showed low levels of non-
specific staining (Figure 5-21). Interestingly, FBMSCs on scaffolds P80-2 formed cell 
aggregates (arrows) with the expression of high content of type I collagen whereas 
this behaviour was not observed on P80-3 scaffolds or the TC control. 
A live/dead staining assay was carried out to have a better understanding of the 
FBMSCs aggregates on P80-2 scaffolds. The assay revealed that cells were alive 
after 21 days despite the compact cell structure (Figure 5-25, 1 and 2). FBMSCs on 
P80-3 were used as a control with the absence of dead cells in both cases. Moreover, 
the morphology of the cell aggregates (arrows) showed cytoplasm and nuclei staining 
(Figure 5-25, 3).  
 
Figure 5-25. FBMSCs viability and aggregation on 3D polymer scaffolds in basal medium. 1) 
and 2) Representative images of live/dead staining of FBMSCs after incubation on scaffolds 
P80-2 and P80-3 for 21 days. Merged images of live (calcein AM, stained green) and dead 
cells (nuclear dye, stained red). 3) Representative image of cytoplasm (CellMask™, stained 
orange) and nuclei (stained cyan) of FBMSCs on a P80-2 scaffold. Arrows show cell 
aggregation. Scale bar = 100 µm. 
 
Enzyme-linked immunosorbent assay (ELISA) was used to quantify FBMSCs type I 
collagen secretion in scaffolds P80-2 and P80-3 after 21 days cell culture in basal 
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medium. FBMSCs total protein content (BIC assay) and DNA concentrations 
(PicoGreen assay) were used to normalise type I collagen secretion. Scaffolds without 
FBMSCS and cells on culture plates were also used as controls. Type I collagen of 
FBMSCs was found significantly higher on scaffolds P80-3 than P80-2 (Figure 5-26) 
while type I collagen of FBMSCs on the TC control was observed below detection limit 
(range 39 pg/mL to 2000 pg/mL). Moreover, the normalised total protein showed that 
FBMSCs on P80-2 secreted more proteins per cell than P80-3, which could illustrate 
the effect of the scaffold characteristics on FBMSCs behaviour.  
 
Figure 5-26. ELISA assay for type I collagen. FBMSCs were incubated on the 3D polymer 
scaffolds P80-2 and P80-3 for 21 days. Type I collagen was shown as: 1) collagen I per total 
protein content (pg/µg) and 2) type I collagen per total DNA content (pg/ng). 3) BIC and 
PicoGreen assays were used to quantify total protein and DNA concentration. Two tailed t-test 
(** p ≤ 0.01 and *** p ≤ 0.001). Mean ± SD, n=3. 
 
III. Biomineralisation on the 3D polymer scaffolds 
 
Mediated by osteoblast cells, biomineralisation is one of the latest events in bone 
formation and healing process.[86] Therefore, it was used as a late FBMSCs 
osteogenic differentiation marker. The following supplemented media were used to 
accelerate the biomineralisation processes: 
 Basal medium: α-MEM medium supplemented with FBS (10% v/v) and 
penicillin/streptomycin/fungizone (1% v/v).  
 Mineralisation medium: basal medium supplemented with 2-phospho-L-
ascorbate (50 µg/mL), β-glycerophosphate (1 to 20 mM) and dexamethasone 
(10 nM).[140–142] 
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 Osteogenic medium: basal medium supplemented with 2-phospho-L-
ascorbate (50 µg/mL) and calcitriol (10 nM).[204,205]  
The effect of the osteogenic and mineralisation media and their combinations were 
explored on FBMSCs cultured on tissue culture well plates (TC) using basal medium 
as a control (Table 5-2 shows the 10 conditions studied). FBMSCs were kept in culture 
for a total of 21 days before assessing mineralisation: 7 days in basal medium and 14 
days in experimental media. Mineralisation was analysed with a colorimetric approach 
using acid alizarin red and cetylpyridinium chloride, as previously published.[143] 
Alternatively, the near-infrared fluorescent dye OsteoSense® 800, for image bone 
growth in vivo, was used as a specific mineralisation dye since alizarin red is a calcium 
chelating agent.[144]  
 
Table 5-2. Media optimisation for inducing biomineralisation in 3D polymer scaffolds. Basal 
medium was supplemented with different combinations of β-glycerophosphate (β-Gly), 










Basal (control) 1 0 0 0 0 
Osteogenic 2 0 0 10 50 
Mineralisation 
3 1 10 0 50 
4 5 10 0 50 
5 10 10 0 50 




7 1 10 10 50 
8 5 10 10 50 
9 10 10 10 50 
10 20 10 10 50 
 
FBMSCs biofilms showed positive staining with alizarin red (Figure 5-27). Staining 
quantification showed a significant increase for the majority of the conditions in the 
presence of mineralisation media. However, statistically significant differences were 
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not observed between the mineralisation media explored. Smaller differences 
compared to basal control were found in the case of combinations between 
mineralisation and osteogenic media. On the other hand, OsteoSense® was not able 
to show significant differences for any condition (Figure 5-27).  
 
Figure 5-27. FMBSCs biomineralisation on tissue culture well plates (TC). FBMSCs were 
incubated for 7 days in basal medium and 14 days in mineralisation (min) media (Table 5-2). 
1) Representative images of FBMSCs on the bottom of a well stained with acid alizarin red 
(scale bar = 2 mm). Absorbance based on the extraction and homogenisation of the alizarin 
red staining recorded in a plate reader (λ = 550 nm). 2) Representative images of FBMSCs on 
a well stained with OsteoSense® 800. Fluorescence intensity was recorded in near-infrared 
Odyssey® CLx imaging system (λex/em = 780/805 nm). One-way ANOVA with Bonferroni post-
test (* p≤0.05 and ** p≤0.01) was carried out between basal control (1) and the supplemented 
(2 – 10) media. Mean ± SD, n=3. 
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Previous experiments of mineralisation staining in 3D polymer scaffolds with alizarin 
red (see 4.2.3) were shown to be highly non-specific. Therefore, a high-throughput 
approach based on the near-infrared dyes OsteoSense® and BoneTag™ (Figure 
5-28) was developed using an array of 3D polymer scaffolds and the in vivo imaging 
system IVIS. FBMSCs were cultured on scaffolds for 7 days before switching to 
medium 6 (Table 5-2) and were kept in culture for a total of 28 days. Medium 6 showed 
statistically significant differences with basal medium and it was composed of the 
highest concentration of β-glycerophosphate, which was thought to accelerate 
biomineralisation. Moreover, differences between medium 6 and media 3 and 4 were 
not observed. P80-2 and P80-3 without FBMSCs in basal medium and on tissue 
culture well plates (TC) were used as controls. Optical inspection of the polymer 
scaffolds P80-2 and P80-3 with cells showed higher fluorescence intensity than 
control scaffolds without cells, which was also confirmed by fluorescence 
quantification (Figure 5-29). In contrast, FBMSCs in 3D polymer scaffolds with basal 
and mineralisation media did not show significant differences. The differences 
observed between BoneTag™ and OsteoSense® were perhaps a consequence of the 
emission intensity of the dyes as total fluorescent radiant efficiency of BoneTag™ was 
higher than OsteoSense® in all the conditions.  
 
Figure 5-28. OsteoSense® and BoneTag™ uses a bisphosphonate conjugated to proprietary 
near-infrared dyes (star) to image bone apatite.[207]  
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Figure 5-29. Analysis of FBMSCs biomineralisation on arrays of 3D polymer scaffolds. 
FBMSCs on scaffolds P80-2 and P80-3 were incubated for 7 days in basal medium followed 
by 21 days in mineralisation medium. Biomineralisation was assessed using the near-infrared 
dyes Osteosense® and BoneTag™. Scaffolds without cells (negative), FBMSCs cultured in 
basal medium on scaffolds (basal) and FBMSCs cultured on tissue culture well plates (TC) 
were used as controls. Images of the arrays and total fluorescent radiant efficiency 
([photons/s/cm2/steradian]/[µW/cm2]) were recorded using an in vivo imaging system (IVIS). 
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5.2.3 Biocompatibility and angiogenesis assay in the CAM 
model  
 
The chick choriallantoic membrane (CAM) model was used as a model to assess 
scaffold compatibility and angiogenesis. Scaffolds P80-2 and P80-3 with and without 
FBMSCs were implanted in 10 day fertile chick eggs following a previously described 
procedure.[208] After 7 days post-implantation scaffold integration with the CAM was 
analysed and the amount of blood vessels in the scaffolds quantified following the 
Chalkley score method (Figure 5-30).[151,152]  Eggs without scaffolds were used as a 
control.  
 
Figure 5-30. CAM experimental design. 1) Scaffolds P80-2 and P80-3 with and without 
FBMSCs were incubated for 7 days before being sectioned (5 mm length × 5 mm width × 1 
mm height). 2) Eggshell was removed (5 mm length × 5 mm width) to expose the CAM. 3) 
Scaffolds were implanted in the CAM and incubated in the chick eggs for 7 days. 4) Scaffolds 
were harvested and their integration with the CAM inspected by microscopy.  
 
High integration into the chick CAM with ECM deposition was observed for scaffolds 
P80-2 and P80-3 (Figure 5-31). Angiogenesis was quantified using a Chalkley score 
method which uses a 25 randomised grid to count microvessels. Scaffolds P80-2 and 
P80-3 were shown to significantly enhance angiogenesis compared with the negative 
control, empty eggs without scaffolds inside (10.5 ± 2.4, p ≤ 0.0001). Differences 
between P80-2 scaffolds with FBMSCs and P80-3 scaffolds with and without cells 
were observed, which suggested that these scaffolds were capable of stimulating 
angiogenesis.   
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Figure 5-31. Analysis of the scaffolds P80-2 and P80-3 with and without FBMSCs implanted 
in the CAM model. Representative images of scaffolds implanted with (+FBMSCs) and without 
(no FBMSCs) cells. Quantification of the CAM vasculature in the P80-2 and P80-3 scaffolds 
by Chalkley score. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05). Mean ± SD, n=10. 
 
Histological analysis using Alician blue and Sirius red (A/S) and Goldner’s Trichrome 
(GT) of scaffolds P80-2 and P80-3 showed high integration into the chick CAM with 
ECM deposition (Figure 5-32 and Figure 5-33). Proteoglycans, stained blue in A/S, 
were observed to present with high prevalence in all the conditions. However, 
significant differences between P80-2 and P80-3 scaffolds, with and without FBMSCs, 
were not observed (Figure 5-32). Presence of collagen, stained red in A/S and marked 
with red arrows, was also identified across all the conditions. The presence of cells in 
all the samples, stained black in A/S, even in scaffolds without pre-seeded FBMSCs, 
suggested chick cellular penetration and recruitment as a consequence of the 
enhanced scaffold’s pore size. Goldner’s Trichrome staining also showed presence 
of collagen, stained green and marked with black arrows, across all the conditions 
(Figure 5-33). Avian erythrocytes, stained orange in GT and marked with blue arrows, 
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were observed for all the conditions suggesting vasculature network infiltration 
through the scaffolds. However, appreciable differences of collagen deposition 
between P80-2 and P80-3 scaffolds with and without FBMSCs were not identified. 
 
Figure 5-32. Histological analysis with Alician blue and Sirius red staining where blue shows 
proteoglycans, red shows collagen and black shows nuclei. Black dashed square, black and 
red arrows indicate areas magnified, proteoglycans and collagen respectively. Scale bar 500 
µm (1) and 100 µm (2). 
 
 
Figure 5-33. Histological analysis with Golner’s trichrome where green shows collagen, red 
shows cytoplasm, black shows nuclei and orange shows erythrocytes. Black dashed square, 
black and blue arrows indicate areas magnified, collagen and erythrocytes respectively. 
Scale bar 500 µm (1) and 100 µm (2). 
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5.2.4 Angiogenesis analysis after subcutaneous implantation 
in mice  
 
Scaffold P80-2 was selected for in vivo analysis based on its osteoblastic phenotype 
expression with higher biomineralization than scaffold P80-3. Scaffold P80-2 
displayed enhanced angiogenesis compared to P80-3 scaffolds. Moreover, large pore 
size and high stiffness were also identified in P80-2 scaffolds, which can enhance 
angiogenesis and osteogenesis.  
An in vivo subcutaneous murine model was used to further investigate the 
angiogenesis and bone forming potential of P80-2 scaffolds in the presence of 
FBMSCs pre-conditioned in basal and osteogenic media for 7 days before 
implantation. The in vivo procedure took a total of 4 weeks and two controls were 
used: P80-2 scaffolds without FBMSCs in basal medium and bulk alginate gel (3% 
w/v). Micro-CT reconstruction assessed mineral deposition in the scaffolds after 4 
weeks post-implantation showing that P80-2, in all the conditions, did not form any 
detectable mineralised tissue in contrast to the alginate control, irrespective of 
implantation site (Figure 5-34).  
Extensive levels of integration with the scaffolds was seen with scaffolds near-
indistinguishable from the surrounding tissue independent of the use of FBMSCs or 
supplemented medium. Poor integration was seen for alginate gels four weeks post-
implantation (Figure 5-34 and Figure 5-35). Histological analysis using Alician Blue 
and Sirius red showed extensive collagen around the P80-2 scaffolds with FBMSCs 
compared with P80-2 without cells and alginate negative controls (Figure 5-35). 
Lumen-like vascular structures were also identified in some conditions at scaffolds 
boundaries (yellow arrows). On the other hand, alginate controls showed high levels 
of proteoglycans staining with low infiltration of murine cells. Goldner’s Trichrome 
stained confirmed extensive collagen around and within the porous scaffolds (Figure 
5-36). Moreover, scaffold P80-2 pre-seeded with FBMSCs displaying elevated levels 
of collagen staining in comparison to control P80-2 scaffolds without FBMSCs and 
alginate gels. Murine erythrocytes blood vessels infiltration (blue arrows) were in 
concordance with a highly biocompatible material.     
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Figure 5-34. In vivo evaluation of subcutaneous implantation of scaffolds P80-2 and 3% (w/v) 
bulk alginate control. 1) Macrographs of scaffolds integration and 2) micro-CT reconstructions 
of P80-2 with FBMSCs after basal conditioning, P80-2 with FBMSCs after osteogenic 
conditioning, P80-2 without cells, 3% (w/v) bulk alginate scaffold with FBMSCs after basal 
conditioning and 3% (w/v) bulk alginate scaffold without cells. Black dashed squares show the 
scaffolds. New highly dense tissue (mineralization) is shown in blue.   
 
The histopathological analysis of the P80-2 scaffolds using H&E staining confirmed 
the presence of lumen-like vascular structures in scaffolds boundaries and scaffold 
inner structure (Figure 5-37). Infiltration of scaffolds by murine host cells, such as red 
blood cells (blue arrows) and multinucleated giant cells (yellow arrowheads), was 
evidenced from the presence of cells in P80-2 without pre-seeded FBMSCs. The 
presence of vascular structures throughout P80-2 scaffolds, including the centre of 
the constructs, confirmed extensive vascularisation. Quantification of blood vessels 
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revealed that P80-2 scaffolds with FBMSCs conditioned with osteogenic media 
enhanced angiogenesis (p ≤ 0.05), in comparison with P80-2 scaffolds with cells 
conditioned with basal media and P80-2 scaffolds without cells (Figure 5-38). 
Although blood vessel in the inner structure of the scaffolds were identified for all the 
conditions, It may suggest that FBMSCs with more differentiated osteoblastic 
phenotype can promote further angiogenesis.[195] 
Angiogenesis was further evaluated using immunohistochemistry (Figure 5-39) to 
assess the expression of the vascular endothelial growth factor receptor-2 (VEGFR-
2). VEGFR-2 expression was predominant at scaffold boundaries and connective 
tissue as a consequence of endothelial cells infiltration. Moreover, VEGFR-2 
markedly reduced in scaffolds P80-2 without cells, in comparison to P80-2 with 
FBMSCs. 
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Figure 5-35. In vivo evaluation of subcutaneous implantation of scaffolds P80-2 and 3% (w/v) 
bulk alginate control. 1) Macrographs of scaffold integration. 2) and 3) Histological analysis 
with Alician blue and Sirius red (A/S) staining where blue shows proteoglycans, red shows 
collagen, black shows nuclei and yellow shows muscles. Dashed squares show magnified 
areas with black, red and yellow arrows indicate proteoglycans, collagen and lumen-like 
vascular structures respectively. Scale bar in (2) = 500 µm and (3) = 100 µm.  
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Figure 5-36. In vivo evaluation of subcutaneous implantation of scaffolds P80-2 and 3% (w/v) 
bulk alginate control. Histological analysis with Golner’s trichrome (GT) where green shows 
collagen, red shows cytoplasm, black shows nuclei and orange shows erythrocytes. Dashed 
squares show magnified areas, blue and black arrows indicate erythrocytes and collagen 
respectively. Scale bar in (1) = 500 µm and (2) = 100 µm. 
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Figure 5-37. Histological evaluation of scaffolds P80-2 by H&E. P80-2 with FBMSCs in basal 
conditioning (A), P80-2 with FBMSCs in osteogenic conditioning (B) and P80-2 without 
FBMSCs in basal conditioning. Dashed squares (a-c) show magnified areas, blue arrows show 
RBCs and yellow arrowheads shows multinucleated giant cells. Scale bar in (1) = 500 µm and 
(2-4) = 100 µm. 
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Figure 5-38. Evaluation of the number of lumens/vascular structures per mm2 of scaffold P80-
2 with FBMSCs after basal conditioning, P80-2 with FBMSCs with osteogenic conditioning and 
P80-2 without any cells. Analysis was performed manually using the software QuPath on the 
histological sections stained with H&E. One-way ANOVA with Bonferroni post-test (* p ≤ 0.05). 
Mean ± SD, n=2 biological replicates. 
 
 
Figure 5-39. Analysis of VEGFR-2 by immunohistochemistry. P80-2 with FBMSCs in basal 
conditioning (A), P80-2 with FBMSCs in osteogenic conditioning (B) and P80-2 without 
FBMSCs in basal conditioning. Dashed lines indicate interface between connective tissue (CT) 




Scaffold composition, mechanical properties and 3D microstructure have shown to be 
capable of controlling stem cell behaviour to promote tissue healing. For example, 
porous scaffolds based on chitosan, poly(vinyl acetate) and poly(L-lactic acid) 
(50:25:25) have been shown to promote skeletal stem cells differentiation with in vivo 
osteogenic potential.[121] Substrate stiffness of porous scaffolds also play a crucial role 
in stem cell behaviour, for instance, by controlling osteogenic or adipogenic 
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differentiation of mesenchymal stem cells (MSCs).[209] Moreover, bone marrow stroma 
cells showed enhanced migration capabilities when cultured on stiffer porous 
substrates, a crucial event in bone tissue repair processes.[210] Scaffold porosity and 
pore size have been observed to control and promote osteogenic differentiation.[22] 
However, in the quest to design an optimal 3D polymer scaffold for tissue repair 
applications, the combined effects of scaffold properties on cell fate need to be 
deconvoluted. 
In the context of bone repair, one of the major unsolved challenges associated with 
the successful integration of implanted scaffolds is their capability to associate with 
the host vasculature. In vivo angiogenesis and scaffold viability are promoted in 
structures that contain a highly interconnected porous network with large pores (200 
to 400 µm).[111–113] However, the currently available approaches for screening and 
designing 3D polymer scaffolds are limited in their ability to assay multiple polymers, 
3D microstructures and mechanical properties simultaneously.        
Herein, a method was developed to obtain arrays of 3D polymer scaffolds with freeze-
casting and photo-polymerisation to explore and assess foetal bone marrow stroma 
cells (FBMSCs) behaviour in libraries of porous polymer scaffolds (Figure 5-1). Aiming 
to discover an optimal candidate for bone repair applications, FBMSCs were used to 
screen the scaffold candidates because of their potential to differentiate into 
osteoblasts. Acrylate-based monomers were chosen due to their proven ability to 
provide polymers capable of binding embryonic stem cells[30] and bone cells (appendix 
A), moreover, the in vivo pro-angiogenic potential of acrylate-based polymers was 
suggested in a previous report.[29,211]  
To analyse FBMSCs proliferation on the 3D polymer scaffolds, an array of 45 
polymers in a flat-bottomed 96-well plate was obtained combining 15 different 
polymerisation mixtures (Figure 5-2 and Table 5-1) with three levels of porogenic 
solvent (DMSO) to give so-called scaffolds with “medium” and “high” porosity, P60 
(60% v/v DMSO) and P80 (80% v/v DMSO), and their non-porous controls P0 (0% 
v/v DMSO). Pores were generated as a consequence of the “slow” cooling procedure 
(5 °C for 16 h and – 20 °C for 4 h) explored above (section 0), which produces a phase 
separation between DMSO and polymerisation mixtures as well as a crystalline 
mould. Scaffold structure was consolidated by UV photo-polymerisation (30 min).  
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Proliferation on the scaffolds was assed using Alamar Blue over 21 days and FBMSCs 
(Figure 5-5 and Figure 5-6).  Polymers 1-6 with porosity P0, P60 and P80 were 
selected for further analysis due to their higher proliferative rates. FBMSCs total 
collagen deposition (Figure 5-7) and ALP activity (Figure 5-8) on these 3D polymer 
scaffolds were used as markers for ECM formation and osteoblastic differentiation 
respectively.[212] The investigation of FBMSCs behaviour on porous scaffolds (P60 
and P80) against non-porous scaffold (P0) and tissue culture well plate control (TC) 
showed an increase of ECM deposition and ALP levels on the porous constructions 
(Figure 5-9). Among the 18 different scaffolds screened, P80-2 and P80-3 were the 
most outstanding materials.  
Scaffold microstructure was observed to be controlled by the level of DMSO as 
expected (Figure 5-10), with porosities greater than 60% and the abundant presence 
of interconnected pores larger than 100 µm (Figure 5-11). Moreover, pores larger than 
200 µm were observed for the P80-2 scaffolds, associated with the potential for 
promoting osteogenesis as well as angiogenesis.[111,113] Indentation moduli (stiffness) 
for scaffolds with “medium” and “high” porosity along with their non-porous controls 
showed the broad range of mechanical properties that these materials were able to 
cover (Figure 5-12). For example, P80-2 was considered a “stiff” scaffold (3.0 MPa) 
while P80-3 was “soft”. Additionally, the relaxation load (the ability to withstand loads 
without breaking) determined after 5 min relaxation (Figure 5-13) confirmed scaffolds 
displayed a range of mechanical properties similar to collagenous bone, articular 
cartilage or trabecular bone.[188,189,213,214]  
The comparison of FBMSCs behaviour with physical properties of the scaffolds 
allowed light to be shone on the complex interplay between cells and scaffolds (Figure 
5-14). Overall, scaffolds P80-2 and P80-3 were observed to be the top candidates 
among polymers 1-6 due to their optimal physical properties and osteogenic potential 
(Figure 5-15).  
Version P80 of polymers 2 and 3 were validated using FBMSCs biomarker 
signatures, which are determinant of cell phenotype. Three stages are distinguished 
in the osteogenic differentiation of skeletal progenitor cells.[212]     
1) Proliferative stage characterised by ALP and type I collagen expression.  
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2) Maturation stage characterised by increasing levels of type I collagen, 
osteopontin, osteocalcin and bone sialoprotein with decreasing ALP 
expression.   
3) Mineralisation stage with reduction of collagen and osteopontin expression.  
The SEM images of FBMSCs laden scaffolds demonstrated cells across the surface 
and the pores forming a “3D” cell microenvironment (Figure 5-16). 
Immunofluorescence analysis confirmed FBMSCs ALP expression (Figure 5-18), 
which is an early osteoblast differentiation marker responsible for the mineralisation 
of the extracellular matrix.[215] The immunostaining quantification showed the 
significant decrease of ALP expression on P80-2 between day 2 and 7, suggesting 
FMBSCs progressed towards a more differentiated osteoblast phenotype, with a 
FBMSCS proliferation rate comparable to the 3D array data (Figure 5-19).  
Type I collagen and osteopontin expression on scaffolds P80-2 and P80-3 seeded 
with FBMSCs were compared to cells on control tissue culture plates (TC) using basal 
medium, α-MEM medium supplemented with FBS and antibiotics, and osteogenic 
medium, basal medium supplemented with calcitriol and vitamin C) (Figure 
5-22.[204,205] FMBSCs maintained in 2D controls displayed less type I collagen 
expression to cells on 3D scaffolds after 21 days in basal and osteogenic 
supplemented media (Figure 5-23). FMBSCs osteopontin expression was maintained 
on the scaffolds P80-3 in both media conditions, however, a decrease of osteopontin 
expression was observed on scaffolds P80-2, which suggested progression towards 
a more differentiated osteoblastic phenotype.[206]  
In support of the enhanced differentiation, aggregates of FBMSCs on scaffolds P80-
2 were observed to be composed of viable cells attached to the polymer matrix (Figure 
5-25). Perhaps, aggregates of FBMSCs could be evidence of an intramembranous 
ossification process where MSCs form dense clusters of cells, with high type I 
collagen expression, to generate cortical bone.[216] Moreover, type I collagen 
production quantified by ELISA showed P80-3 increased collagen expression 
compared to P80-2 (Figure 5-26). However, both porous scaffolds had higher 
collagen expression than the TC control, which was below the assay detection limit 
(human pro-collagen I, abcam, range 39 pg/mL to 2000 pg/mL). This supported 
excellent osteoblastic differentiation as evidenced by high type I collagen matrix 
production.  
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Mineralisation is a slow biological mediated process that involves apatite minerals 
deposition into collagenous ECM and it is used to confirm bone formation as a late 
osteoblastic differentiation marker.[86] To accelerate biomineralisation, 2-phospho-L-
ascorbate, β-glycerophosphate and dexamethasone are commonly used as 
supplements although their effects are not always fully understood.[140,141,182] 2-
phospho-L-ascorbate has been shown stable under culture conditions and it is a 
source of ascorbic acid via enzymatic hydrolysis mediated by ALP, which promotes 
osteoblastic differentiation upregulating type I collagen expression.[217] 
Dexamethasone has been shown to induce osteoblastic differentiation by activating 
WNT/β-catenin signalling and RUNX2 expression with β-glycerophosphate acting as 
a second phosphate source upregulating osteogenic gene expression; however, β-
glycerophosphate concentration presents large variations (1 to 20 mM) in the 
literature and its use has been identified with non-osteogenic dystrophic 
mineralisation.[218]  
Hypothesising that FBMSCs differentiate to osteoblastic phenotype before 
mineralising, the effect of osteogenic and mineralisation media along with their 
combinations (Table 5-2) on FBMSCs culture on TC well plates was assessed using 
alizarin red (non-specific to bone apatite minerals) and OsteoSense® 800 (in vivo 
near-infrared bone staining).[144] Mineralisation medium was stablished as basal 
medium supplemented with 2-phospho-L-ascorbate (50 µg/mL), β-glycerophosphate 
(20 mM) and dexamethasone (10 nM) based on alizarin red staining although 
significant differences between media were not observed for the near-infrared dye 
(Figure 5-27).   
FBMSCs biomineralisation on scaffolds P80-2 and P80-3 was assayed with 
OsteoSense® 800 and BoneTag™ (Figure 5-28) as a consequence of alizarin red non-
specificity (high in porous materials) and to improve specificity of mineralisation 
assessment.[207,219] FBMSCs mineralisation was observed for porous scaffolds P80-2 
and P80-3 in comparison to the controls, scaffolds without cells and FBMSCs on 
tissue culture well plates, even though differences between basal and mineralisation 
media were not identified (Figure 5-29). These results suggest mineralisation could 
happen on the scaffolds in the absence of supplemented medium; however, 
mineralisation needs to be evaluated further.  
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Chick chorioallantoic membrane (CAM) ex vivo model provides a highly vascularised 
bed to evaluate scaffolds P80-2 and P80-3 biocompatibility and angiogenesis before 
experimentation in more advanced models (Figure 5-30).[208] Angiogenesis on 
scaffolds P80-2 and P80-3 with and without FBMSCs was quantified with the Chalkley 
score method with P80-2 scaffolds displaying the highest level of vasculature (Figure 
5-31). Moreover, the scaffold integration in the CAM with vasculature network 
formation and infiltration of avian host cells supported scaffold biocompatibility (Figure 
5-32).  
Scaffold P80-2 were selected for in vivo analysis on the basis of their capacity to 
promote FBMSCs aggregation, indicative of biological functions and improved cell-
cell communications,[220] osteoblastic phenotype expression and enhanced 
angiogenesis. Furthermore, P80-2 had an excellent interconnected porous structure 
with pore size larger than 200 µm and mechanical properties in matching with 
musculoskeletal needs.   
In vivo angiogenesis of the scaffold, a necessary step in bone repair 
applications,[95,221] was assessed using a subcutaneous murine model.[222] P80-2 
scaffolds were shown to be highly integrated in the host tissue four weeks post-
implantation with an absence of abnormal mineralisation in the subcutaneous pocket 
(Figure 5-34). The observation of extensive collagen deposition (Figure 5-35) and 
vasculature (Figure 5-37) within the scaffolds, an uncommon observation in the 
absence of exogenously supplied VEGF factors or endothelial cells,[223] supported the 
development of a new class of synthetic angiogenic materials.  
Host multinucleated giant cells were identified in scaffolds P80-2 with and without pre-
seeded FBMSCs (Figure 5-37). These cells are part of the host immune response 
and have functions comparable to osteoclasts in resorption and remodelling,[224] 
moreover, they are known to trigger vascularisation.[195] VEGFR-2 expression 
suggested scaffolds P80-2 pre-seeded with FBMSCs improved the recruitment of 
endothelial cells, which could enhance vasculogenesis (Figure 5-39). In agreement 
with our results, an earlier report suggested that primary human osteoblasts guide 
host multinucleated giant cells and endothelial cells into scaffolds, improving scaffold 
vascularisation.[195] Therefore, scaffolds pre-cultured with FBMSCs appear to 
increase vasculogenesis in concert with host immune response.  
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5.4 Conclusions 
 
An array of 3D polymer scaffolds was used to design a highly functional 3D scaffold 
which displayed exceptional angiogenesis ability. The array enabled the rapid 
fabrication and screening of tailored libraries of functional 3D polymer scaffolds via 
freeze-casting and UV photo-polymerisation. 
Scaffold microstructure was tuned by modifying the level of the porogenic solvent to 
provide highly interconnected porous materials with porosities greater than 80% and 
average pore sizes larger than 150 µm. Moreover, the scaffold mechanical 
characterisation showed they could be excellent candidates for skeletal repair 
applications due to their indentation moduli ranging from 10 KPa to 10 MPa and their 
high capacity for load reduction.  
Foetal bone marrow stroma cells (FBMSCs) were used to interrogate the arrays and 
select two porous candidates, P80-2 and P80-3, which exhibited excellent cell 
proliferation rate with collagen deposition and ALP expression indicating the 
progression of osteoblastic cellular differentiation. During the screening process, 
FBMSCs on porous scaffolds were compared to FBMSCs on scaffolds without pores 
(P0) and tissue culture plates (TC) to assess how the 3D microenvironment tuned 
cellular fate.  
Biocompatibility and angiogenesis of the 3D polymer scaffolds were analysed ex vivo 
using a chick CAM model and in vivo applying a mouse subcutaneous model. 
Biocompatibility of scaffolds P80-2 and P80-3 was evidenced by the CAM assay, 
which showed significant angiogenesis and host cell recruitment. The P80-2 scaffolds 
implanted subcutaneously in mice showed extensive vascularisation within and 
throughout the synthetic 3D porous polymer, which confirmed its regenerative 
potential in a mammalian model.  
Overall, the array of 3D polymer scaffolds allowed the rapid screening of both multiple 
polymer combinations and varying physical properties leading to the identification of 
a new class of osteogenic and angiogenic materials. Furthermore, this remarkable 
vascularisation potential, a crucial property for tissue regeneration, makes scaffolds 
of co-polymer 2, poly(MTEMA36-co-IBA36-co-HDOBA18), promising for applications in 
hard and soft skeletal tissues.  
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6. Concluding remarks and outlook 
 
Fabrication strategies of 3D polymeric biomaterial to date have focused on exploring 
how either scaffold composition or scaffold microstructure can promote tissue 
regeneration. However, fewer examples can be found where both of these 
characteristics are tuned simultaneously.  
Herein, an array of 3D polymer scaffolds was developed to explore the potential of 
acrylate-based 3D polymers in providing biomimetic microenvironments that support 
the expansion and differentiation of bone progenitor cells. Freeze-casting with DMSO 
as the porogenic solvent and UV photo-polymerisation were identified as the best 
approach to control the 3D microstructure and composition of the scaffolds. This 
method enabled the fabrication and screening of up to 96 different polymer scaffolds 
in a convenient platform suitable for the majority of biological settings. 45 different 3D 
polymers were interrogated with foetal bone marrow stromal cells (FBMSCs) to 
discover scaffolds that promote cell proliferation and ECM formation, while the array 
approach using micro-CT allowed the high-content morphological screening of 12 
polymer scaffolds in a single scan.  
The 3D polymer scaffolds identified in vitro were validated ex vivo, with a CAM assay, 
and in vivo, with subcutaneous implantation in mice, with the leading 3D polymer 
showing high biocompatibility, integration in the tissue and vascularisation. Next steps 
will entail the assessment of the 3D polymer scaffolds in a bone defect model for its 
ability to integrate with bone tissue and promote osteogenesis.   
Although this proof-of-concept strategy has been proven successful in identifying 
biocompatible 3D polymer scaffolds, there are some aspects that could improve the 
method. Fine control of cooling gradients using Peltier-based coolers with PID 
controllers could be employed to enable the fabrication of new porous arrays. 
Moreover, exploring different porogenic solvents such as water, which has multiple 
ice crystal structures (e.g. hexagonal, stellar, dendrite) that can be translated to 
scaffold microstructure, could reveal new structures that can tune cell fate.  
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8. Appendices 
A Polymer substrates for bone cell attachment  
 
Microarrays were fabricated using a selection of polymers previously identified in the 
Bradley group. These polymers were chosen based on their ability to support the 
growth of suspension cells,[166] endothelia progenitor cells,[29] human embryonic stem 
cells,[30,167] bone cells[121] or mesenchymal stem cells.[31] 1,6-hexanediol diacrylate and 
hydroxy-2-methylpropiophenone were used in all the polymers as cross-linker and 
UV-photoinitiator respectively. Different ratios of monomers were explored (monomer 
1 to monomer 2: 0:100, 25:75, 50:50, 75:25 and 100:0) in the case of polymers 
composed of two acrylate monomers.  
Inkjet printing (Scienion S5, Germany) was used to in situ fabricate 180 different 
acrylate polymers (Table 8-1 and Table 8-2) on a single glass microscope slide. Glass 
slides were acrylate functionalised before printing and three replicates were 
generated for each polymer including internal controls (see section 3.4 for details of 
the microarray fabrication). Microarrays (two replicates) were interrogated with SAOS-
2 and MG-63 cells and their attachment to the polymers were quantified (number of 
cells per mm2 of polymer) after two days of cells culture. 
Both cell lines showed good cell attachment on the large number of polymers 
interrogated (Figure 4-1 and Figure 4-2). The large standard deviation in the screening 
with SAOS-2 cells (285 ± 184 SAOS-2 cells/mm2) illustrated that these cells were 
perhaps more selective to the composition of the polymers than MG-63 cells (256 ± 
95 MG-63 cells/mm2). As such polymer composition were selected based on SAOS-
2 cell attachment*.  
 
 
* Polymers with monomers that produced excessive swelling (e.g. AEtMA-CL, NIPAAm, 
DMAEMA) were discarded as swelling can disrupt the 3D microstructure. Polymers 43-
45, 58, 73-74, 111, 131-132. 
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Table 8-1. Monomers explored in the microarray fabricated to identify polymer substrates 
capable of supporting the attachment of SAOS-2 and MG-63 cells. 
Abbreviation Monomer name CAS 
MMA Methyl methacrylate 80-62-6 
St Styrene 100-42-5 
NIPAAm N-isopropylacrylamide 2210-25-5 
AAH Acrylic acid 79-10-7 
DEAEA 2-(diethylamino)ethyl acrylate 2426-54-2 
MA-H Methacrylic acid 79-41-4 
GMA Glycidyl methacrylate 106-91-2 
MEMA 2-methoxyethylmethacrylate 6976-93-8 
HEMA 2-hydroxyethylmethacrylate 868-77-9 
VP4 4-vinylpyridine 100-43-6 
VP2 2-vinylpyridine 100-69-6 
EMA Ethyl methacrylate 97-63-2 
BMA Butyl methacrylate 97-88-1 
DMAEA 2-(dimethylamino)ethyl acrylate 2439-35-2 
HBMA Hydroxybutyl methacrylate mixture of isomers 29008-35-3 
DEAEMA 2-(diethylamino)ethyl methacrylate 105-16-8 
DMAEMA 2-(dimethylamino)ethyl methacrylate 2867-47-2 
HPMA Hydroxypropylmethacrylate 27813-02-1 
AEtMA-CL 2-(acryloyloxyethyl) trimethylammonium chloride 44992-01-0 
DEAA N,N-Diethyl acrylamide 2675-94-7 
DMOBAA N-(1,1-Dimethyl-3-oxobutyl)acrylamide 2873-97-4 
Aam Acrylamide 79-06-1 
DMAA N,N-Dimethyl acrylamide 2680-03-7 
HBA 4-Hydroxybutyl acrylate 2478-10-6 
BHA 4-tert-Butylcyclohexyl acrylate 84100-23-2 
CEA 2-Carboxyethyl acrylate 24615-84-7 
IBA Isobornyl acrylate 5888-33-5 
EGDPEA Ethylene glycol dicyclopentenyl ether acrylate 65983-31-5 
MTEMA 2-(Methylthio)ethyl methacrylate 14216-23-0 
AEMA-Cl 2-Aminoethyl methacrylate hydrochloride 2420-94-2 
TBAA N-tert-Butylacrylamide 107-58-4 
HPPA 2-Hydroxy-3-phenoxypropyl acrylate 16969-10-1 
HDOBA (CL) 1,6-hexanediol diacrylate 13048-33-4 
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Table 8-2. Composition of the acrylate polymers explored in the microarray fabricated to 
identify polymer substrate capable of supporting the attachment of SAOS-2 and MG-63 cells. 
Solutions were prepared in NMP (1 M). 1,6-hexanediol diacrylate was used as cross-linker 














1 BMA (25) DMAEA (75) 21 EMA (75) 
DEAEA 
(25) 
2 BMA (50) DMAEA (50) 22 MEMA (25) HEMA (75) 
3 BMA (75) DMAEA (25) 23 MEMA (50) HEMA (50) 
4 HEMA (25) VP2 (75) 24 MEMA (75) HEMA (25) 
5 HEMA (50) VP2 (50) 25 St (25) NIPAA (75) 
6 HEMA (75) VP2 (25) 26 St (50) NIPAA (50) 
7 MMA (25) 
DMAEMA 
(75) 
27 St (75) NIPAA (25) 





















11 MMA (50) 
DMAEMA 
(50) 
31 MMA (25) GMA (75) 
12 MMA (75) 
DMAEMA 
(25) 
32 MMA (50) GMA (50) 
13 BHA (25) BMA (75) 33 MMA (75) GMA (25) 
14 BHA (50) BMA (50) 34 BHA (25) DMAA (75) 
15 BHA (75) BMA (25) 35 BHA (50) DMAA (50) 
16 BMA (25) DEAEA (75) 36 BHA (75) DMAA (25) 
17 BMA (50) DEAEA (50) 37 MMA (25) MAH (75) 
18 BMA (75) DEAEA (25) 38 MMA (50) MAH (50) 
19 EMA (25) DEAEA (75) 39 MMA (75) MAH (25) 

















41 MMA (50) DEAEA (50) 61 EMA (25) 
DEAEMA 
(75) 
























65 EMA (50) 
DMAEMA 
(50) 
46 HBMA (25) 
DEAEMA 
(75) 
66 EMA (75) 
DMAEMA 
(25) 
47 HBMA (50) 
DEAEMA 
(50) 
67 HPMA (25) 
DMAEMA 
(75) 
48 HBMA (75) 
DEAEMA 
(25) 
68 HPMA (50) 
DMAEMA 
(50) 
49 HBMA (25) 
DMAEMA 
(75) 
69 HPMA (75) 
DMAEMA 
(25) 
50 HBMA (50) 
DMAEMA 
(50) 
70 HPMA (25) DEAEA (75) 
51 HBMA (75) 
DMAEMA 
(25) 
71 HPMA (50) DEAEA (50) 
52 HBMA (25) DEAEA (75) 72 HPMA (75) DEAEA (25) 
53 HBMA (50) DEAEA (50) 73 HBA (25) 
DMAEMA 
(75) 
54 HBMA (75) DEAEA (25) 74 HBA (50) 
DMAEMA 
(50) 
55 HBMA (25) 
DMAEA 
(75) 
75 HBA (75) 
DMAEMA 
(25) 
56 HBMA (50) 
DMAEA 
(50) 
76 HPMA (25) 
DEAEMA 
(75) 
57 HBMA (75) 
DMAEA 
(25) 
77 HPMA (50) DEAEMA(50) 
58 NIPAA (25) 
DMAEMA 
(75) 
78 HPMA (75) 
DEAEMA 
(25) 







60 NIPAA (75) 
DMAEMA 
(25) 


















81 IBA (50) 
MTEMA 
(50) 












DEAA (25) 104 CEA(25) IBA (75) 
85 DEAEA (25) 
DMAEMA 
(75) 
105 CEA(25) IBA (75) 






















































95 MEMA (50) 
DMAEMA 
(50) 
115 AAH(25) DEAEA (75) 
96 MEMA (75) 
DMAEMA 
(25) 














NIPAA (75) 119 DMAEMA(50) 
EGDPEA 
(50) 



























122 Aam (50) 
DMAEMA 
(50) 
142 HPPA (25) HEMA (75) 
123 Aam (75) 
DMAEMA 
(25) 
143 HPPA (50) HEMA (50) 
124 DMAA (25) 
DMAEMA 
(75) 
144 HPPA (75) HEMA (25) 
125 DMAA (50) 
DMAEMA 
(50) 
145 MEMA (25) EGDPEA (75) 
126 DMAA (75) 
DMAEMA 
(25) 
146 MEMA (50) EGDPEA( 50) 
127 DMAA (25) DEAEA (75) 147 MEMA (75) EGDPEA( 25) 
128 DMAA (50) DEAEA (50) 148 MMA (100) - 



















133 HEMA (25) IBA (75) 153 MAH (100) - 
134 HEMA (50) IBA (50) 154 GMA (100) - 











137 HEMA (50) 
EGDPEA 
(50) 
157 VP4 (100) - 
138 HEMA (75) 
EGDPEA 
(25) 




























- 171 HBA (100) - 








- 174 IBA (100) - 















- 178 TBAA (100) - 
169 Aam (100) - 179 HPPA (100) - 
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B Thermogravimetric analysis 
 
 
Figure 8-1. Thermal stability of co-polymer 174 (Table 8-2), poly(IBA72-co-HDOBA18), with 
high level of porosity (P80). Thermogravimetric analysis showed polymer degradation above 
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C Analysis of immunofluorescence using the Imaris 
platform 
 
Image acquisition of the immunostaining (ALP, type I collagen and osteopontin) was 
carried out using a confocal microscope to obtain images at different heights (z-stack) 
of the polymer scaffolds. The software Imaris was used to analyse these images to 
obtain 2D projections of the 3D FMBSC-scaffold assemblies (Figure 8-2). 
Fluorescence intensity was deconvoluted by channels applying a threshold that 
separated cell cytoplasm and nuclei from the background. It allowed quantification of 
the intensity of the antibody staining and counting of cell numbers in addition to 
construction of 3D models that showed cell distribution across the 3D polymer 
scaffolds (Figure 8-3).   
 
Figure 8-2. Representative 2D image projection of a Z-stack (3D) with ALP stained red and 




Figure 8-3. Immunofluorescence assessment of FBMSCs ALP expression on a scaffold P80-
2 after 7 days incubation. 3D image with ALP stained red and nuclei stained cyan (DAPI 
nuclear staining). Scale bar = 70 µm. 
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